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CHAPTER 1 
General introduction and problem statement 
Historical introduction 
The heart has been considered for centuries as a pump, its role in circulation 
homeostasis being primarily mechanical. During the last century however, several 
investigators found arguments for the heart as an endocrine gland as well. The 
concept of the heart as a source of hormonal secretion has its roots in 1935, 
when Peters speculated on the existence of a volume controlling system being 
capable to 'sense the fullness of the blood stream' (1). It was only in 1956, that 
Henry et al. demonstrated that balloon insufflation in the left atrium evoked an 
acute diuresis (without a natriuresis !) (2). At about the same time Kisch et al. 
reported the presence of certain granules in atrial cells (3). In later experiments 
using essentially identical techniques, Lydtin & Hamilton did find a natriuretic 
response by atrial ballooning (4). In 1960, De Vries et al. from the group of 
Borst, observed a polyuric phase in humans following paroxysmal supra-
ventricular tachycardia (5). One year later, De Wardener et al. published the 
well-known cross circulation experiment in the dog, showing that when the GFR 
(first factor) and aldosterone (second factor) were kept constant, a volume and 
saline load resulted in acute diuresis and natriuresis in the isolated serially-linked 
kidney; this was thought to be induced by a third factor (6). In 1964 the close 
contact of the atrial granules with the Golgi complex was described, underscoring 
the secretory function of these granules (7). In 1976 Marie et al. showed that the 
number of granules varied with the sodium intake (8). The amount of specific 
atrial granules was correlated negatively with the volume of extracellular fluid 
(9). Further, the number of atrial granules increased by water deprivation and 
decreased by saline loading (9). In 1981 De Bold et al. performed the historical 
experiment of infusing crude atrial extracts in rats (10). These intravenous 
infusions resulted in a thirty-fold increase of sodium excretion, whereas infusions 
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of ventricular extracts evoked only minimal changes in sodium excretion. Cantin 
and Genest confirmed that the atrial granules were responsible for this natriure-
tic response (11). Shortly after De Bold's infusion studies, the amino acid se-
quence of this atrial natriuretic factor (ANF) was identified (12) and ANF was 
synthetized (13). After developing specific radioimmunoassays for ANF, it was 
demonstrated that a number of atrial peptides are circulating in plasma (14,15). 
The gene encoding for ANF was characterized (16) and ANF receptors were 
localized (17) Since 1985 many publications on ANF appear annually, demon-
strating its significant role in the (patho)physiology of the circulation. Whether 
the problem of the third factor really had been solved by defining ANF, 
remained questionable. Indeed, only recently two new natriuretic peptides, the 
brain natriuretic factor (BNF) and C-type natriuretic factor (CNF), were isolated 
(18,19). These new natriuretic hormones are supposed to modulate vascular tone 
and growth, and to control fluid volume in concert with ANF (20). 
Biosynthesis 
The gene for ANF consists of three exons, coding for a 151 amino acid pre-
propeptide, and two intervening non-coding introns The N-terminal 25 amino 
acid chain (127-151)ANF is cleaved from the pre-prohormone (1-151)ANF, 
resulting in the granular storage form of the prohormone (1-126)ANF. After 
cleavage of the C-terminal 98 amino acid chain (1-98)ANF the major circulating 
hormone form (99-126)ANF, or simply ANF, is obtained. 
ANF's major part in circulating peripheral blood is in the alpha-form. Only 
a minority circulates in the beta-form, being the antiparallel dimer of alpha-ANF, 
and in the gamma-form being the prohormone itself. 
ANF's gene is most strongly expressed in the right atrium (8); but under 
physiological conditions immunoreactive ANF is present in both atria (11). 
However, when ANF demand increases, such as in cases of chronic volume over-
load, it has been demonstrated that the ventricles become increasingly more 
important in the ANF production. But the ratio of atrial versus ventricular ANF 
is under physiological circumstances about 300:1. 
Physiologically, ANF gene expression occurs only at very low levels in the 
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cardiac ventricles, cerebral tissues, adrenal chromaffin cells, anterior pituitary, 
aorta, lungs, and possibly in the kidneys, as well as in the submaxillary and 
thyroid gland. 
Release 
Atrial distension has been established to be the principal stimulus for the release 
of ANF (21). In secretion a circadian rhythm is debated. Controversy exists about 
the time points at which ANF concentration is lowest and highest. Analogous to 
hormones like insulin and glucagon, pulsatility has been reported in ANF 
secretion. Baseline ANF secretion shows regular pulses every 9 minutes (22). 
A number of humoral and neurogenic factors seem capable to influence 
the ANF release. Both a- and ß-adrenergic activation have been demonstrated to 
stimulate the ANF release (23). However, there are no hard data unambiguously 
proving that ANF release is mediated by endogenous neurotransmitters (24, 25). 
The role for atrial neurogenic reflexes as modulating factors in the control of 
ANF secretion remains to be determined. 
The recently discovered endothelium-derived relaxing factor (EDRF) 
inhibits, whereas the potent vasoconstrictor endothelin-I stimulates the cardiac 
release of ANF (26,27). Paracrine effects on the vascular wall are still being 
investigated. 
ANF receptors 
An abundance of ANF binding sites exists in the human body. Autoradiographic 
studies have demonstrated binding sites in the lungs, liver, adrenal cortex, 
cerebrum, colon and small intestine, kidney and vascular tissue itself. 
It has been demonstrated that the ANF receptor pool is functionally and 
structurally heterogeneous (28,29). Presently, the following types of ANF 
receptors, characterized by a different preferential hormone affinity or a different 
dissociation constant (Kd) (being defined as the concentration at which 50% of 
the binding sites are occupied), are known: ' the membrane-bound 180 Kd 
biologically active A-ANF receptor, coupled to the enzyme guanylate cyclase and 
responding with equal sensitivity to both ANF and BNF; ) the membrane-bound 
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130 Kd biologically active B-ANF receptor, coupled to guanylate cyclase and 
binding preferentially with BNF and to a lesser extent with low affinity to ANF 
or ANF fragments containing more than 24 amino acids; and ) the ±70 Kd 
biologically silent C-ANF receptor, which is not linked to guanylate cyclase and 
which aspecifically binds with high affinity to ANF or ring-deleted analogues. The 
latter aspecific receptor type explains that ANF analogues may induce specific 
ANF effects by competing with endogenous ANF for the binding with C-ANF 
receptors. The C-ANF receptors are considered to serve as specific peripheral 
storage-clearance binding sites for ANF (30,31). 
Second messenger system 
Following the binding of ANF to its biologically active receptor the membrane-
bound particulate guanylyl cyclase is activated and cyclic guanosine 
monophosphate (cGMP) is produced. cGMP is an intracellular signalling 
molecule that regulates ion channels and cyclic adenosine monophosphate 
concentrations, the latter by virtue of its effects on selective phosphodiesterases 
and protein kinases. 
cGMP is the second messenger for ANF, and evokes via a cGMP-
dependent protein kinase several biological effects. Antagonism of the cGMP-
dependent receptors with ANF antibodies prevents the cGMP production. This 
abolishes the ANF-mediated effects, whereas the administration of a permeable 
analogue of cGMP mimickes the ANF-induced effects, in vitro as well as in vivo. 
The cGMP production can be estimated by measuring the cGMP level in plasma 
or urine. In comparison to ANF, cGMP has a longer half-life of about 10 to 20 
minutes in man (32), cGMP is not affected by proteolysis and continuously 
produced when the ANF concentration increases. The measurement of the 
cGMP level therefore may be of complementary use when investigating target 
organ responsiveness to ANF. However, interpretations from cGMP data certain-
ly have restrictions because relevant quantities may be derived from the 
continuous stimulation of the nitric oxide (NO) pathway. Figure 1 shows the 
pathways of NO- and ANF-dependent relaxation of smooth muscle cell via intra-
cellular cGMP stimulation. 
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The synthesis of cGMP from guanosine 5'-triphosphate (GTP) is catalyzed 
by a family of cell surface and cytoplasmic receptors known as the guanylyl 
cyclases (GC). In the mammal there are now six different forms of GC known. 
They can be currently divided into two groups with a different major isozyme 
form: ' the cytosolic soluble GC, which is activated by nitrodilators as NO, and 
) the membrane-bound particulate GC, which can be activated by the heat-
stable toxin of Escherichia coli (28). With the discovery of ANF, the first 
physiological activator of the particulate GC has been found (33). In 
endothelium-intact vessels vasoactive agents, such as acetylcholine and brady-
kinin, evoke an endothelium-dependent vasodilation via production of EDRF, 
mostly considered to be NO, which activates the soluble GC (34). ANF-induced 
vasodilation however, occurs via an endothelium-independent pathway (35). 
Cell Membrane 
f intracellular 
Figure 1. Relaxation of smooth muscle cell by ANF and NO. R, receptor; ANF, atrial natriuretic 
factor; NO, nilric oxide; part GC, particulate guanylyl cyclase; sol GC, soluble guanylyl cyclase; 
cGMP-PK, cGMP-dependent protein kinase. 
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Though cGMP is the major second messenger for ANF's biological effects, 
cGMP is not thought to be second messenger in all tissues responding to ANF 
Several responses to ANF are evoked without the cGMP-signalhng pathway, but 
via alternative pathways, inhibition of adenylate cyclase in arterial tissue (36) and 
in pituitary homogenates, cultured cardiocytes and platelet membranes (37-39) 
The exact mechanisms involved in all actions of ANF, and the various receptor 
subtypes eliciting these functions are only partially known 
ANF-induced effects 
Renal action 
ANF evokes a marked enhancement of renal solute and free water excretion and 
firmly diminishes renin release (40,41). Although most studies have been 
performed using pharmacologic doses of the polypeptide, ANF can evoke a 
natnuresis and diuresis at physiological concentrations (42) The administration 
of antisera directed against ANF reduces urine volume and sodium excretion 
(43), indicating that physiologically circulating concentrations of endogenous ANF 
continuously stimulate diuresis and sodium excretion. 
It is generally accepted, that ANF ' increases the filtration fraction and the 
glomerular filtration rate (by means of a preglomerular arteriolar dilation and 
postglomerular arteriolar constriction) (44), 2) inhibits the net sodium 
reabsorption (in the proximal tubule), 3) inhibits the renin secretion (in the 
macula densa) and thus indirectly the adrenal release of aldosterone (45), but 
also inhibits the aldosterone release via a direct effect (in the adrenal), 4) inhibits 
the vasopressin-mediated water reabsorption (in the cortical collecting duct) in 
the kidney, by directly suppressing plasma arginine vasopressin levels (46) and by 
inhibiting the hydraulic conductivity response to arginine vasopressin, and ) 
inhibits the net sodium reabsorption (in the cortical and inner medullary 
collecting duct) 
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The ANF-induced effects are opposite to those of the renin-angiotensin-
aldosterone system (RAAS) (47). The close relationship between ANF and 
RAAS regulation is funded by the complementary localization of their receptors 
in brain, adrenal gland, vasculature and kidney (48). Following most stimulations 
reciprocal changes are observed in RAAS on the one hand and ANF on the 
other hand. Both systems are simultaneously activated in cases of physical 
exercise and in hepatic cirrhosis. Thus, ANF may be considered as the 
endogenous functional antagonist of the RAAS, thereby allowing fine-tuning of 
volume and pressure by the body. 
Cardiovascular action 
The family of natriuretic peptides plays an important role in the physiology of 
cardiovascular homeostasis as can be deduced from studies in which ANF-
antisera are administered (49). In most experiments however, the acute 
hemodynamic effects of high doses of ANF are explored. Summarizing all these 
studies, ANF serves to defend the central circulation from acute volume but 
perhaps also from pressure overload by decreasing venous return with a decrease 
in cardiac filling pressures and cardiac output, before a state of dehydration is 
obtained yet. In figure 2 a schematic presentation shows the central role of ANF 
in the defense of the central circulation against an increase of the extracellular 
central volume (ECV). When the ECV increases the atria become distended 
leading to elevation of the ANF plasma concentration. Before reaching the 
systemic circulation, the major part of secreted ANF must pass through the lung 
circulation where the vascular resistance is reduced in order to minimize 
pulmonary passing time. Arrival of ANF into the systemic circulation will lead to 
effects on blood pressure (BP) via > a modulation of the autonomic nervous 
system, 2) a decrease of the cardiac output (CO), 3) a decrease of the total 
peripheral resistance (TPR), 4) a reduction of the intravascular fluid volume by a^ 
a stimulation of the renal diuresis/natriuresis, > an inhibition of RAAS and c ' a 
microvascular extravasation, (figure 2.) Thus, by stimulating the ANF system the 
heart is capable to modulate its own work loading conditions. 
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Figure 2. Schematic drawing of ihe effects of an elevation of the ANF plasma concentration on 
different regulatory systems and blood pressure (BP). 
In studies using pharmacological dosages, ANF induces a fall in blood 
pressure. This fall in blood pressure is mediated by the reduction of cardiac 
output, cardiac afterload and cardiac preload coupled with a decrease in venous 
return, which is at least partly due to a shift in fluid volume from the 
intravascular into the extravascular compartment (50,51). Lower ANF doses, 
leading to plasma levels in the physiological range, elicit a natriuresis and diuresis 
together with a fall in blood pressure when infused for several days (52). 
Baroreflex-modulating action 
Cardiac sensory receptors with vagal afférents are important contributors in 
maintaining the homeostasis of the circulation. Established modulators of these 
receptors are calcium antagonists, cardiac glycosides, vasopressin (ADH) or 
alterations in the sodium balance (53). A role for ANF in baroreflex functioning 
is claimed, since in several studies exogenous ANF reduces blood pressure 
without simultaneously raising the heart rate. These assumptions are 
strengthened by the demonstration of ANF and its receptors in certain cerebral 
areas, as well as in the aortic baroreceptor unit (54,55). 
Hemodynamic changes induced by ANF (decreased arterial and central 
venous pressure) reflexively cause an increase in sympathetic nerve activity and 
an acceleration of heart rate, opposing the direct volume-depleting effects of 
ANF. Therefore, in vivo studies investigating the sympathetic nervous system are 
complex to interpret, as reflex changes in sympathetic nerve activity are a 
function of competing influences of altered reflex control by ANF and hemo-
dynamic changes. The systemic administration of ANF reveals its sympatho-
inhibitory action (56), which may be abolished by bilateral vagal sectioning. The 
sympathoinhibitory effect therefore, seems to be mediated by the activation of 
afferent vagal activity (57,58). The activation of vagal afférents by ANF attenua-
ted arterial baroreceptor reflex control of heart rate. Distinct from an attenuated 
reflex tachycardia, ANF was also demonstrated to augment reflex bradycardia 
(59). There are still questions to be answered upon the mechanisms by which 
ANF increases vagal influences on the heart. It is suggested however, that the 
increased vagal activity induced by ANF may be related to a functional anta-
gonism of a central and/or peripheral vagolytic effect of angiotensin II (60,61). 
However, it remains to be determined whether this interaction occurs on the 
level of the central nervous system, the ganglion, the adrenergic nerve terminal 
or combinations of them. 
Action on the lung circulation 
Though systemic vascular responses to ANF have been extensively investigated, 
the lung circulation has received much less attention with respect to ANF-
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dependent vascular tone regulation However, several observations point to an 
important role for ANF in the lung circulation ANF is primarily delivered to the 
lungs, being the first organ through which right atrial blood passes In man high 
circulating concentrations of ANF are found in pulmonary arteries (62) In vivo 
experiments in animal models, reveal that up to 60% of administered ANF is 
removed after one single passage through the lungs following a bolus injection 
(63). Pulmonary clearance is reported to be about 5-times higher than renal or 
splanchnic clearance (64). The pulmonary vasculature contains specific receptors 
for ANF (17). Functionally, in isolated vascular lung preparations a dose-
dependent dilation can be evoked by the administration of ANF (65). A 
comparative study on the vasodilator potency between pulmonary and systemic 
vessels may reveal a modulator role of ANF in the lung circulation 
Fluid-shifting action 
De Bold et al. were the first to describe hemoconcentration following infusion of 
natriuretic atrial extracts (10). In more recent studies ANF appeared to produce 
a fluid shift from the intravascular compartment to the interstitial space in­
dependent of any renal mechanism (66) This leads to hemoconcentration and 
decreased plasma volume ANF directly and reversibly elevates capillary hydrau­
lic conductivity (67) and increases postcapillary resistance (68), but the precise 
mechanism is still debated. The ANF induced fluid and protein shift out of the 
intravascular compartment, is not supposed to be selective with respect to 
various peripheral vascular beds (69). Whether or not such shifts occur, depends 
on the local circulatory ANF concentration (70). Ал interesting but perhaps 
somewhat contradictory finding is that ANF, in pharmacological concentrations, 
may protect the lungs by actually preventing pulmonary albumin escape (70) 
The precise mechanism and significance of the ANF-induced fluid shift remain 
yet to be elucidated 
Metabolism 
Two mechanisms have received most consideration with regard to ANF's inacti-
vation: ) receptor-mediated clearance, and ) enzymatic degradation via the 
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neutral metallo-endopeptidase (NEP), a membrane-bound, zinc-containing hydro­
lase. The relative roles of these mechanisms, under both normal conditions and 
under conditions with enhanced endogenous ANF levels, are not yet fully eluci­
dated. Under physiological conditions however, the receptor-mediated clearance 
appears to be the predominant mechanism of inactivation (71). The C-ANF 
receptor acts via rapid internalization of receptor-bound ANF (72), and a 
subsequent degradation. At higher concentration, ANF also binds to the NEP, 
characterized by a Michaelis-Menten constant (Km) of about 6 μΜ (73), indica­
ting that at higher concentrations both receptor and enzymatic clearance are 
operative. 
There is a discrepancy between the inactivation of ANF in blood in vitro 
and in vivo. ANF is characterized by a relative stability in blood in vitro. The 
slow degradation of ANF in vitro, being about 10% in 30 minutes, indicates that 
blood components do not contribute essentially to the rapid disappearance of 
ANF in vivo (74). The in vivo disappearance of ANF is best fitted by a bi-
exponential plasma decay curve. Plasma half lives of the first phase range 
between 1.2 and 4.7 minutes in man (75-78). The shorter plasma half lives, 
probably resulting from analyzing only the fast component of the plasma decay 
curve, account for about 90% of ANF removal. 
In vivo extraction studies demonstrate that ANF is cleared from the circula­
tion in the pulmonary, splanchnic/hepatic and renal vascular beds. In an animal 
study, Tang et al. found the rank order of degradative potency to be: kidney > 
liver > lung > plasma > heart (74). The kidneys play the major role by extrac­
ting approximately 70% of the presented ANF. The renal brush border appears 
to be rich of NEP, which in vitro is responsible for the degradation of ANF (73). 
Since a widespread distribution on plasma membranes has been demonstrated 
for NEP (79), enzyme-linked degradation of ANF may well occur at other sites 
as well. Major enzyme activity further has been found in the brain and lungs 
(80). In dogs, there are conditions in which enzyme activity diminishes under 
pathological situations such as acute congestive heart failure (81). 
11 
Modulation of the ANF system 
Several ways have been found to influence the ANF system. Of these, the 
inhibition of the ANF-degrading endopeptidase was most promising with respect 
to therapeutic usage (82). Thereby, plasma ANF half-life increased, and 
consequently ANF plasma concentration rose. Less promising has been the 
development of peptide analogues with prolonged half time, as the analogue had 
lost ANF-related biologic activity (83). 
Pharmacological agents may potentiate the ANF-induced effects Such 
potentiation has been described for the potassium-sparing diuretic amilonde. 
Amiloride increases the sensitivity of particulate GC to ANF (84). Further 
research in this field may be of clinical importance. 
Sensitivity studies in normal ageing 
Human ageing is associated with increases m (systolic) blood pressure, decreases 
in renal function with associated impairment in the ability to excrete salt and 
water loads, and with decreased levels of renin and aldosterone (85-87). In man 
higher circulating plasma levels of ANF have been found with advancing age 
(88,89). At least partly, this may be based on alterations in ANF pharmaco-
kinetics occurring with normal ageing. Therefore a study to the in vivo human 
sensitivity for ANF may be relevant. 
Chronic exposure to increased circulating plasma levels of ANF may well 
lead to decreased responsiveness for ANF. As a marker for ANF sensitivity one 
may examine ^ the density of ANF receptors, 2) the réponse of ANF's second 
messenger system, and ' the response of ANF-induced biological effects. Investi-
gating the sensitivity for ANF may be of pathophysiological relevance in cases 
of chronic elevation of ANF plasma levels, as well as of clinical importance 
before the introduction of new classes of drugs, especially those acting via the 
elevation of ANF concentrations in plasma. 
Receptor density studies 
Down-regulation of ANF receptors has been reported in rat vascular smooth 
muscle cell following exposure to elevated ANF levels, and in renal cortices after 
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the experimental induction of diabetes mellitus (90,91). Hypertension has been 
demonstrated to be associated with a decreased number of vascular ANF binding 
sites in rats (92), although this could not be confirmed in human hypertension 
(93). The administration of angiotensin II has recently been demonstrated to 
induce down-regulation of glomerular and vascular ANF receptor subtypes in rat, 
probably by increasing the plasma ANF levels (94). 
Second messenger response studies 
In vitro experiments with cultured vascular smooth muscle cells demonstrate that 
exposure to elevated ANF concentrations, is capable to induce diminished cGMP 
production, even when exposed for less than 24 hours (95). There are however 
conflicting data with regard to the regulation of ANF receptor density, resulting 
from studies in which the cGMP production following the ANF-induced GC 
stimulation is measured (91,96,97). 
Biological response studies 
Quite elegantly, one may attempt to provide arguments on the point of the 
sensitivity for ANF by investigating its biological effects. It is clear that this is an 
indirect method and thus may be confounded by other variables. 
Whether the increase in circulating ANF plasma concentration itself is 
directly involved in down-regulation in vivo, remains questionable. Details about 
the in vivo self regulation of the ANF receptors by ANF plasma concentrations 
remain to be elucidated. For example, is each type of ANF receptor, in each 
tissue prone to be affected? After which period of exposure does regulation of 
the ANF receptor density occur? 
Insulin-dependent diabetes mellitus and ANF 
Patients with insulin-dependent diabetes mellitus (IDDM) have an expanded 
extracellular volume, even before the development of hypertension or micro-
albuminuria (98). The expansion in extracellular volume is associated with 
sodium retention and an enlarged total body sodium pool. Interestingly, the 
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glomerular filtration rate (GFR) is elevated in approximately 30% of IDDM 
patients (99) Systemic hypennsulinemia, resulting from peripheral insulin 
administration, may play a role in the increased renal sodium reabsorption in 
IDDM. The role for ANF in the pathogenesis of sodium retention in IDDM has 
not yet been determined. Indeed, increased baseline plasma levels of ANF have 
been reported in IDDM (КЮ). Impaired biological responses from the kidneys 
following water immersion, sodium loading or exogenous ANF administration are 
reported in diabetes mellitus (98,101-103) Whether in IDDM the peripheral 
vasodilator effect of ANF is abnormal too, remains to be elucidated. 
Aim of the present studies 
In this thesis we will focus on the acute in vivo effects of ANF on several 
hemodynamic and microcirculatory parameters. All the present studies were 
confined to the short-term effects of ANF 
The human in vivo investigations were preceded by an animal in vitro study 
comparing the vasodilator effect of ANF on pulmonary and renal vasculature-
chapter 2. 
All human studies from chapter 3 - 6 compared the responses between a 
group of healthy elderly and a group of healthy young volunteers In chapter 3 
the pharmacokinetics of ANF were studied following the elevation of ANF to 
pharmacological plasma levels by means of an exogenous ANF infusion In the 
same session it was investigated whether ANF induced any vasodilation in 
normal human skin: chapter 4. To improve our understanding about the pheno­
menon that the ANF plasma level gradually rises with advancing age, we further 
investigated whether ageing was accompanied with an impaired ANF-dependent 
vasodilator effect in chapter 5 the hemodynamic responses to ANF were studied 
following the ANF administration using the intravenous route, in the same 
experimental session as used in chapter 3. In a separate experimental design with 
a new group of healthy human subjects, the forearm vasodilator potency of ANF 
was studied following the locoregional, intra-artenal route of ANF 
administration chapter 6. 
In insulin-dependent diabetes mellitus elevated ANF plasma concentrations 
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were reported to be associated with an impaired diuretic/natriuretic response. An 
identical experimental design as in chapter 6 was used in the study of chapter 7 
with a group of IDDM patients without manifest microcirculatory complications. 
In a distinct human in vivo study we investigated the effects elicited by 
ANF on the vascular adrenergic nerve terminal; via a central, possibly even 
ganglionic pathway ANF was supposed to evoke sympathoinhibitory effects. By 
infusing ANF locoregionally, one might differentiate non-peripheral from peri-
pheral effects at the neuroeffector junction. The vascular neuroeffector junction 
was examined functionally, following a sympathostimulation test, i.e. lower body 
negative pressure (LBNP): chapter 8. 
Therefore we have formulated the following questions: 
1) Do atrial peptides have vasodilator effects in the pulmonary vasculature, in 
vitro ? (chapter 2) 
2) Is advancing age accompanied with alterations in ANF pharmacokinetics ? 
(chapter 3) 
3) Does ANF evoke acute (within 1 hour) microcirculatory effects in human 
skin, in vivo, and is there an influence of age ? (chapter 4) 
4) Does ANF evoke acute (within 1 hour) hemodynamic effects, in humans, in 
vivo, and is there an influence of age ? (chapter 5) 
5) Is human ageing accompanied by a reduced vasodilator response to ANF ? 
(chapter 6) 
6) Is uncomplicated IDDM accompanied by a reduced vasodilator response to 
ANF ? (chapter 7) 
7) Does ANF modulate the baroreceptor-induced reflex at the level of the 
vascular adrenergic nerve terminal ? (chapter 8) 
In this thesis the abbreviations ANF and ANP are both used to designate the 
atrial natriuretic factor or peptide in accordance with the original papers. The 
author apologizes for this mixture in nomenclature. He wishes to emphasize that 
the abbreviation of ANP is not in accordance with ANF nomenclature consensus 
designation. 
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CHAPTER 2 
A comparison of the vasodilator responses to atrial natriuretic 
peptides in the pulmonary and renal arteries of the pig in vitro 
(Reproduced with permission from: 
Br J Pharmac 1987; 91: 687-91) 
A comparison of the vasodilator responses to atrial 
peptides in the pulmonary and renal arteries of the pig 
in vitro 
' Tim L.Th.A. Jansen, 2Alyn H. Morice & Morris J. Brown 
Clinical Pharmacology Unit, Addenbrooke's Hospital, Hills Road, Cambridge CB2 2QQ 
1 Noradrenaline preconstricted pulmonary and renal artery segments from 20 large White pigs were 
examined in vitro for their responses to α-human atrial natriuretic peptide (a-hANP), rat-atnopeptin I 
(AP I) or rat-atnopeptin III (AP III) added in a cumulative manner The role of the vascular 
endothelium in atrial peptide-induced relaxation was examined in the presence of indomethacin and 
propranolol by removal of the endothelium in one of a pair of arterial segments 
2 Pulmonary artery was significantly (P < 0 001) more sensitive than renal artery to a-hANP with а 
potency ratio of approximately 10. a-hANP appeared to be a more potent relaxant than AP III and AP 
I in pulmonary artery Potency ratios were approximately 2 (AP III vs a-hANP, Ρ < 0.05) and 30 (AP I 
vsa-ANP; / > < 0 001) 
3 Removal of the endothelium increased the sensitivity of renal artery to a a-hANP, but made no 
difference to the pulmonary arterial relaxations 
4 In man the highest circulating concentrations of ANP are found in the pulmonary artery The 
demonstration of its potent relaxant effects at this site in the pig indicates a possible role in the 
modulation of pulmonary arterial tone 
Introduction Methods 
Atrial myoctyes release in response to distension a 
peptide, atrial natriuretic peptide (ANP) (DeBold et 
al, 1981, Dietz, 1984), which has potent natriuretic 
and vasodilator properties (Garcia et al, 1985; 
Needleman & Greenwald, 1986, Waldhausl et al, 
1986) In man the highest circulating concentrations of 
ANP arc found in pulmonary arteries (Richards et al. 
1986) We hypothesized that A N P may have a role in 
the regulation of pulmonary artery tone in response to 
volume load and have therefore investigated the in 
vitro responsiveness of preconstricted arterial rings to 
ANP and the closely related peptides rat-atnopeptin I 
(AP I) and rat-atnopeptin III (AP III) We have also 
investigated the role of the vascular endothelium in 
these responses, in both the renal and pulmonary 
artery, in order to determine whether smooth-muscle 
relaxation induced by atrial peptides is mediated via 
the recently discovered endothehum-derived relaxing 
factor (EDRF) (Furchgott et al, 1984) 
1
 Present address University of Nijmegen. The Netherlands 
'Author for Correspondence 
Twenty Large White pigs, 6 months old, were killed by 
electric shock at the local abattoir The pulmonary and 
renal arteries were carefully removed immediately post 
mortem and placed in aerated, room temperature, 
Krebs solution of the following composition (in mM) 
K H 2 P 0 4 1 2, MgS0 4 7H,0, 1 2, KCl 4.7, glucose 111, 
N a H C O , 25 0, NaCl 118, CaCl, 2 H 2 0 2 6 Those rings 
which were not used immediately were stored in a 
refrigerator ( + 4°C) for up to 48 h 
Experimental procedures 
Main, hilar and segmental pulmonary arteries were 
examined, the latter being carefully dissected to the 
adventitia, clear of surrounding lung parenchyma. 
Renal vessels were removed en bloc and segments 
subsequently dissected from the main renal artery 
Arterial rings with internal diameter 0 5 to 1 5 cm were 
mounted in 2 ml baths with cotton thread and immer­
sed in aerated Krebs solution at 36 0 ± 0 5°C 
Isometric tension was measured by Grass force-dis­
placement transducers FT03D, connected to Hugo 
Sachs strain gauge couplers and continuously recor-
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ded on a chart recorder mark VII, lype WR 3101 
(Watanabe Instr Corp) The rings were subjected to a 
passive tension of 1 g and allowed to equilibrate for 
45 mm before the addition of any drugs After 
equilibration noradrenaline (NA) was added in a 
cumulative fashion in final bath concentrations from 
100 пм to 3μΜ, the latter concentration of which 
produced a submaximal contraction and a similar 
degree of contractile preload in both renal and pul­
monary vessels ANP, AP 1 or AP III were then added 
in a cumulative fashion in bath concentrations from 
lOnM to 300 пм 
The role of the vascular endothelium in the relaxa­
tion produced by atrial peptides was investigated by 
removal of the intimai surface in one of a pair of 
segments Removal was performed by gentle rubbing 
of the internal surface of the vessels with a wooden 
stick To demonstrate the completeness of this 
procedure the rings were exposed to acetylcholine 
(ACh, ΙΟμΜ) at the end of each experiment 
All experiments were peformed in the presence of 
indomethacin (ΙΟμΜ) and propranolol (8μΜ) All 
vascular strips were used only once in quantitative 
measurements In order to demonstrate adequate 
vascular responsiveness, NA dose-response c u n e s 
were obtained in each preparation 
Results are expressed in terms ofpercentage change 
of the contractile tension induced by 3μΜ NA, a 
relaxation being a positive percentage Data, expres­
sed as a mean percentage of relaxation with its 
standard error (s e ), consist of 8 groups containing 6 
different arterial strips Comparison of the data was 
performed by a two-way analysis of variance Sig­
nificance was accepted at the 0 05 level of probability 
Drugs 
The atrial peptides were obtained from Cambridge 
Research Biochemicals, Harston, Cambridge, and 
reconstituted allowing for percentage purity (peptide 
contents were a-hANP, 78%, AP III, 75%, AP I, 
75%) All other chemicals were of analytic grade The 
inorganic salts of the Krebs solution were obtained 
from Fisons PLC, except calcium chloride which was 
obtained from BDH Noradrenaline (Arterenol), 
acetylcholine (acetylcholine chloride), indomethacin 
and propranolol were obtained from Sigma 
Results 
Vasodilator responses to ANP 
A N P potently relaxed the NA-preconstricted renal 
and pulmonary arteries of the pig Relaxation was 
concentration-dependent, slow in onset and sustained 
(Figure 1) Maximum relaxation was obtained within 
« « t * 
0 1 1 3 
0 3 
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10 30 100 
«-hANP 
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10 m m 
Figure 1 Vasodilator effects of α-human atrial 
natriuretic peptide (ot-hANP) on pig pulmonary arlery 
The record is an original tracing Doses of «-hANP 
(cumulative concentrations in пм) were applied after a 
dose-response curve had been obtained to noradrenaline 
(NA), represented in the figure by arrows (cumulative 
concentrations in μΜ) 
5 min and lasted in excess of 20 mm Control segments 
preconstneted with 3μΜ NA showed a mean loss of 
constrictor tone over the duration of the experiment ot 
less than 10% (n = 6) ANP was significantly more 
potent at relaxing pulmonary arlery when compared 
with renal artery at all doses ( Я < 0 001) and the 
potency ratio at 40% of relaxation was approximately 
10 (и = 24) (Figure 2) 
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Figure 2 Dose-response curves obtained in pulmonary 
artery (D η = 12), pooled with and without endothelium 
and renal arlery (• η = 6) with endothelium to «-human 
atrial natriuretic peptide (a-hANP) Data are presented 
as mean values, vertical lines show s e a-hANP was 
added in a cumulative fashion lo arteries preconstneted 
with noradrenaline (3 μΜ) in the presence of indometh­
acin and propranolol 
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Table 1 The effect of endothelial removal on the vasorelaxant responses to atrial peptides of pulmonary and renal 
arteries in the pig 
Encloih >hum 
Renal artery 
A N P 
Pulmonary a 
ANP 
AP III 
AP I 
+ 
-
rtery 
+ 
-
+ 
-
+ 
-
η 
6 
6 
6 
6 
6 
4 
6 
6 
IO 
4(1) 
18(4) 
44(10) 
36(11) 
21(2) 
27(5) 
2(1) 
8(1) 
Concentration (пм) 
30 
16(4) 
33(5) · 
62(7) 
61(9) 
47(2) 
Я (4) 
9(2) 
20(3) · 
100 
35(5) 
56(6)* 
81(4) 
83(6) 
68(4) 
78(3) 
5(1) 
2 9 ( 4 ) " 
300 
60(9) 
91(9)*** 
99(3) 
111(6) 
83(5) 
94(3) 
38(7) 
52(8)* 
Results are expressed as mean % relaxation or noradrenaline preconstnction with s e in parentheses 
* / " < 0 0 5 " P < 0 0 l *** ƒ" < 0 001 significantly different from endothelium intact preparation ANP = α human 
atrial natriuretic peptide ΛΡ III = atnopeptin III and API =atnopeptin I 
The role of endothelium in \asodilator responses to 
artrial peptides 
Removal of the vascular endothelium, as demon­
strated by failure to relax in response to 10μΜ AC h 
made no significant difference to the responses of 
pulmonary artery to ANP and AP III The data from 
these studies have therefore been pooled for further 
analysis 
A slight increase in sensitivity to AP I occurred in 
rubbed pulmonary artery when compared with the 
cndothehum-intact segments Renal artery relaxed 
slightly but significantly moie to ANP after removal of 
the vasculai endothelium the higher the concentra 
Hon the more significant the differences were (Table 
I) Where endothelial removal caused a significant 
difference in response data Irom endothelium intact 
segments have been used to calculate potency ratios 
Vasodilator responses m pulmonar \ arter\ to atrial 
peptides ANP AP UI and API 
The closely related atrial peptides AP I and AP III 
produced potent relaxation of the pulmonary artery 
segments AP I was, however, significantly less potent 
that AP III and APIII was significantly less potent 
than ANP (Figure 3) Potency ratios at 40% relaxa­
tion were approximately 30 ( P < 0 001) for AP I vs 
ANP and 2 (P < 0 05) for AP III vs ANP API and AP 
III produced, in some segments, a brief period of 
relaxation of less than 3 mm followed by a return to 
constriction ( 15 and 30%, respectively η = 5 for AP I 
and η = 11 for AP III) These atypical results have 
been excluded from analysis but warrant further 
investigation 
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Figure 3 Vasorelaxant potencies of various atrial pep 
tides α human atrial natriuretic peptide (ot hANP Π 
η = Ι2) atnopeptin III (APIII Ο η = 10) and atriopep 
tin I (API 9 η = 6) in pig pulmonary artery Each point 
represents the mean (vertical lines show s e ) of data 
pooled regardless of the state ol the endothelium except 
for the AP I responses which arc those of pulmonary 
artery preparations with endothelium 
Discussion 
Following the discovery of peptide-containing gran­
ules in the atrial myocytes and the demonstration of 
the potent natriuretic and vasodilator properlies of rat 
atrial extracts (De Bold et al, 1981 ), ANP, a 28 amino 
acid peptide containing a disulphide bridge, has been 
hypothesized to be the major circulating hormone of 
the family ofpeptides which may be extracted from the 
atria (Schwartz et al, 1985) Infusions of synthetic 
ANP in animals and man lead to a natnuresis and 
diuresis and at higher infusion rates a fall in blood 
pressure is observed (Kangawa & Matsuo, 1984, 
Garcia et al, 1985, Waldhausl et al, 1986) Precon-
strictcd, isolated, vascular tissues respond to applica­
tion of ANP by a relaxation which appears to be 
mediated by activation of guanylale cyclase (Furch-
gott&Jothianandan, 1983, Rapoport& Murad, 1983, 
Furchgott et al, 1984, Hirata et α/, 1985) In man 
circulating levels of ANP are highest in the pulmonary 
artery, hence, we examined the responses of pulmon­
ary artery and compared these with the responses of a 
systemic artery of similar size, the renal artery 
Our finding that a given concentration of ANP 
relaxes pulmonary artery significantly more than it 
does renal artery suggests a possible role of ANP in the 
modulation of pulmonary vascular tone at concentra­
tions which arc unlikely to affect systemic blood 
pressure ANP is released in response to a fluid load 
and the stimulus for release is thought to be right atrial 
distension The modulation of pulmonary vascular 
resistance in response to fluid load would be a useful 
mechanism in the control of left atrial pressure 
Other atrial peptides have been shown to be released 
into the circulation in animals and we have therefore 
examined Ihe effect on the pulmonary artery of the two 
atrial peptides most closely related to ANP AP III 
differs from ANP by the loss of 4 amino acids on the 
N terminal (Geller et ui 1984, Kangawa & Matsuo, 
1984) Ral AP III was used in these experiments and 
this differs from human AP III in respect of an 
ìsoleucine substitution Tor methionine at position 12 
(Kangawa er я/ 1984) AP I differs from AP III by the 
loss of a further 3 amino acids on the C-terminal 
(Geller et al 1984) Both peptides siili contain the 
cystine disulphide bridge which is essential for its 
biological activity (Misono et al 1984 Hirata et al 
1985) and the Phe-Arg sequence in the carboxyl 
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CHAPTER 3 
Kinetics of atrial natriuretic peptide in young and elderly subjects 
(Reproduced with permission from: 
Eur J Clin Pharmacol 1992; 42: 449-52) 
Kinetics of atrial natriuretic peptide in young and elderly subjects 
A.C.I .T.L.Tan l ,T. I . .Th.A.Jünsen-\ E.F.S.Termond', ^.G.M.Rus^el^Th.Th¡en : , P.W.C.KIoppenborg', 
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Pharmaeolonv and M I A I I U I K Division ol Lndoermolnev Si Radboud I kapi ta l I mversilv ol \ i imegen Niimegeii I he Netherlands 
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Summary losiudv the inlluencc ofagc on the kinetics ol 
atrial natriuretic peptide ( A N P ) in man human (99-
126)ANP 2 0 ng min ' was nilused IV lor 6() min m 8 
heallhv young (18 to 25 v) and 9 healthy elderlv (71 to 
,44 \ ) subjects 
Both baseline A N P salues and the levels at the end ol 
inlusion were higher in the elderlv sub|ccts The mean 
residence lime ol A N P in (he two age groups was not 
significantly diflerent whereas total body clearance (C I ) 
was markedly diminished in the elderly as compared to 
the voung sublets (mean ± SD 3 1 ± 1 0 I mm ' and 6 2 
± 4 11 min respectively) I he apparent volume ol 
distribution at sleadv stale was lower in the elderly than 
in the young bul the dille re nee was nol signilicant (mean 
± SD 44 ± Í9 and 103 ±111 respectively Ì he decrease in 
С I largely explained the higher A N P levels lound in 
the elderly subjects The М К Г and the plasma hall life 
of the terminal phase did not differ between the two 
groups 
In the elderly but not in the young sub|eets the calcu­
lated endogenous creatinine clearance was closely coi-
relaled with the C L (r = 0 40 I' < 0 001 ). therebv empha-
si/ing Ihe importance ol Ihe kidnev in the metabolic 
clearance ol A N P in the elderly 
Key words: Atrial natriuretic peptide, kinetics ageing 
Atrial nalnuict ic peptide ( A N P ) is a hormone secrelLd 
bv the heart II possesses potent diuretic natriuretic and 
vasorelaving activities | l . 2] Ihe short-lasting eflccl ol 
Λ Ν Ρ suggests rapid clearance o l the peptide several in 
vestigators have observed a plasma half life ol only a few 
minutes in man [3 4 5] Plasma levels ol Λ Ν Ρ arc higher 
in elderly than in voung sub|ects [6. 7| It was hvpo-
thesi/ed thai Ihe higher levels might well be induced by 
decreased clearance ol A N P in elderly sub|cels Io inves­
tigate this possibility the kinetic parameters of A N P have 
been studied in 8 healthy young and 9 healthy elderly 
subjects 
Materials and methods 
The studv proUx.nl wasapptoved bv Ihe local I Iospn.il I ihiLs Com 
millL'L Alter ці іпц informed eonscnl 8 hcallllv voung (agL 18 lo 
2S ν 4 m ami 4 I) and У healths elderlv (agi. 71 ioX-1 ν 4 m and s I) 
subiscls noitakinganv meelicalion parliupali-d mine studv P R O N O 
il a ph ν sie al examination was pet lormed to e\elude .inν e \isl nitidis 
ease in parlieulareardiovaseul.il renal or endocrine disorders 
( 9 и l2f>)hANP was purchased Irom Bisscntlorl Peptide O m h H 
Wcderni.uk 1 RO This peptide eorrcsponils lo ihe bioactivc pep 
tide circulating in humans [I 2) A l terant) mm equilibration permei 
in the supine position Λ Ν Ρ 121) μii dissolved in 4<S 0 ml H.iemaeeel 
was inluseel m m an anleeubil.il vein over nO mm at 2 О ЦП nun 
Ulood lor Ihe détermination ol Λ Ν Ρ was sampled M\ mm before and 
Itisi pnoi to ihe mlusion at 1 s 10 4s ,md 60 minutes durine the inlu 
sion and I 1 s 7 |(| |S 20 «I 4(1 and ( idmm aller it had ended 
Rlood samples lor Λ Ν Ρ de le т и п а I ion were eollecleel Irom a venous 
cannula in Ihe eoniralalcial aim placed in ehilleel I D I A v.ieiium 
lubes kepi on lee ее 111 Π fulled vvilhin I h ( I SIK) χ ц 4 ( 10 mm »and 
storeel at St) С in aliquota enniaimnu 200 M l ol aproiinin ml 
plasma pending analvsis 
1000-, 
100-
ANP 2цд/тіп 
30 0 30 90 
Time 
Fig. 1. Plasma A N P (log sea le) be I ore during and alter infusion ol 
(9°-Ι2η)Ι ιΛΝΡ Ί 0 Mg/m ι η in voung and elderly suh|ccts Mcdn with 
SEM Λ Ν Ρ levels minus Ihe baseline values were used tor calcula 
l ion ol Ihe ph.imidcokincue parameters · voung subjects O el 
elerlv sub|eets 
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I L I L I index Ρ \ iluc between eioups 7 ' < l ) 0 i /> m i l 
NS non slamili, ml 
ihc lo i i l imouni ol A N P intused b\ ihc ire ι under UIL concenlr i 
l ion urne curve ( A L O The A l Γ ( loeir i l l inuc I r i p c / o i d i l 
method) w i» determined from the A N P concei i imion il I 0 
(niiniis Insellile \ N P \ ilue) unni Ihc A N P conccii l idl ion il 
ι PO nun (minus b isehne ANP \ ilue) ind evlr ipol lied aller e il 
cul mn > lliL k r u i m il slope In regression m iks ison the Lui k w loe 
I I I IL ir concentration linie pomls I sum ι smul ir method ih«, i r e i 
under lliL moment curve ( A I M O wis ι. i k u l iteci Ι he m e i n 
residence lime ( M R T ) was Uien obiaii ied Irom ih«, lormul ι 
M M( \L ( I ' where Τ is ihc duranonoí infusion T I n ι pp ir 
(.ni \olunit. t i l disinbuhon il sic id\ stale (V ) was calculated ísihc 
piodULl ol M R I ImiLs ( 1 The chmm ilion h ill l i k ( ι ) was c i t i 
m i k d Irom OIL k r m i n i l slopL ol the semilog i r i l h m k concentr i 
l ion lime curée T I I L endogenous crcit ininc clear mee (1 ( ( ) w is 
e ilcul lied Irom ItiL SLrumcrcatiniiie level corrected for ige SL \ ind 
hod\ WLiLhl [10] ind Ihcn normalized for the hod\ suifaLL ire 1111 ] 
Suitisiiuil tiiiul\\i\ 
ANP w is me isiircd is prLwousk described [S] Ι π bru. E 1 0 ml 
ILKIIMLLI pi ism ι w is ippliLd [ο ι SLpp ík С IK column cluted md 
OIL pLpluk snbsLi|iiLiul\ г idioiminunoass i\Ld in ι non Lt|uilibrium 
iss ι\ usine ι hiehlv spLLiliL iniihodv raised in sheep md ι W L I I 
dclnicd nionoiodo i\ros\l II ICLT TllL sellsltlvllV ОІ lile Iss l\ W is 
DSp per lu lu (correspondu!, io 4 pu ml p l u m ι) ind гесо\сі\ 
l\cr leed 4b I ill г I mil 111 k r iss IV COelllclenls ol V 1Г1 Ilion Were 
s b niel 11 b icspccmck Ml ι-)! ism is iniplcslronic ich person 
W L I L measured consccUll\el\ 111 lile Slnle Iss l\ lo minnill/c 1 111 г I 
md i n k r lssl\ ν in mon 
\s \NPcoiHLnirHions n i 120 nun did nol Ji I Ici l iomihosL 
il Minim IxlorL mlusion or Irom Ihosc pisi hdorL inlusion (I 0) 
lIlL IllL 111 ОІ lIlLSL ll l lcc \ lilies w Is Used Is lile b Ischnc \ N P V lille 
( A N P ) ANP ν llucs lowcl 111 in \ N P Welc considered lo bc 
el|UlllO \ N P 
No eh in.с in \ N P conccnlralions was observed d u m i . Ihc 
pi icebo inlusion I )| Al ler si ir l ing Ihe inlusion pi ism ι A N P con 
celili liions L|uiekk lose ind ippe ired lo re ich ι sic uk si ile il 
b() min (Γη. 1 ) For с ìlcul nions the ANP ν llucs il 4 i nul h() min 
were i\ei iced nid deliiiLd as A N P 1 sing a model independent 
ippro ich tin loi il bodv clear mec (CL) w i s calcul lied h\ dividine 
20 cO 60 80 100 
ECC ( m l / m n / 1 7 3 m 2 ) 
120 
I ij j 2 Rei itionship belwLLtl UIL loi il bodv de irance (C 1 ) ol Λ Ν Ρ 
nul tliL LiidouLiious CIL limine ele ir mec (1 С ( ) in \otine ( · ) nul 
clderK ( O (silhjLLtS 
1 he kinetic ρ ir i i i iLkrs in the NOunL and the cldcrk sub|ecb weic 
comp ned using the non ρ ir imelnc Wilcovon two sample lest ind 
the Spe inn in r ink coirci mon test Siunilie incc w ts assessed it the 
a 0 01 lc\el (two sided) A l l Vllues ire expressed Is nie in Willi 
(SD) except when mentioned Olile rw ISL NS IllL Ills noi sigillile ini 
Renili» 
I lie calculated endogenous creatinine clearance (hCC ) 
nomi il i/ed Uir hoch suilacc arca was markcdlv lower in 
the clderK subjects (\alucs rangine Mom M S lo 
6-4 I mi min 1 74 m ) as compared lo Ihc \ouni i 
suhjccls (\alucs ranging Irom 78 7 lo I 2 i Mill 
min ' I 74 m ) According lo the hlctatuic [12] these 
\ alucs aie normal lor sex and age 
В iscline A N P values (ANPi ) the values al Ihc end ol 
Ihc. A N P inlusion ( A N P ) and the A N P level al 120 min 
were significantly higher in the elderly (Tig 1 ) The me in 
residence lime ( M R T ) of A N P was similai m both gmups 
(young range 8 1 to 24 9 elderlv range 10 4 to 17 1 NS) 
Ihc t o n i bodv clearance (( L voung range 4 24 to 
14 41 min elderly range 1 1 8 t o 4 s 9 1 mm /><0()S) 
was m irkccllv diminished in the elderly subjects ( 1 able 1 ) 
The apparent volume ot distribution at stcadv stale (V ) 
was numcncalK lower in the cldcrlv but varied markcdlv 
in the group ot voung subjects and no s t a t i s t i c a l signtti 
cant group dil lcrcncc was round (voung range 27 6 to 
isS 1 cldcrlv lange 12 2 lo 66 6 1) The two sub|ccts with 
Ihc highest С L had Ihc highest V 
Ihc plasma half life (t, ) ol Ihc cl ini inal ion phase ol 
A N P did not di l ler between the two groups (voting lange 
о I to 24 1 mm cldcrlv range 7 1 to 1 1 s mm NS) In ihc 
cldcrlv hut nol in the voungsuh|ccls a positive correi i l ion 
(voung r = 0»2 NS elderlv r = 0 90 P< 0001) was oh 
served between ihc calculated ЬСС and ihc Π ol Λ Ν Ρ 
( H e 2) 
Discussion 
В ischnc A N P levels in hcalthv elderly subjects weic n g 
nilicantly elevated as compared to those m healths voting 
subjects I his continus other reports lhat the A N P level 
29 
mercases with advancing age [6 7] Hevaled ANP values 
have been reported in several palhological conditions 
such as congestive heart failure [13| Acute elevation of 
endogenous ANP levels is considered to be a mechanism 
to protect the cardiovascular system Irom volume over­
load, by limiting stimulation of (he renin angiotensin 
aldosterone svstem and by mereasing renal sodium excrc 
tion. despite the hypotensive effect of ANP and by 
augmenting extravasation of fluid [1 2] Whether the 
gradual, chronic elevation ol ΛΝΡ with increasing age af­
fords the same protection is debatable as this would re­
quire that ANP retained the same potency with advancing 
age Since it has been demonstrated that the haemody-
namic potency of ANP was constant when comparing 
hcalthv voung and heallhv elderly sub|ccts [9] we suggest 
that the elevated plasma AN Ρ concentrations found in the 
elderlv so have the anticipated benelicial effects It then 
remains a prerequisite to study whether the pharmaco 
kinetic parameters have changed with normal ageing and 
it so whether the alterations could explain the age-related 
elevated ANP values Accordingly, the pharmacokinetics 
of ANP in young and elderlv subjects weie examined 
Using a model independent method, there was a mark 
edly diminished С L in the elderlv persons Looking at the 
values for CL and ANP,,, m Table 1 it can be calculated 
that the production rale (RM a) in the elderlv was 
approximately Ü 75 limes lower in the voung since for an 
endogenouslv produced peptide R,, j = CL χ sleadv 
stale-concentration (in this case ANP,,,.) It is suggested 
that the mam mechanism explaining ihe higher ANP, , 
levels in Ihc elderlv is a deci eased С 1 inlhcm 
A similar MRT was found in both of the present 
groups When calculating the MR1 as AL MC/AL'C sev­
eral assumptions must be laken into consideration [14] 
birst ALMC/AL'C represents the V1RT ol those mole 
cules which are eliminated Irom the bodv hence implying 
that no irreversible binding occurs m the bodv further 
more the formula assumes thai the system is linear and 
lhal ANP elimination lakes place horn Ihe sampling 
space 
Ihe apparent volume ol disliibulion al steady state 
( V J tended lo be lower in Ihe elderlv V„ was calculated 
using the product ol M RI limes ΓΙ . both of which are 
sub|ccts to biological vanation Due to the icsulting large 
variation in V„ the dilfcrencc between the voung and the 
elderlv tailed to achieve statistical significance 
The values for CI MRT V and ti found here were 
more oi less in line with those lound in other studies [3-5] 
Ohashietal [15] using bolus inieelionsol ANP observed 
a prolonged second phase ot (99-126)hANP disappear 
ance and a decreased metabolic clearance rate in elderlv 
subjects In their sludv ANP was measured using a direct 
assav The latter assav is sub|ccl lo interference- from plas­
ma components and gives less reliable results than one 
based on prior exlraclion ol the plasma |16 17] 
Because ΛΝΡ is degraded by the kidney [ 18] and is not 
excreted in the uime the CL probably represents meta 
bolic clearance' rather than icnal clearance of ANP Maru 
mo el al [19] using a direct assav delected immunoreac 
live ANP in human urine That lmmunorcactivitv was 
probably caused bv the presence of urodilatin a 32-amino 
acid containing polypeptide corresponding to (95 
12ft)ANP which is produced locally in the kidncv and se 
creled into the urine [20] 
In man ihe lung liver and kidney contribute subslan 
liallv lo the metabolic removal of ANP from ihe circula­
tion [21[ Luti et al [22| showed lhal ihe I, ^  of ANP was 
markedly prolonged in anephnc rats as compared to con 
trol rats Holhstcr et al [23] observed in hypertensive hu­
mans a high ANP extraction ratio in the kidney but, due to 
the lower blood flow, a lower clearance rale of ANP as 
compared to the lung and the liver They also found a posi 
live correlation between the endogenous creatinine clear 
ance and total clearance of ANP More than 95 % of ANP 
receptors in rat kidncv arc biologically silent [24] Binding 
of ANP to Ihese receptors (called C-ANP receptois) docs 
not result ma functional response or in cGMP production, 
in distinction to (he B-ANP receptors which mediate Us 
biological ellects through the second messenger cGMP 
When Ihe С ANP receptors are specificiallv blocked bv 
ring-deleted ANP analogues the endogenous plasma 
ANP concentrations increase suggesting that the С 
ANP receptors play an important role in the clearance of 
ANP 
Various lactors influence the glomerular filtration rale 
Amongst Ihem are the amount ol dietary sodium the 
blood volume total renal mass and the age ol the sub|ccl 
With advancing age Ihe number of functioning glomeruli 
declines in proportion to the decrease in glomerular lillra 
tion rate [12 25] The endogenous creatinine clearance 
(hCC ) can be regarded as an esumale of ihe glomerular 
fillralion rale A highly significant positive correlation 
was lound here between CI and the ECC in the elderlv 
but not in the voung subjects Since one of the main deter 
minants of glomerular filtration rate in the elderlv is the 
number ol lunclioning glomeruli (with its numerous re 
ccptors lor ANP [26]) it is a plausible hypothesis that this 
numbci isa ma|orlaclonn ANPclearancc Therefore Ihe 
present dala support the assumption that the kidney is a 
major determinant ol ANPclearancc 
In conclusion (he kinetics of ANP has been compared 
in healthy voung and elderly sublets It had a similar 
mean residence time but the total body clearance was 
lower in the latter group In the elderly bul nol m Ihc 
young the total body clearance of ANP was strongly 
correlated with the calculated creatinine clearance Thus 
the higher basal ANP levels found in the elderlv may 
largely be attributable to a decrease in the total bodv 
cleat mice of ANP in those subjects 
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CHAPTER 4 
Age-dependent vasodilation of the skin microcirculation by atrial 
natriuretic factor 
(Reproduced with permission from: 
J Cardiovasc Pharmacol 1991; 18: 622-30) 
Age-Dependent Vasodilation of the Skin Microcirculation 
by Atrial Natriuretic Factor 
Τ L Th A Jansen, *A С Ι Τ L Tan, Η Wollersheim, *Th J Benraad, and 
Th Thien 
Department of Medicine Dmsion of General Internal Mediani and 'Department of Experimental and 
Chemical Endocrinology St Radboud Hospital Unntrut\ of Nijmegen The Netherlands 
Summary The microcirculalory responses io systemi 
Cdlly administered alpha human alnal natriuretic factor 
((99-l26)hANF) (ANF) were investigated in the skin of 
eight voting ( 18—2s years) and eight elderly (71-84 years) 
healthy volunteers in a double-blind randomized pia 
ccbo-controlled study Laser Doppler flux (LDF) trans 
cutaneous oxygen pressure (TcPO;) and skin tempera 
tures on the finger (Td) and on the cheek (To were mea 
sured during 60 mm of ι ν ANF administration at a low 
rate (0 2^ μ£Ληιη) resulting in plasma ANF concentra 
tions in the upper normal range and at a high rate (2 0 
μιΐ/min) inducing a 17 to 23-fold increase in plasma 
ANF ANF infusion did not induce consistent changes in 
TcPO, or Td at either rale Placebo corrected LDF in 
creased significanti) following low rate ANF infusion in 
the elderly but remained unchanged in the young (mean ΐ 
SD) +22 ± 21% (ρ < 0 O'S) and +7 i 32% (ρ -> 0 1) 
respectively following high rate ANF infusion in LDF 
the changes were greater with + 28 ± 56% and +19 ΐ 
42% respectively Because of the large SD the increases 
were no longer significant During high rate ANF infusion 
Tc remained unchanged in the young but in the elderly 
Tc decreased—1 1 ± 1 39r (p < 0 05) which is probably 
due to the fall in blood pressure which was more pro 
nounced in the elderly than in the young mean arterial 
blood pressure (MAP) decreased - 9 * 3% (p < 0 05) in 
the elderly and just - 6 ± 3% (p < 0 05) in the young 
both corrected for placebo changes Laser Doppler resis 
tance in the skin calculated as MAP/LDF significanti) 
decreased in the elderly - 23 ± 27% (p = 0 05) during 
low-rate and in the voung - 28 ί 40% (ρ = 0 0^) during 
high rale ANF infusion indicating that ANF induced 
some vasodilation in the skin of healthy subjects We 
conclude that ANF induced mild vasodilator responses in 
the skin microcirculation of healthy volunteers being 
most pronounced in the elderly The effects of high rate 
ANF infusion however were obscured by changes in 
blood pressure and by the widespread microcirculatory 
reactivity Key Words Aging—Atrial natriuretic factor 
((99 I261ANF)—Hemoconcentration—Laser Doppler 
flux—Laser Doppler resistance—Skin microcirculation 
The hormonal system of atrial natriuretic factor 
(ANF) comprises a family of polypeptides of which 
(he 28-amino-acid (99-l28)hANF called α-human 
atrial natriuretic factor is the major circulating form 
( 1 ) An important physiological role (2 ) for elevation 
of endogenous A N F is emerging as studies reveal 
its potent diuretic natriuretic (3) and vasodilatory 
actions (4 5) Furthermore, A N F may produce in­
travascular fluid shifts independently of any renal 
mechanism (6 7) 
The cardiovascular effects of A N F have been 
thoroughly studied л fall in blood pressure (BP) and 
total peripheral resistance and a rise in heart rate 
(HR) The effects of A N F on the skin microcircu­
lation have only just begun to be investigated ANF 
has been demonstrated to increase skin perfusion 
upon ι ν administration of megadoses (8) and upon 
intraarterial infusion of pharmacological dosages 
(9) A N F s potent vasodilation in the vascular beds 
of the skin might well be of relevance to conditions 
with a decreased circulation in the skin such as 
occurs with normal aging 
Therefore we studied the effect of exogenous 
A N F on total skin blood flow as indicated by laser 
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Doppler flux (LDF) and skin temperatures on two 
different vascular beds on the finger (Td) and on 
the cheek (Tc) Because LDF determines capillary 
and shunt blood flow in the skin, we also measured 
transcutaneous oxygen pressure (TcPO ; ) . which 
can be considered the result of skin capillary blood 
flow A low rate, chosen to research high physio-
logical levels, resulted in A N F values in the upper 
normal range A high rate , chosen to research 
pathophysiological/pharmacological levels, resulted 
in A N F values comparable to those observed in 
states associated with chronic volume overload, 
such as severe congestive heart failure (10) Since 
age may play a role in the reaction to ANF and 
since elderly persons have increased baseline ANF 
levels, we chose to study two extreme age groups of 
healthy volunteers 
MATERIALS AND METHODS 
Subjects 
The study protocol was approved bv the Ethics Com-
mittee of our institute Two groups of healthy young (n = 
8) and elderly (n = 8) volunteers, recruited from the gen-
eral population, were studied All subjects gave written 
informed consent Participants were submitted to clinical 
examination betöre admission to the sludv No abnormal-
ities were observed either upon phvsical examination or 
laboratory investigation None ot the subjects smoked 
took any drugs including oral contraceptives or abused 
alcohol The subjects were instructed to eat their usual 
diet and not lo drink coffee or tea and ю retrain from 
strenuous phvsical activity for 24 h prior to the experi­
ment 
Design of the study 
The study was performed over 3 davs each separated 
by at least I week in a dimatized room (mean room 
temperature and humiditv i SD 246 ; 0 2°C and S5 = 
2%. respectively η = 48) On the study day after a 2-h 
fast, a catheter was introduced into an antecubual vein of 
both arms The subjects remained in supine position 
throughout the studv period ot 2 h including short peri­
ods for passing unne 
Methods 
After I h of acclimatization to (he supine position, pla­
cebo or ANF at the low rate (0 25 μ£.'πιιη) or high rate 
(2 0 μg/mln) was infused for 60 mm at random order in a 
double-blind manner Blood for determination of ANF 
was sampled from an antecubual vein in the contralateral 
arm 30 mm and just pnor.to the start ot infusion at 30. 45, 
and 60 mm after the start of inlusion 
To assess a potential reduction in capillary skin circu­
lation the TcPCK was monitored by a heated (45°C) Clark 
electrode with the probe adjusted to a portable transcu­
taneous oxygen monitor (Tacomette. TM no 809 A. No-
vametnx) Before fixation the Clark electrode was heated 
for at least 30 mm. The electrode was attached to the right 
distal dorsal phalanx of ihe lourth linger Baseline oxvgen 
tension was obtained 20 mm alter fixation ot the electrode 
to the finger when TcPO, values stabilized Continuous 
recording of digital skin blood flux was performed using 
LDF (Penflux Pf Id Penmed Sweden) with the 90° an­
gular probe attached bv a double-sided adhesive nng to 
the center of the right distal palmar tip of the third finger 
The flux was expressed in arbitrary units (AU) Before 
each experiment an electrical calibration procedure was 
performed according to the instructions given in the man­
ual Skin temperature was measured in degrees Celsius 
with one probe (Thermocouple Ellab Instruments, Den­
mark) attached to the cheek and one attached palmar to 
the distal phalanx on the right index finger 
Systolic and diastolic blood pressure (SBP. DBP) were 
measured with a semiautomatic device, the Artenosonde 
1225 (Roche Medical Electronics Division. Hoffmann-La 
Roche Ine , Orangeburg, NJ, U S A ) HR was electro-
cardiographically monitored continuously 
Laboratory determinations 
ANF was measured as described previously (II), using 
a specific radioimmunoassay based on prior extraction of 
the plasma on Seppak C-18 columns Sensitivity of the 
assay was 0 8 pg/tube (corresponding to 4 pg/ml) Recov­
ery averaged 96%, intra- and interassay coefficients of 
variation were 8 6 and 11 6%. respectively Normal val­
ues in 66 healthy subjects in the sitting position ranged 
from 8 3 to 87 3 pg/ml (mean ± SD 35 3 ± 16 2 pg/ml) 
Methods for determination of plasma catecholamines 
have been published previously (12) 
Drugs 
(99-l26)hANF was purchased from Bissendorf Peptide 
GmbH. Wedemark. F R G Immediately before use ANF 
was diluted in a 48 ml Haemaccel (Hoechst) solution 
Haemaccel is a plasma-expanding solution, and was used 
for placebo infusion as well as for dissolving ANF Re­
sults of pilot studies revealed (hat dissolution of lodinaled 
\NF in Haemaccel solution resulted in a 20% loss of 
radioactivity to the infusion system, compared with a 
50% loss when ANF was dissolved in 0 9% saline solu-
uon 
Data report 
All results are expressed as mean values ± SD unless 
otherwise indicated LDF was averaged over every 1-min 
period For all variables a mean value was calculated ev­
ery 15 mm bv averaging the two values at time point 10 
and 15 The averages of data gathered 45 and 60 mm after 
the start of ANF infusion are called steady-state values, 
and were used to calculate percentage changes from base­
line values The net effects were investigated by subtract­
ing the effects of placebo infusion from the efTects of high 
or low ANF infusion rate in each subject The mean ar­
terial pressure (MAP) was calculated as the sum of DBP 
and one-third of the pulse pressure 
Statistical analysis 
Statistical analysis was performed using an S A S soft­
ware package (Statistical Analysis System, Version 5 0 
Cary N С . U S A ) To analyze the effects of ANF in­
fusion within each group of subjects, the mean percentage 
ANF-induced changes was corrected for placebo for each 
infusion rate and subsequently compared to zero by the 
Wilcoxon test for matched pairs To evaluate the differ 
enee in response on BP HR. and skin temperature be­
tween young and elderlv subjects, these placebo-
corrected data were compared with each other by the 
Wikoxon two-sample test Intergroup comparison re-
35 
garding LDF and TcPO
:
 was performed using the un­
paired Wilcoxon test Significance was accepted at the 
0 05 level of probability (two-sided) 
RESULTS 
Table 1 presents characteristic data of both age 
groups Besides the difference in age due to selec­
tion, the groups differed significantly (p < 0 05) in 
serum creatinine levels as well as in the calculated 
creatinine clearance [according to the formula of 
Cockcroft and Gault (13)] This difference, how­
ever, may be ascribed entirely to the normal de­
crease in renal function with age 
Atrial natriuretic factor concentrations 
Figure 1 shows the course of ANF levels before 
nd during the three infusion experiments in both 
groups studied As expected, the baseline ANF lev­
els were elevated in the elderly when compared to 
the young (50 ± 13 vs 35 ± 9 pg/ml; ρ < 0 051 
Placebo infusion induced no significant change in 
either group, with respective values after 60 min 
infusion of 44 ± 9 vs 33 ± 12 pg/ml (elderly versus 
young, NS). Following both ANF infusions clear 
increases in the ANF levels were observed, leading 
to a steadv state beginning 30 mm after the start of 
infusion During low-rate infusion ANF levels sig­
nificantly increased (averaged for time points 45 
and 60 min), three- and twolold in elderlv and young 
(elderly versus young, NS). respectively, and dur­
ing high-rate infusion ANF levels significantly in­
creased. 23- and 17-fold, in elderly and young (el­
derly versus young, NS). respectively 
Microcirculatory parameters 
Baseline parameters of skin LDF in elderly and in 
young were equal respective LDF values (mean -
SD) 46 = 13 and 38 i 16 AU. ρ > 0 1 Baseline 
parameters of nutritional blood flow of the skin 
tended to be lower in elderly than in young subjects' 
TABLE 1 Group thurcutenstics measured under 
baseline conditions 
Character i s t ic p a r a m e 
Sex ratio (M/F) 
Age (yr) 
Height (m) 
Weight (kg) 
Quetele i index (kg/nv) 
[ers 
Serum creatinine Ιμπιυΐ/L) 
E С С (ml/min/ n r i 
Young 
(η = 8) 
4/4 
23 ΐ 3" 
175 * 9 
69 ± 15 
2 2 - 4 
72 ~ Π " 
S l ; 9 " 
Elderlv 
(η = 8) 
4/4 
76 i 4 
165 ~ 14 
67 ~ 12 
25 ϊ 4 
94 - 32 
29 - 6 
Quetelei index we.ght/height (kg/m:) F C C endogenous 
creatinine dearance. calculated by Cockcroft and Gault s for­
mula 113) 
Group companion revealed a significant difference in age se 
rum creatinine and E С С 
Means = SD are given 
" ρ < 0 0 s Young versus elderlv ρ values thai were not sig­
nificant are not shown 
respective TcPO
:
 values were 35 ± 26 vs 51 ± 40 
mm Hg. ρ = 0 08. Table 2 presents baseline and 
steady-state microcirculatory parameters for pla­
cebo, low-rate, and high-rate ANF infusion. 
Laser-Doppler Flow When placebo-corrected, 
the microcirculation in the skin, as measured by 
LDF. only slightly increased in the young subjects, 
+ 7 ± 32% (NS),'during low-rate, and + 19 ± 42% 
(NS), during high-rate ANF infusion In the elderly 
the LDF increased significantly, +22 ± 21% (p < 
0 05) during low-rate ANF infusion; during high-
rate infusion LDF increased also, though signifi­
cance was not reached because of the large intenn-
dividual scattering of response: +28 ± 56% (NS). 
The mean LDF increase was not significantly dif­
ferent between the young and elderly group at ei­
ther infusion rate. 
During high-rate infusion ANF lowered MAP in 
elderly and young subjects, - 9 ± 3% (p < 0.05) and 
- 6 ± 3% (p < 0 05), respectively During low-rate 
infusion MAP increased in the elderly, +5 ± 7% (p 
< 0 05), but remained unchanged, - 1 ± 6% (NS), 
in the young Because of the differential BP-
lowenng effect of ANF we felt a new parameter was 
necessary indicating resistance in microcirculation 
We therefore introduced laser-Doppler resistance, 
calculated as the quotient of MAP and LDF Fol­
lowing low-rate infusion laser-Doppler resistance 
decreased in elderly and young subjects. -23 ± 
27% (p < 0.05) and - 7 Î 34% (ρ > 0 1). respec­
tively High-rate ANF infusion induced a decrease 
in laser-Doppler resistance -24 ± 44% (p = 0 16) 
and -28 3 40% (p < 0 05), in elderly and young, 
respectively 
Figure 2 shows the course of the placebo-
corrected percentage changes from the individual 
baseline values of MAP, LDF, and laser-Doppler 
resistance (MAP'LDF) in the elderly and young 
group, respectively 
Transcutaneous oxygen pressure (45°C) In 
TcPO
:
 no consistent changes following low- or 
high-rate ANF infusion were observed in either the 
young or the elderly subjects, as placebo-corrected 
TcPO
:
 remained constant during both infusion 
rates. 
Cheek temperature. When placebo-corrected, no 
changes in Tc were observed following low-rate 
ANF infusion. Following high-rate ANF infusion, 
Tc decreased equally in both groups studied, al­
though the decrease was significant only in the el­
derly group [elderly. -1.1 ± 1.3% (p < 0.05); 
young. - 1.0 - 17% (NS)] 
Fint>er temperature When placebo-corrected, no 
change was observed in either the young or the el­
derly following low-rate ANF infusion Following 
high-rate ANF infusion placebo-corrected Td 
slightly increased in the young + 1 6 ± 5.3% (NS). 
but slightlv decreased in the elderly -0.9 ± 3 8% 
(NS) All changes were insignificant 
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FIG. 1. The course of the mean (±SD) ol plasma 
concentrations of immunoreactive atrial natri-
uretic factor (ir-ANF) before and during the in-
fusion of placebo (squares), low-rate (open tri-
angle/circle), and high-rate (solid trlan-
gleclrcle) ANF in young (left), and elderly 
subiects (right). Significant elevation in ANF lev-
els was obtained as indicated "p < 0 05 vs pla-
cebo time-course 
30 ¿5 60 
Time (mm) 
Hemoconcentration 
The baseline hemoglobin (Hb) and hematocrit 
(Ht) were equal in the elderly when compared with 
the young (Hb in elderly versus young. 8 17 ± 0 12 
vs. 8 05 ± 0.22 mmol/L. respectively (NS). and Ht 
in elderly versus young. 0 38 ± 0 01 vs 0 39 i 0 01 
L/L respectively (NS), see Table 3) Placebo infu-
sion induced no significant change in either group, 
respective changes in elderly versus voung. Hb 
τ 0 08 ± 0 08 vs 0.06 ± 0 18 mmol/L(NS). Fol­
lowing both ANF infusions clear increases in the 
Hb and Ht values were observed in the young, lead­
ing to a steady state beginning 30 mm after the start 
of infusion Low-rate ANF infusion induced a sig­
nificant increase in Hb and Ht in the young +0.34 
± 0 08 mmol/L (p < 0.01) and +0 013 ± 0 010 L/L 
(p < 0.05). respectively The changes obtained in 
the elderlv were +0.09 ± 0 10 mmol/L (NS) and 
- 0 004 ± 0 006 L/L (NS) During high-rate ANF 
infusion Hb and Ht rose significantly in both the 
young and elderly - 0 48 ± 0.08 mmol/L (p < 0 01) 
with T 0 028 ± 0 009 L/L (p < 0 05). and +0 64 ± 
0 17 mmol/L (p <^  0 05) with τΟ 027 ± 0 003 L/L (p 
< 0 05). respectively Changes in Hb and Ht values 
are shown in Fig 3 ANF induced concentration-
dependent hemoconcentration in all subjects stud-
TABLE 2 Means l*SD) of MAP HR LDF, TcPO, and Tc and Td before and during placebo, ¡он, 
and htgh-rate infusion of ANF in \oung and elderls subjects 
P a r a m e t e r s 
M A P (mm Hg) 
HR (beats/mm) 
L D F (AU) 
T c P O , (mm Hg) 
Tc C O 
Td (°C) 
M A P (mm Hg) 
HR (beats/min) 
L D F (AU) 
T c P O , (mm Hg) 
Те ГС) 
Td (°C) 
Base 
81 ~ 
70 -
36 ± 
48 -
35 2 Ξ 
33 4 -
97 Í 
62 ± 
46 ΐ 
38 =: 
34 8 ι 
34 4 ± 
P l a c e b o 
ine 
9 
6 
16 
24 
0 4 
2 4 
10° 
10 
i r 
14 
0 9 ° 
1 3° 
Steac 
Young 
V 
stale 
85 -
71 -
32 ΐ 
52 ± 
35 3 = 
32 4 ± 
102 ± 
60 ± 
32 ± 
41 ΐ 
34 6 i 
33 5 = 
9 
7 
15 
20 
0 4 
2 7 
ElderK 
12 
10 
II 
π 
0 7 
0 9 
subjects (n - 8) 
Lov, 
Baseline 
82 -
68 ± 
44 ± 
47 -
34 8 -
M 8 -
subiects 
96 ~ 
61 ± 
4S -
32 -
33 2 -
34 3 -
10° 
8 
Π 
23° 
0 6 
1 0 
in = 
11° 
11 
20 
13 
2 9 
1 5° 
8) 
rale 
Stead \ 
s late 
86 
68 
39 
59 
M 8 
33 8 
103 
60 
39 
35 
33 0 
33 1 
-
~ 
± 
± 
= 
± 
r 
-
± 
-
8 
9 
15 
15 
0 6 
1 9 
13 
10 
17 
14 
2 7 
2 1 
High 
Baseline 
85 ± 8 
74 = 7 
37 = 23 
58 ± 10 
35 4 ± 0 6 
32 8 ΐ 3 1 
9 9 - 1 0 ° 
6 2 - 1 1 ° 
48 ± 23 
35 - 14 
34 4 ± 14 ° 
33 6 = 2 7 
rale 
Sie 
St 
84 
77 
34 
56 
35 1 
32 4 
93 
67 
36 
40 
33 8 
32 4 
ady 
ate 
= 6 
± 13 
- 21 
i 11 
- 0 7 
í 3 8 
- 11 
* 12 
r 16 
= 15 
= I 1 
î 2 0 
MAP, mean arterial pressure HR heart rate LDF, laser-DoppIer flux AU arbitrais units. TcPO-, transcutaneous oxygen pressure 
Tc, cheek temperature Td, finger temperature 
a
 ρ < 0 05 vs baseline ρ values that were not significant are not mentioned 
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TABLE 3. Means I ~5Dl of ι he placebo baseline values 
and the placebo-corrected percentage change î during 
steady stale induced by low- and high-rate infusion of 
ANF on humoral parameters 
ДНЫ mmol/I ) 
Humoral parameters 
Young 
(n = 8) 
Elderly 
(n = 8) 
lr-ANF 
Placebo baseline (pg/ml) 
Low-rale ANF 
minus placebo {%) 
High-rate ANF 
minus placebo (%) 
Norepinephrine 
Placebo baseline 
(nmol/L) 
Low-rate ANF 
minus placebo (%) 
High-rale ANF 
minus placebo (%l 
Epinephrine 
Placebo baseline 
(nmol/L) 
Low-rate ANF 
minus placebo (9?) 
High-rate ANF 
minus placebo (Tí) 
Hemoglobin 
Placebo baseline 
(mmol/L) 
Low-rale ANF 
minus placebo (T) 
High-rate ANF 
minus placebo (*>! 
Hematocrit 
Placebo baseline (L.L) 
Low-rate ANF 
minus placebo (Τ) 
High-rate ANF 
minus placebo (^) 
34 5 ± 8.9" 
+ 137 - 31* 
+ 1.723 3 1.033* 
0 69 ± 0.17" 
+ 3 - 6 8 
+ 14 ± 93 
0 09 ± 0.04 
- 4 ΐ 73 
- 7 r 39 
8 05 » 0 63 
3 1 г 3 8" 
- 4 9 = 2 7" 
0 39 - 0 1)2 
+ 4 0 - 3 9 " 
+ 6 6 * 2 3" 
49.6 = 12.5 
+ 163 г 37.5" 
+ 2044 г 872" 
1.50 ϊ 0.37 
+ 0.1 - 28 
+ 0.8 - 54 
0 14 г 0.07 
+ 11 î 41 
+ 27 г ПО 
8 17 г 031 
- 3 0 - 6 5 
+ 8 8 г 12 2" 
0 38 * 0 02 
+ 1 0 * 4.6 
+ 9 6 * 10.7* 
ANF. atrial natriuretic factor: ir-ANF. immunoreactive ANF 
Only the placebo baseline values are presented, as no differ­
ences were observed between the three preinfusion values. 
u
 ρ < 0.05, young versus elderly groups. 
* ρ < 0 05 versus zero 
partially induced by a fall in BP and hemoconcen-
tration during these experiments. 
An interesting rise in MAP was observed during 
ANF infusion at the low rate in the elderly, which 
may at least in part be explained by ANF-
independent factors. It may be an intrinsic effect of 
the supine position, as this increase in MAP is well 
known from investigations performed in the supine 
position (14). To our knowledge, it is not yet known 
whether this position effect of forearm vasocon­
striction is more pronounced in elderly than in 
young subjects. The simultaneous infusion of ANF 
has to overcome the position effect before it can 
induce further vasodilation. From our data, how­
ever, we cannot deduce whether a modulation of 
the position-dependent vasoconstrictor response or 
an impaired ANF-dependent positive inotropic ef­
fect induces the net vasoconstriction in the elderly 
group compared with the young group. The possi-
-, 
0.05 -
young 
• p < 0 05 
> · p < 0 01 , _ 
Ϊ 
, Í 
I 
· • 
jjjp 
elderly 
JL 
ШШ 
'Ш 
FIG. 3. Changes from baseline hemoglobin (Hb) and hemat­
ocrit (Ht) during steady state of placebo (P), low-rate (L), and 
high-rate (H) ANF infusion in young (left) and in elderly sub­
l e t s (right). Means ΐ SD are shown. Signihcance of ρ values 
refers to comparison with zero 
bility that the direct vasodilator response is attenu­
ated in the elderly compared with the young also 
cannot be excluded. 
De Bold et al. (3) are the first to describe hemo-
concentration following infusion of atrial extracts 
producing natriuresis. However, in more recent 
studies ANF is reported to produce, independently 
of any renal mechanism, a fluid shift from the intra­
vascular compartments (6.7) leading to hemocon-
centration and decreased plasma volume. ANF di­
rectly and reversibly elevates capillary hydraulic 
conductivity (15). Elevated hydraulic conductivity 
combined with increased capillary pressure might 
well lead to fluid shift to the extravascular compart­
ment (16). The precise mechanism as well as the 
threshold of hemoconcentration remain to be eluci­
dated. The hemoconcentration observed in this 
study was of such a small magnitude that it most 
probably does not influence the microcirculation. 
In the present study baseline LDF parameters are 
in agreement with higher skin blood fluxes found 
with aging by others (17). Omission of biological 
LDF calibration results in overestimating fluxes by 
1-2 AU ( 18); this seems to be important in low flux 
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Norepinephrine 
(nmol/l ) 
Epinephrine 
2 η 
placebo 
I 
0 
2-, 
low 
high 
yxninglN-8) (nmol/ l ] eiaerlylN-β) /oungfH.8) 
• 0 
j _ 
l·-
i -
I -
o-
I , 
_ j _ 
4- Ц—1 
Д , 
¡"г" 
ή 
•"• 
Ц-
60 О 60 
mm 
О 
0 2 
О 1 
О-
1 
L °2 
О I 
elderly IN.81 
DG 
t -
0 60 
m i n 
О 60 
min 
FIG. 4. The mean ( ΐ SEM) of the 
plasma concentrations of nor­
epinephrine (left) and epineph­
rine (right) just before and over 
60 mm infusion of placebo (up­
per panel), low-rate ANF (mid­
dle panel), and high-rate ANF 
(lower panel) in young (n = 8) 
and elderly (n = Θ) subjects 'p 
< 0 05 refers to comparison of 
values during versus just before 
infusion 
states Most LDF baseline values, however, ex­
ceeded 35 AU in both groups studied Therefore the 
possible error was small Moreover intergroup 
comparison was not atfected. because this small er­
ror appeared in both groups studied LDF measures 
skin perfusion including arteriovenous shunt flow, 
and is directly responsible for skin temperature 
(19) In vitro (20) and in vivo experiments (8) dem­
onstrated that facial vascular beds are readily va­
sodilated The fingertips, in contrast to the cheeks 
have a relative excess of arteriovenous shunts 
LDF measures both the superficial nutritional flux 
and the subpapillary shunt flux ( 17) ANF at a high 
physiological level increases LDF, indicating a 
modulation of skin perfusion This finding is in 
agreement with intraarterial studies performed by 
others (8,9) Bussien et al (8) have studied LDF 
responses using ANF administration at megadoses 
in only tour healthy volunteers Therefore a puta­
tive vasodilator action of ANF in the skin necessi­
tated further study Our data clearly demonstrate 
that ANF acts in the skin microcirculation, al­
though it is not as potent as suggested previously 
ANF plasma concentrations reached pharmaco­
logical levels using the high infusion rate These 
ANF levels induced several effects, and the expla­
nation of the changes in microcirculation was by 
that means complicated For instance, high-rate 
ANF infusion complicated interpretation by inter­
fering with decreased BP, together with only minor 
hemoconcentrating effects Calculation of a param­
eter indicating microcirculatorv resistance seemed 
necessary, and prompted us to calculate the laser-
Doppler resistance, defined as the quotient of MAP 
and LDF ANF tended to decrease this quotient, 
supporting the conclusion that ANF does indeed 
have a vasodilator action in the skin microcircula­
tion, although it is not as imposing as suggested in 
studies using megadoses of ANF (8) 
Il might have been interesting to know the digital 
BP, since a decay of intraarterial pressure occurs 
lollowmg to the periphery of the vascular tree It 
has been demonstrated, however, that in healthy 
subjects the digital/brachial BP index is high (0 85 ± 
0 02) (21) Since a decay in BP will occur in both age 
groups, it seems permissible to use the brachial 
pressures 
TcPO ; measurement is a technically simple, non­
invasive, and continuous method indicating nutri­
tional blood flow (22), it measures local tissue per­
fusion while skin capillaries are maximally vasodi­
lated by heating (23) During maximal vasodilation 
induced by heating to 45°C, no further vasodilation 
could be registered The absence of any further 
ANF-induced vasodilation after warming the skin 
up to 45°C was expected, and does not allow spec­
ulation on a possible modulating effect in the micro­
circulation with respect to the nutritional perfusion 
of the skin Further vasodilation of the vascular 
beds in the skin might have been possible if the skin 
had just been heated to 37°C No arguments could 
be found for severe orthosympathetic activation 
during these experiments, as no increase in cate­
cholamines was observed, whereas the constant 
TcPO
:
 indicates that there was no important vaso­
constriction of the capillary skin vessels This study 
enables differentiation of the ANF-induced effects 
on the shunt circulation and of the hypotension-
39 
Δ MAP (V.) 
30 60 
Tim« {mm) 
FIG 5 Time-courses over 60 mm infusion of placebo 
(squares), low rate ANF (open triangle/circle), and high rate 
ANF (solid triangle circle) Data are means (±SEM) of per 
centage changes from the individual baseline values of mean 
arterial pressure (ΔΜΑΡ) laser Doppler flux (ALDF) and la­
ser Doppler resistance [A(MAP/LDF)J in young (left) (n = 8) 
and elderly (right) (n = 8) subiects The significance of the 
difference in the area under the curve is indicated by 'p < 
0 05 vs placebo infusion 
induced effects on the nutritional circulation As the 
nutritional flux, indicated by TcP0 2 , remained un­
changed, the increasing LDF was probably mainly 
based on changes in arteriovenous shunt flow 
In agreement with" the literature, baseline shunt 
fluxes of the skin tend to be higher in the elderly 
than in the young Nutritional skin fluxes, however, 
tend to be lower in the elderly than in the young In 
this study ANF evoked a minor hemoconcentration 
that probably did not interfere in microcirculation 
The skin microcirculation responded in an age-
dependent manner Furthermore, within high phys­
iological plasma ANF concentrations the shunting 
microcirculation in the skin of healthy subjects is 
modulated by ANF At pharmacological concentra 
tions ANF tends to induce vasodilator response in 
the shunt microcirculation of the skin and is more 
pronounced in the young than in the elderly Our 
data, however, are not consistent with ANF being a 
potent vasodilator of the skin microcirculation 
Whether it is suited for therapeutic use in low-flux 
states of the skin, therefore remains questionable 
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CHAPTER 5 
Hemodynamic e (Tec t s of atrial natriuretic Tactor in young and elderly 
subjects 
(Reproduced with permission from: 
Clin Pharmacol Ther 1990; 48: 179-88) 
Hemodynamic effects of atrial natriuretic 
factor in young and elderly subjects 
Because levels of plasma atrial natriuretic factor (ANF) increase with advancing age, a diminished 
hemodynamic responsiveness to ANF m the elderly has been hypothesized in the literature. Therefore 
hemodynamic effects after two infusion rates (0.25 and 2.0 μg/min) of atrial natriuretic factor (99-126) 
were investigated in young (n = 8) and elderly (» = 9) volunteers in a double-blind, randomized, and 
placebo-controlled protocol. After low-rate infusion, ANF concentrations increased to the upper normal 
range, and only minor effects were observed. In contrast, high-rate infusion resulted in a decrease in 
blood pressure and forearm vascular resistance, whereas an increase in heart rate was observed in both 
groups. Between young and elderly subjects, a significant difference was observed in the ANF-induced 
decrease in systolic blood pressure (mean ± SD, —4% ± 4% versus — 12% ± 7%, ρ < 0.05) and mean 
arterial pressure ( — 6% i: 5% versus - 1 1 % ± 4%, ρ -~ 0.05) during the high rate infusion. When 
compared with the concentrations of the young subjects, the ANF concentrations reached at both ANF 
dosages were higher m the elderly subjects; this was the result of a diminished ANF clearance in the 
elderly subjects. After correction of the changes of systolic blood pressure and mean arterial pressure for 
the higher ANF levels reached within this cldcrlv group, no difference between young and elderlv subjects 
remained. We conclude that a diminished cardiovascular responsiveness to ANF with advancmg age could 
not be demonstrated. In contrast, the high-rate infusion of ANF induced an increased hemodynamic 
response in the elderly subjects, but this seems to be the result of the higher ANF levels reached within 
this group. (CLIN PHARMAÍ OÍ THKR 1990;48:179-88.) 
Tim L. T. A. Jansen, MD, Adriaan С. I. T. L. Tan, MD, Paul Smits, MD, 
Theo de Boo, MD, Theo J. Benraad, PhD, and Theo Thieii, MD 
Níjmajcn, The Netherlands 
Alridl natriuretic factor (ANF) comprises a family of 
peptides ot which the 28 amino acid (99-l26)ANb 
(.ailed •'-human atrial natriuretic lactor C-nANF). is 
the m,<|or circulating form ' ANF has potent diuretic. 
natriuretic.1 and vasorelaxing properties ' s In addition. 
ANF may inhibit the release of renin, aldosterone."* 
and vasopressin " 
The cardiovascular effects of ANF are well delin-
eated hypotension, rise of heart rate, increase ol fore-
arm blood flow, and decrease ol lorearm vascular re-
sistance '" ' Many ot these effects have been observed 
when ANF was inlused with a high pharmacologic dose 
or when ANF was locally (ι e . intra-arterially) inlused 
Circulating ANF concentrations increase with advanc 
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ing age '4 " Suiches have been perlormed U> ciuci 
date the association between higher ANI levels and 
aging '" ' Whether the increase in ANI- level is .isso 
ciated with advancing age b> down regulation ol l.ir 
get organ responsiveness warrants lurther investigation 
We therelore compared hemodynamic ellects ol an (99-
I26)ANF inlusion, both in a physiologic and in a phar 
macologic dosage, on the cardiovascular system in 
young and elderly subjects This was a randomized, 
double-blind, and placebo-controlled study design 
MATERIAL AND METHODS 
Subjects. 1 he study protocol was previously ap­
proved by the local ethical committee ol the University 
Hospital. Ni|mccen, 'I he Netherlands Two groups ol 
healthy young (л = 8) and elderly (/ι = 91 volunteers, 
recruited from the general population, were studied 
Each sub|ect gave inlormed consent, and each sub|cct 
was submitted to clinical examination belore admission 
in the study Physical examination revealed no relevant 
abnormalities None of the subjects smoked, look any 
drugs (including oral contraceptives) or drank exces­
sive amounts ol alcohol The sublets were instructed 
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Table I. Group characteristics measured during 
baseline conditions 
Young Elder h 
subjects subjects 
Chnu al parameters 
Sex ratio (M/F) 
Age (yr) 
Height (m) 
Weight (kg) 
Quetelet index 
(kg/m')* 
Endogenous C L
r
, 
(ml/min/ m )+ 
Serum creatinine 
(μπιοΙ/L) 
Crealinine range 
In = 8) 
4/4 
23 ± 3 
175 ± 9 
69 ± 15 
22 ± 4 
63 ± 9 
72 +. 13 
43-93 
ρ Value 
<0 05 
NS 
NS 
NS 
<0 05 
<0 05 
In - 9) 
4/5 
76 ± 4 
165 ± 14 
6 7 + 1 2 
25 + 4 
29 ± 6 
94 ± 32 
59 170 
(μπιοΙ/L) 
Data are mean values ± SD 
NS Not Mgmtkanl CU-R creatinine clearance 
*Quelelu inde* Wcight/hughl 
+Endogenous CLTR calculated according to the lomiula ol totkcroll and 
Gaull » 
to maintain their usual diets, not to drink any cottee 
or tea, and to refrain from hard labor during the 24 
hours preceding the experiment Because of complaints 
of urgency associated with difficulty in micturalion, 
one subject of the elderly group was excluded from 
analysis 
Design of the study. The study was performed during 
3 days, separated by at least 1 week, in a climatized 
room (mean ± SD temperature, 24 6° ± 0 2° C, hu­
midity, "54 7% ± 2 1%, η = 48) Placebo or ANF 
was infused in random order in a double-blind manner 
On the study day, after a subject had fasted for at least 
2 hours, a catheter was placed into an antecubital vein 
of each arm The subjects remained supine throughout 
the study period of 3 hours, including short periods tor 
urinating 
After a subject had been in the supine position tor 1 
hour, placebo or ANF (low rate, 0 25 μg/mιn high 
rate, 2 0 μg/mln) was infused for a 60-minute period 
In a preliminary study these infusion rates resulted in 
a twofold increase of plasma ANF levels during the 
low-rate infusion and in a 20 fold increase during the 
high rale infusion Blood for determination of ANF was 
drawn in prechillcd EDTA tubes from an antecubital 
vein (intravenous catheter inserted 60 minutes belore 
infusion) 30 minutes before and immediately before 
infusion, at 30, 45, and 60 minutes after the start of 
infusion, and at 30 and 60 minutes after the end of the 
infusion 
Systolic and diastolic blood pressure were measured 
with a semiautomatic device (Artenosonde 1225, Roche 
Medical Electronics Division, Hoffmann-La Roche 
Ine , Orangeburg, Ν Y ) Heart rate was electrocardio 
graphically monitored continuously Forearm blood 
flow was measured by venous occlusion plethysmog 
raphy by use of mercury-in-rubber strain gauges Cir 
culation of the hand was excluded during all forearm 
blood flow measurements by inflation of a wrist cult 
to 50 mm Hg 
From 30 minutes before until 60 minutes after the 
start of the infusion, measurements of systolic blood 
pressure, diastolic blood pressure, and heart rate (each 
consisting of two readings) and forearm blood flow (six 
readings) were averaged to one mean value for each 
period of 15 minutes These calculated means were used 
for data analysis 
Laboratory determinations. The method for ANF 
determination has been described previously M A spc 
cific radioimmunoassay was used that was based on 
previous extraction of the plasma Sep-Рак С ] Я columns 
(Waters Associates, Milford, Mass ) Sensitivity of the 
assay was 0 8 pg per tube (corresponding to 4 pg/ml) 
Recovery averaged 969!, intraassay and interassay co­
efficients of variation were 8 b% and 11 6%, respec 
tively ' ' Normal values in 66 healthy volunteers ranged 
from 8 3 to 86 8 pg/ml (mean ± SD 35 3 ± 16 2 
pg/ml) The methods tor determination ol plasma cat 
echolamines and plasma renin activity have been pub 
lished previously ч s 
Drugs ANF(99-I26) was purchased from Bissen 
dorf Peptide GmbH, Wcdcmark, West Germany Im 
mediately before use ANF was diluted in a 48 ml 
Haemaccel (Hoechst, Bchnng-Werke AG, Marburg 
West Germany) solution Haemaccel is a polygeline (35 
gm/L) plasma expanding solution, and it was here used 
for placebo infusion and for solving ANF Results of 
pilot studies revealed that dissolution of ìodinated ANF 
in the Haemaccel solution resulted in a 20% loss of 
radioactivity to the inlusion system, compared with a 
50% loss when ANF was dissolved in 0 9<7t saline 
solution 
Data report. All results are expressed as mean val-
ues + standard deviation (SD) unless indicated other 
wise Hemodynamic eflects were averaged when a 
steady-state level of ANF was obtained during the last 
two time points of infusion (at 45 and 60 minutes) 
These data were used to calculate percentage changes 
from values just before inlusion The net hemodynamic 
effects were investigated by subtracting effects ol pia 
cebo infusion from effects of high or low ANF infusion 
rate The forearm vascular resistance was calculated as 
the quotient of mean arterial pressure (MAP) and fore 
45 
ANF (pg/ml) 
1000-, У°ипЯ 
Δ high 
G lOW 
о placebo 
100-
10 
60 
infusori 
Kig. 1. Course of [he mean (±SE) of plasma concerKrations of atrial natriuretic factor (ANF) 
before, during, and after the infusion of placebo, low dose ANF and high-dose ANF in young 
and elderly subjects 
arm blood How and is expressed in arbitrary units The 
MAP was calculated as the sum of the diastolic and 
one third of the pulse pressure 
Total body clearance of ANF was calculated by di­
viding the ANF infusion rate by the difference of 
steady-state and baseline ANF concentration 
Statistical analysis. Statistical analysis was per­
formed with the SAS software package (Statistical 
Analysis System Version 5 0, Cary, North Carolina) 
To analyze the hemodynamic effects of ANF infusion 
within each group of subjects, the mean percentage of 
ANF-induced changes were corrected for placebo for 
each infusion rate and were subsequently compared 
with zero by paired Student / tests To evaluate the 
difference in response between young and elderly sub­
jects, these placebo-corrected data of both groups were 
compared with each other by unpaired Student ι tests 
Correlation coefficients were calculated by the method 
of Spearman Significance was accepted at the 0 05 
level of probability (two sided) 
RESULTS 
Tabic I presents the clinical data of both groups 
Besides the difference in age (due to selection), the 
groups differed significantly (p < 0 05) in serum cre­
atinine levels and in the calculated creatinine clearances 
(formula of Cockcroft and Gault2fl) This significant 
difference, however, can be entirely ascribed to the 
decrease in renal function with age 
Atrial natriuretic factor concentrations. Fig 1 
shows the course of ANF levels before, during, and 
after the three infusion experiments in both groups As 
expected, the baseline ANF levels were elevated in 
the elderly subjects compared with the young sub­
jects (50 :E 13 versus 35 ± 9 pg/ml, ρ < 0 05) Pla­
cebo infusion induced no significant change in either 
group, with values after 60-minute infusions of 44 ± 9 
pg/ml versus 33 ± 12 pg/ml After both ANF infu­
sions, clear increases in the ANF levels were observed, 
leading to a steady state from 30 minutes after the start 
of inlusion The ANF values during low-dose infusion 
(averaged for the 45- and 60-minute time points) in­
creased to 133 ± 65 for the elderly subjects versus 
76 ± 38 pg/ml for the young subjects (elderly versus 
young, not significant) The respective mean values of 
the plasma ANF levels after the high-dose ANF infusion 
were 1001 ± 429 versus 570 ± 237 pg/ml (elderly 
versus young, not significant) In young subjects, the 
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Table II. Mean values ( ± SD) of systolic blood pressure, diastolic blood pressure, heart rate, mean arterial 
pressure, forearm blood flow, and forearm vascular resistance (in arbitrary units) before and during placebo 
and during low- and high-rate infusion of atrial natnuretic factor in young (n - 8) and elderly 
(л = 8) subjects 
Hemodynamic 
parameters 
Young subjects 
SBP (mm Hg) 
DBP (mm Hg) 
HR (beats/min) 
MAP (mm Hg) 
FBF (ml/100 ml/mm) 
FVR (AU) 
Elderly subjects 
SBP (mm Hg) 
DBP (mm Hg) 
HR (beats/mm) 
MAP (mm Hg) 
FBF (ml/100 ml/mm) 
FVR (AU) 
Placebo 
Baseline 
111 
66 
70 
81 
7 8 
17 
137 
77 
62 
97 
6 3 
21 
± 
± 
+ 
+ 
± 
± 
± 
± 
± 
± 
+ 
ί 
15 
7 
6 
9 
6 6 
10 
14 
10 
10 
10 
3 4 
14 
infusion 
During 
placebo 
infusion 
112 ± 
71 ± 
71 ± 
85 ± 
6 8 ± 
19 ± 
145 ± 
80 ± 
60 ± 
102 ± 
5 3 ± 
27 ± 
15 
7* 
7 
9 
5 7 
11 
17* 
II 
10 
12* 
2 9 
19* 
LOH rate 
Baseline 
110 
68 
68 
82 
6 4 
15 
133 
77 
61 
96 
7 1 
16 
± 
± 
± 
± 
-+-
± 
± 
± 
-+-
-+-
+ 
+ 
11 
7 
8 
10 
2 6 
8 
17 
9 
11 
11 
3 2 
6 
ANF infusion 
During 
low-rate 
infusion 
111 ± 12 
74 ± 6* 
68 ± 9 
86 ± 8* 
6 2 ± 2 8 
17 ± 9 
145 ± 23* 
83 ± 10* 
60 ± 10 
103 ± 13* 
6 6 ± 3 2 
19 ± 8* 
High-rate 
Baseline 
113 
71 
74 
85 
7 9 
18 
138 
80 
62 
99 
6 7 
18 
+ 
± 
± 
± 
+ 
+ 
± 
-t-
± 
± 
-b 
Ï 
11 
9 
7 
8 
6 2 
11 
15 
11 
11 
10 
3 5 
8 
ANF infusion 
During 
high-rate 
infusion 
110 ± 10 
71 ± 6 
77 ± 13 
84 ± 6 
8 1 ± 4 8 
14 ± 7 
129 ± 15* 
75 ± 11* 
67 ± 12* 
93 ± 11* 
8 9 ± 3 6* 
12 ± 4* 
ANF Atnal natriuretic Tactor SBP systolic blood pressure DBP diastolic blood pressure HR heart rate MAP mean arrena] pressure ГВГ forearm blood flow 
FVR forearm vascular resistance AU arbitrary units 
'p < 0 05 versus baseline 
Table III. Mean values ( ±SD) of the percentage changes (Δ) from baseline to steady state (averaged for 
time points 45 and 60 minutes) of systolic blood pressure, diastolic blood pressure, heart rate, mean arterial 
pressure, forearm blood flow, forearm vascular resistance in young {n = 8) and elderly (n = 8) subjects 
during low- and high-rate infusion of atnal natnuretic factor after correction for the changes induced 
by placebo 
Hemodynamic 
parameters 
ASBP (%) 
ADBP(%) 
AHR(%) 
ΔΜΑΡ (%) 
AFBF (%) 
AFVR (%) 
Low-
Young 
subjects 
- 0 0 ± 9 6 
- 0 6 ± 8 0 
- 1 1 ± 5 6 
- 0 2 ± 8 1 
+ 8 7 ΐ 38 9 
- 7 8 ± 36 9 
rate 
Ρ 
ANF infusion 
Value 
NS 
NS 
NS 
NS 
NS 
NS 
Elderh 
subjects 
+ 3 3 ± 4 8 
+ 3 5 ± 6 2 
+ 1 8 ± 12 6 
+ 3 4 ± 4 7 
+ 6 0 ± 24 2 
- 8 7 ± 32 7 
High 
Young 
subjects 
- 3 7 ± 3 6* 
- 8 4 ± 7 1* 
+ 3 2 ± 8 7 
- 6 2 ± 4 5 * 
+ 27 4 ± 36 0 
- 29 6 :t 27 7* 
rate ANF infusion 
ρ Value 
< 0 05t 
NS 
NS 
< 0 05+ 
NS 
NS 
Elderly 
subjects 
- 1 1 9 + 6 6 * 
- 10 1 ± 4 8* 
+ 11 0 ± 1 1 3 * 
- 11 0 ± 4 1* 
+ 56 8 2: 41 9* 
- 5 7 7 ± 32 6* 
ANF Atnal natnuretic factor SBP systolic blood pressure NS not sißnilicant DBP diastolic blood pressure HR heart rate MAP mean artenal pressure FBF 
forearm blood How FVR forearm vascular resistance 
*p < 0 05 versus zero 
tp < 0 05 versus elderly 
calculated total body clearance of ANF averaged 5 3 ± 
4 4 (high-dose ANF) and 6 8 ± 1 9 L/min (low-
dose ANF), whereas these values were significantly 
(p < 0 05) lower in the elderly subjects, numbering 
2 2 ± 0 7 a n d 3 8 ± 14 L/min Immediately after 
interruption of ANF administration, the ANF levels de-
creased very fast and were almost at baseline 30 minutes 
later At 60 minutes after discontinuation of the infu-
sion, the ANF level had returned to baseline for all 
three infusion experiments 
Hemodynamic effects. Table II presents basal and 
steady-state hemodynamic parameters for placebo and 
47 
60 
Time (min) 
Fig. 2. Mean ( ± SE) of the placebo corrected percentage changes (Δ) of systolic blood pressure 
(SBP), diastolic blood pressure (DBP), heart rale (HR), and forearm vascular resistance (FVR) 
induced by low-rate infusion of human atrial natriuretic factor (*-hANF) in young and elderly 
subjects 
for low-rate and high-rate ANF infusion No significant 
differences in the three baseline hemodynamic values 
were observed After placebo infusion, small increases 
in blood pressure were observed in the young and in 
the elderly group Further, slight reciprocal changes in 
forearm blood flow, and forearm vascular resistance 
occurred in both groups, but heart rate remained un­
changed during placebo administration During low-
rate ANF infusion, the changes from baseline were 
equal in direction and magnitude when compared with 
the placebo study These changes seemed slightly more 
pronounced in the elderly subjects than in the young 
subjects During high-rate ANF infusion, the changes 
in systolic and diastolic blood pressure, forearm blood 
48 
60 
Time (min) 
Fig. 3. Mean (±SE) of the placebo-corrected percentage changes (Δ) ot systolic blood pressure 
(SBP). diastolic blood pressure (DBP), heart rate (HR), and forearm vascular resistance (FVR) 
induced by high-rate infusion ol human atrial natriuretic factor (*-hANF) in young and elderly 
subjects 
flow, and forearm vascular resistance were opposite in 
direction when compared with placebo and with the 
low-rate ANF infusion. Now, a decrease in MAP was 
observed that was associated with a decrease in forearm 
vascular resistance and a rise in heart rate, especially 
in the elderly group, indicating a vasodilatory etlect 
Table III presents the ANF-induced percentage 
changes from baseline to steady state of both groups 
for the two infusion rates of ANF. all corrected lor the 
changes induced by placebo For the sleady-state val­
ues, the mean of the time points 45 and 6Ü minutes 
after the start of ANF infusion were used The placebo-
corrected changes induced by low-rate ANF infusion 
were nol significantly different from zero in either the 
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Table IV. Mean values ( ±SD) of the placebo baseline values and the placebo-corrected percentage changes 
(using the average values of time points 45 and 60) induced by low rate and high-rate infusion of atrial 
natriuretic factor on humoral parameters in young (n = 8) and elderly (n = 8) subjects* 
Humoral parameters 
Young subjects 
ir ANF (pg/ml) 
Noradrenaline (nmol/L) 
Adrenaline (nmol/L) 
PRA (nmol/L/hr) 
Hemoglobin (mmol/L) 
Hematocrit (L/L) 
Elderh iubjeit\ 
ir ANF (pg/ml) 
Noradrenaline (nmol/L) 
Adrenaline (nmol/L) 
PRA (nmol/L/hr) 
Hemoglobin (mmol/L) 
Hematocrit (L/L) 
Placebo 
baseline 
34 5 
0 69 
0 09 
0 87 
8 05 
0 39 
49 6 
1 50 
0 14 
0 5 1 
8 17 
0 38 
± 
± 
± 
± 
± 
± 
+ 
+ 
± 
+ 
± 
± 
8 9 t 
0 17t 
0 0 4 
0 48 
0 63 
0 02 
12 5 
0 37 
0 07 
0 41 
0 3 1 
0 02 
Lon rati • ANF minus 
phuebo (%) 
+ 136 6 
+ 2 6 
3 9 
+ 3 8 
+ 3 3 
+ 4 0 
+ 163 3 
+ 0 1 
+ 10 9 
+ 2 6 
+ 3 0 
+ 1 0 
+ 
+ 
± 
± 
± 
+ 
± 
± 
± 
-+• 
+ 
•+• 
31 0Í 
68 
73 
17 3 
3 8Í 
3 9Í 
37 5+ 
27 6 
41 
23 
6 45 
4 6 
High rate ANF ттич 
placebo (%) 
+ 1723 ± 
+ 14 4 ± 
- 7 1 ± 
+ 50 8 ± 
+ 4 9 ± 
+ 6 6 ± 
+ 2044 ± 
+ 0 8 ± 
+ 27 0 ± 
+ 26 6 ± 
+ 8 8 ± 
+ 9 6 ± 
1033t 
93 1 
88 9 
75 8 
2 7Í 
2 3Í 
872t 
54 I 
109 7 
26 9 
12 2t 
10 7t 
ANF Atrial natriuretic factor ir ANF- nnmunoreactive atrial natriuretic Uuur PRA pi ism ι renin activity 
•Only the placebo baseline values tre presented because no differences were observed between the three ргсіпіиыоп values 
t / j < Ü 05 youne versus elderly 
+ p < 0 05 versus 7ero 
young or the elderly subjects Moreover, there was no 
hemodynamic parameter showing any difference be 
tween young and elderly subjects during this low dose 
of ANF In contrast, high-rale ANF infusion disclosed 
significant hemodynamic changes, both in young and 
elderly subjects (Table III) a reduction in systolic 
blood pressure (young versus elderly, — 3 7% ± 3 6% 
versus - 11 9% ± 6 6% ρ < 0 05), diastolic blood 
pressure ( - 8 4 % ± 7 1% versus - 10 1% ± 4 8%, 
not significant), and MAP ( - 6 2% ± 4 5% ver 
sus - Il 0% ± 4 1%, ρ < 0 05), and a decrease 
in forearm vascular resistance ( — 30% ± 28% ver 
sus 58% ± 33%, not significant) The increase in 
heart rale ( + 3% ± 9% versus + 1 1 % ± 11%, 
not significan!) and the increase in forearm blood 
flow ( + 27% ± 36% versus + 57% ± 42% not sig 
nificant) were only significant in the elderly sub 
jects 
During high-rate infusion of ANF, the reductions in 
systolic blood pressure and MAP were significantly 
more pronounced in the elderly subjects than in the 
young subjects (Table III) Because of a disproportion 
ate increase in ANF levels in the elderly subjects after 
identical infusion rates as in the young subjects, a com­
parison ot hemodynamic responses by normalizing he 
modynamic changes with changes in ANF concentra 
tions was warranted When the percentage changes in 
systolic blood pressure and MAP were expressed per 
100 pg/ml of ANF increase, no difference between 
young and elderly subjects remained (change in blood 
pressure in percent per 100 pg/ml increase in plasma 
ANF, young versus elderly, systolic blood pressure 
- 1 1 + 1 2 versus - 1 4 ± 0 9 ρ = 0 44, MAP 
- 1 4 ± 1 4 versus - 1 2 ± 0 6, ρ = 0 90) 
Fig 2 shows the course of the hemodynamic per 
centage changes from baseline, corrected lor the 
changes induced by placebo, during low-dose infusion 
of ANF for both the young and the elderly subjects, 
now presented for each time point Intcrgroup com­
parison did not reveal any difference Fig 3 shows 
comparable data but with respect to the high-rate ANF 
infusion During this dose, hemodynamic responses 
were rapid at onset and were sustained during the du­
ration of steady-state ANF concentrations In the elderly 
subjects a clear decrease of MAP was obtained av 
eraging - 11% ± 4% for the 45- and 60-minute time 
points The forearm vasculature simultaneously showed 
a vasodilatory response, with an increase of forearm 
blood flow of 57% ± 42% The changes in MAP and 
forearm blood How together produced a substantial 
decrease of forearm vascular resistance of - 58% ± 
33% Probably because of this vasodilation, a com 
pensatory increase in heart rate of 11% ± 11% was 
observed 
Humoral effects Table IV demonstrates the baseline 
humoral data in both groups and the changes by both 
ANF infusions after correction for responses to placebo 
infusion As expected, baseline noradrenaline concen 
trations were higher and plasma renin activity values 
were lower in the elderly subjects compared with the 
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young subjects Both changes are well known to occur 
with advancing age 
Low- and high-rate ANF administration did not in-
fluence concentrations of catecholamines or ol plasma 
renin activity in either group Correlation coefficients 
were studied between both placebo-corrected hemo-
dynamic changes and humoral changes but failed to 
achieve statistical significance 
After the high-rate infusion a slight, though definite, 
hcmoconcentration occurred in both groups, but low-
rate ANF infusion induced hemoconcentration in the 
young group only 
Side effects. During ANF infusion no severe hypo-
tension, hght-headedness, or bradycardia was ob-
served. With regard to the diuretic effects ot ANF, no 
urgency of micturation was observed during placebo 
infusion or in the first 30 minutes after discontinuation 
of placebo infusion In contrast, after ANF ïnlusion 
urgency was perceived by five subjects (one elderly and 
four young subjects) during the low-dose infusion and 
by 10 subjects (four elderly and six young subjects) 
after the high-dose infusion of ANF When urgency 
was experienced, the subjects micturated instantly in 
the supine position One elderly woman could not uri-
nate while remaining supine, consequently, she was 
excluded from the study 
DISCUSSION 
In the present study we have examined hemodynamic 
parameters as effects of ANF levels after a placebo and 
a low-rate and high-rale ANF infusion in two different 
age groups The findings of the present study demon-
strate that healthy volunteers of these two different age 
groups both showed a vasodilatory response to intra-
venous infusion at high-rate ANF (2 0 μg/mlπ), with 
a decrease in blood pressure and forearm vascular re­
sistance The associated rise in heart rate probably oc­
curred as a result of cardiovascular reflex mechanisms 
to attenuate the decrease in blood pressure Moreover, 
the high dose of ANF resulted in a significant hemo­
concentration, as measured by changes in hematocrit 
The achieved plasma levels of ANF during these ex­
periments were far above the physiologic range The 
clinical relevance of these findings may therefore be 
restricted On the contrary, infusions of ANF at a low 
rate resulted in plasma ANF concentrations in the upper 
normal range (Table IV) These slight increments ol 
plasma ANF levels, however, failed to induce signifi­
cant changes in any parameter in either group, except 
a slight hemoconcentration m only the young subjects 
Until now, several studies have been performed on 
the circulatory effects of ANF at plasma concentrations 
in the high range "' " l s : 7 The currently observed va­
sodilatory response to the high dose of ANF is consis­
tent with reports from other investigators "•l7 Compar­
ison of these studies, however, is complicated by dif­
ferences in study design, especially with respect to the 
nature of the atrial peptides used, vehicle, mode ol 
administration (e g , bolus veisus infusion or intrave­
nous versus intra-arterial), duration of administration, 
and biologic characteristics of subjects (age. renal func­
tion, and other selection cnttna) In contrast to the 
high-rate infusion of ANF, we achieved plasma ANF 
concentrations at the upper normal physiologic range 
during low-rate ANF infusion :* The absence of a sig­
nificant hemodynamic responsi- at this low infusion rate 
seems to disagree with the findings of Bolli et al ,'7 
who observed significant increments of forearm blood 
flow within this concentration lange, suggesting a phys­
iologic role for ANF as an endogenous vasodilator 
These investigators, however, used a low-rate ANF in­
fusion intraartenally. and it i> not known whether re­
gional ANF levels after intraarterial infusions can be 
compared with those achieved alter intravenous sys­
temic infusion Moreover, it may be that the duration 
of the low-dose ANF infusion was too short in our 
study, inasmuch as previous reports with longer infu­
sion periods showed signifie int cardiovascular effects 
at ANF levels that are only «lightly elevated -" "' 
During infusion of ANF at both low and high rates, 
the plasma ANF concentrations reached at steady state 
were markedly higher in elderly subjects compared w ith 
the young subjects (Fig 1) This cannot be attributed 
to differences in height, we ght. or Quetelet index be­
cause these parameters were similar in both groups stud­
ied The only difference was a lower endogenous cre­
atinine clearance, as calculated by the formula of Cock-
croft and Gault'ft in the elderly group I his suggests a 
diminished (renal) clearance ol ANF with advancing 
age, as described previously " This lower clearance 
may also explain the higher baseline ANF concentra­
tions within the elderly group that were observed in 
this study and in other studies '* ''' Apparently, elevated 
plasma levels of ANF do not lead to a down-regulation 
of functional ANF receptors, inasmuch as our current 
data do not show a diminished response to exogenous 
ANF with advancing age We even lound a more pro­
nounced decrease in blood pressure after the high dose 
of ANF in the elderly With respect to this, the findings 
of Heim et al -" are of interest because they show that 
responses to bolus injections of ANF were also in­
creased in the elderly subjects compared with the young 
subjects However, it must be stressed that the differ­
ences between young and elderly subjects in our study 
disappeared completely when the hemodynamic re­
sponses were corrected for the higher increase ot ANF 
1 
level in the elderly subjects Indeed in the study of 
Heim et al " the elderly subjects also reached higher 
plasma ANF concentrations than the younger volun 
teers after a bolus ANF injection but unfortunately the 
hemodynamic responses were not presented per in 
crease of plasma ANF 
The high dose of ANF induced an increase of he 
moglobin and hematocrit levels, indicating hemocon 
centration ANF influences the intravascular volume by 
way of both a renal dependent pathway and an inde­
pendent pathway 3 1 Others have suggested that ANF 
stimulates transcapillary water movement " In this 
study a slight, though significant, hemoconcentralion 
is demonstrated to occur at the upper normal range of 
ANF in only the young and not in the elderly group 
Because the young subjects but not the elderly sub 
jects showed this response during low dose ANF in­
fusion, one might suggest that with respect to these 
processes a diminished susceptibility occurs with ad 
vancing age, confirming the hypothesis that a down 
regulation of ANF receptors in the elderly is a result 
of increased levels of circulating ANF However this 
seems to be contradicted because in elderly subjects if 
any an increased susceptibility was found for the he 
modynamic response to ANF Therefore with regard to 
this item on age related changes in sensitivity to ANF, 
there is still a need tor further research, especially re 
search of hemodynamic responses to similar levels of 
ANF in different age groups 
In conclusion, low rate infusion of ANF did not exert 
major cardiovascular effects in young subjects or in 
elderly subjects High rate infusion induced a vasodi 
latory response in both age groups with a decrease in 
blood pressure, an increase in forearm blood flow and 
an acceleration in heart rate In general, the effects of 
high rate ANF infusion were more pronounced in el­
derly subjects than in young subjects However, ANF 
concentrations reached at this dose rose disproportion­
ately more in the elderly subjects and, after correction 
of the hemodynamic response for this greater increase 
in ANF levels the response of both groups was essen 
tially identical Our data are therefore not consistent 
with the hypothesis that the cardiovascular responsive 
ness to ANF decreases with advancing age 
Wc thank Mrs В Theelcn and Mrs J Rcycnga RN for 
their helpful advice and technical assistance and Mrs J Ben 
neker tor the randomization procedure 
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CHAPTER 6 
Attenuated forearm vasodilator response to atrial natriuretic factor 
in elderly 
(Reproduced with permission from: 
Hypertension 1991; 18: 640-7) 
Attenuated Forearm Vasodilator Response to 
Atrial Natriuretic Factor in the Elderly 
Tim L Th A Jansen. Paul Smits, Adnaan С I Τ L Tan, and Theo Thicn 
The vasodilator potency of human atrial natriuretic factor-(99-126) was investigated in the 
forearm vascular bed of 10 young and 10 elderly nurmotensive volunteers with venous occlusion 
strain gauge plethysmography. Atrial natriuretic factor was infused at six increasing dose steps 
into the brachial artery from 0.001 up to 0.3 /ig/min/100 ml of forearm volume. This induced 
a mean±SEM increase in blood How from l.4±0.2 up to 6.0±1.0 ml/min/100 ml in the young 
and from 1.4±0.2 up to 3.9±0.6 ml/min/100 ml in the elderly. The dose-response curves of 
forearm blood How and of forearm vascular resistance after increasing infusion rates of atrial 
natriuretic factor were shifted to the right in the elderly when compared with the young 
subjects. The mean percent decrease in forearm vascular resistance, induced by atrial 
natriuretic factor, during this dose-response curve averaged - 3 1 ± 3 % in the elderly versus 
- 5 6 ± 3 % in the young subjects (/» = 0.0002). The calculated forearm spillover of the second 
messenger of atrial natriuretic factor, cyclic guanosine monophosphate, significantly increased 
from baseline values of 1.2±1.1 and 0.7±0.5 pmol/min/100 ml in young and elderly subjects, 
respectively, up lo 23.2±5.0 and 30.5±7.0 pmol/min/100 ml during the highesl dose of atrial 
natriuretic factor (both p<0.01 versus baseline). There were no significant differences in the 
increments ol the forearm spillover of this second messenger between both age groups. Further, 
both age groups demonstrated an equal vasodilator response to increasing infusion rates of the 
control vasodilator sodium nitroprusside, with a maximal decrease in forearm vascular 
resistance of 6 5 ± 3 % and 61 ± 2 % in the young and elderly group, respectively. This study 
demonstrates that advancing age in humans is accompanied by a specific reduction in vascular 
responsiveness to atrial natriuretic factor, without evidence for a diminished response of its 
second messenger. Therefore, we hypothesize that changes in postreceptor processes arc 
involved in the age-related reduction in vascular sensitivity for atrial natriuretic factor. 
(Hypertension 1991;18:640-647) 
A trial natriuretic factor (ANF) comprises a 
/ \ familv ot peptides of which the 28-amino 
i l a t i d ANI-(99-126). called human ΑΝΓ-
(99 126) is the major circulating form ' ANF is 
considered to contribute importanth to the control 
ol circulation homeostasis at physiological and 
pathophysiological conditions - One might wonder 
whether sensitivity to AN! changes during chronic 
exposure to elevated ΑΝΓ levels in ν ivo С ontradic-
tory reports have been published on the in vitro 
density ot vascular binding sites alter exposure to 
elevated ANF levels in rats •·ч A group of individ­
uals continuously exposed to elevated A N F levels 
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arc elderlv subjects ' Therefore it is ot interest to 
know whether sensitiv its to ANI has decreased in 
healths elderlv subjects In vitro studies in rats 
clearly demonstrate that vascular smooth muscle 
relaxation induced bs ANF is reduced with advanc­
ing age ч Up to now however, the lew studies in this 
area were difficult to interpret toi two reasons 1) 
ssstemic administration ot A N ! yielded higher 
ANI levels in the elderlv because ol dillerences in 
the total bods clearance of ΑΝΓ between young and 
elderlv. and 2) observed dillerences in the response 
to systemic ΑΝΓ intusion may be explained by an 
altered cardiovascular reflex activity in aged sub­
jects rather than by changes in vascular sensitivity lo 
ANI '' " Го avoid such difficulties in the interpre­
tation of results, we compared the in vivo vascular 
sensitivitv to ANF in young and elderlv subjects in the 
local vascular bed of the forearm and we hypothe 
sized that the high baseline plasma ANI levels in the 
elderlv arc accompanied bv a reduced lorearm vascu 
lar sensitiv its to ANF Apart from the vasodilator 
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response (о ANF. the forcami production of A N F s 
second messenger cyclic guanosinc monophosphate 
(cGMP) was studied in both groups To enable exclu­
sion of a nonspecific loss of vascular sensitivity with 
advancing age, the vasodilator response to ANI was 
compared with the response to the control vasodilator 
sodium nitroprusside (SNP) 
Methods 
Subjects 
The study protocol was previously approved by the 
ethics committee ol our institute Two groups ol 
healthy young (n = 10) and elderly (/1 = 10) volunteers 
recruited from the general population, were studied 
Before participation informed written consent was 
obtained from each subject All subjects underwent 
clinical examination bclore admission to the studv 
Physical examination revealed no relevant abnormal 
ities The two groups were matched tor blood pres­
sure which was noninvasivclv measured at screening 
examination None of the subjects smoked look any 
drugs oral contraceptives included, or abused aleo 
hol Further the subjects were instructed to eat their 
usual diet not to drink any соІГсе or tea and to 
refrain Irom hard labor during the 24 hours preced­
ing the experiment 
Design <>j tin Sliiih 
Ihe study was performed during a 1 hour immo­
bilization period in a climatizcd room (temperature 
22 ή ± 0 2°C, n = 20) The subjects were allowed to eat 
a light meal but not within 2 hours belore the test 
The tests were pcrlormed alter an equilibration 
period of at least 45 minutes with subjects in the 
supine position The left brachial artery was cannu-
lated with a 20-gauge Angiocath cannula (Deserei 
Medical Ine , Bccton Dickinson and C o , Sandy, 
Utah) for intra-artcrial blood sampling and drug 
infusion (automatic syringe infusion pump, type 
S 1С-521 Terumo Corp , Tokyo) as well as for blood 
pressure monitoring (Hewlett Packard monitor type 
78351B, Hewlett Packard GmbH, Böblingen, FRO) 
On the ipsilateral side an antccubital vein was can-
nulated for blood sampling Since the dosages ot all 
drugs were calculated per 1(H) ml of forearm volume 
(FAV), we measured the FAV in all participants by 
water displacement The subjects remained supine 
throughout the 3-hour study period 
During the study systolic and diastolic blood pres-
sure and mean arterial pressure were recorded intra-
arterial^ Heart rate was monitored continuously by 
an electrocardiographic registration Forearm blood 
flow (TBF) was measured by venous occlusion plethys-
mography using mcrcury-in-rubber strain gauges 
The circulation ol the hand was completely excluded 
during all FBF measurements by inflating a wrist cuff 
up to 100 mm Hg above the systolic blood pressure 
All Ihese parameters were measured during the 
several infusions of the study The infusions started 
simultaneously with the inflation of the wrist cuff, 
and FBF recordings were started from 1 minute after 
starling the infusion until the end of the infusion, 
during which at least three FBF recordings per 
minute were obtained During the last minute of each 
infusion rate a minimum of 10 consecutive values of 
systolic blood pressure, diastolic blood pressure, 
mean arterial pressure, and heart rate were regis-
tered and averaged to one representative mean value 
for that time point 
Alter the equilibration period, the experiment 
started with the infusion of placebo for 5 minutes 
(placebo 1) After a 10-minule pause, during which 
the wrist cuff was deflated, the ANF infusions were 
started with six increasing infusion rates from 0 001 
to 0 3 μg/mιn/100 ml I AV hach dose was adminis­
tered during 5 minutes, and two consecutive infusion 
rales were applied within one 10-minute period ol 
measurements Afterward, the wrist cuff was deflated 
again for a period of 10 minutes to allow recovery of 
the hand circulation I hus, three 10-minutc periods 
were needed to complete the lull dose-response 
curve lor ANF (0 001-0 004, 0 01-0 01, 0 1-0 3 μg/ 
min'100 ml FAV) 
Forty-hve minutes after cessation of the highest 
ANF administration, a second period with infusion of 
placebo was performed lor 5 minutes (placebo 2) 
I en minutes afterward, SNP was ìnlused in one 
session using three increasing infusion rates (10 10, 
and 100 ng SNP/min/100 ml FAV, 4 minutes per 
dose) 1 he sequence of administration of the several 
drugs (placebo, AN! , SNP) was blinded for the 
subjects 
Blood for determination of ANF was sampled in 
prechilled EDTA-tubcs from the antccubital vein 
and from the brachial artery at the last minute of the 
first placebo mlusion and at the highest ANF dosage 
cGMP was determined in plasma Irom prechilled 
EDTA tubes, sampled from the antccubital vein and 
from the brachial artery at the last minute of placebo 
infusion and at the fourth and sixth ANF dosage 
Laboratory Determinations 
The method for ANF determination was described 
previously r A specific radioimmunoassay based on 
prior extraction of the plasma on Scppak C-18 col-
umns was used Sensitivity ol the assay was 0 8 
pg/lubc (corresponding to 4 pg/ml) Recovery aver-
aged %f/r, intra-assay and interassay coefficients ot 
variation were 8 6% and 11 Ь7с respectively Normal 
values in 66 healthy volunteers ranged from 8 1 to 
86 8 pg/ml ( m c a n ± S D , 35 3± 16 2 pg/ml) 
Plasma cGMP concentrations were measured by 
radioimmunoassay as described previously ' ' 
Dnti>\ 
Human ANF-(us>-126) was purchased from Bis 
sendort Peptide G m b H , Wedemark, FRG Since we 
previously observed that adhesion ot ANF to the 
Silastic infusion system was greatly reduced when 
ANF was dissolved in Haemacccl (Hoechst Beh­
ring Werke AG, Marburg, FRG) instead of sa-
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line," we diluted ANF in Haemaccel immediately 
before use Consequently, pure Haemaccel was 
used during the placebo 1 period SNP was pur 
chased from Hoffmann-La Roche, Mijdrecht, The 
Netherlands, and dissolved in glucose 5% solution 
just before use Consequently, placebo 2 consisted 
of a pure glucose 5% solution 
Data Repon 
All results are expressed as mean ±SEM, unless 
indicated otherwise During the last 3 minutes of each 
dose, when steady-state effects were obtained, FBFs 
were averaged These data were used to calculate 
absolute and percent changes from the preceding 
placebo values The FVR was calculated as the quo­
tient of mean arterial pressure and FBF and was 
expressed in arbitrary units (AU) Forearm extraction 
of ANF was calculated as the quotient of the arterio 
venous difference in ANF plasma levels and the 
arterial ANF plasma concentration and was expressed 
as a percent The local forearm spillover of cGMP was 
calculated as the product of the arteriovenous differ­
ence in plasma cGMP and the FBF and was expressed 
in picomoles per minute per 100 milliliters FAV The 
spillover was considered to be a valuable measure of 
the regional production of cGMP 
Statistical Anahsi\ 
To analyze the response to ANF infusion within 
each group of subjects, the mean percent ANF-
induced effects were compared with placebo by 
paired Wilcoxon test To evaluate the difference in 
response between young and elderly subjects, the 
mean percent ANF-induced change in FVR of the 
complete dose-response curve was calculated for 
both groups, and subsequently they were compared 
with each other by the unpaired Wilcoxon test For 
correlations between parameters, the Pearson corre 
Idtion coefficient was calculated Significance was 
accepted at the 0 05 level of probability (two sided) 
Results 
Table 1 presents the characteristics of the subjects 
of both age groups Apart from the difference in age 
due to selection, the groups differed significantly 
(p<0 05) in mean arterial pressure and in the endog 
enous creatinine clearance, which was calculated 
from serum creatinine levels via the formula of 
Cockcroft and Gaull M The latter finding can entirely 
be ascribed to the physiological decrease in renal 
function with age The blood pressure levels pre­
sented in Table 1 concern measurements performed 
with a mercury sphygmomanometer in the supine 
position at the moment of screening 
Hemodynamic Effects 
Table 2 presents steady-state hemodynamic pa­
rameters during each last minute of infusion of the 
placebo and the several ANF and SNP doses Nei­
ther intra arterial administration of ANF nor that of 
SNP induced a significant change in blood pressure 
T A B L L 1 Group Characteristics Measured Under 
Baseline Conditions 
Young Elderly 
Baseline chdrdderistics (n = IO) ρ (л = 10) 
Sex rdii i i (M/F) 9/1 5/5 
Age (yr) 21 i I * 752:3 
Quelelet index (kg/m ) 22= 4 NS 24 + 3 
SBP/DBP (mm Hg) 135±5/73*f> NS/NS 142+11/79 + 8 
MAP (mm Hg) 94-5 t HK)± 10 
Serum creatinine (дтоІ/І) 79±8 NS 75±9 
Creatinine range (мтоІ/І) hK-94 61-89 
ECC (ml/min/m ) 70*8 t 35 + 7 
"Values are mean + SD Ddta of blood pressure are given as 
measured at screening Group comparison revealed a significant 
difference in age mean arterial pressure and endogenous creati 
nine clearance SBP systolic blood pressure DBP diastolic blood 
pressure MAP mean arterial blood pressure Queielet 
index=weight/height (kg/m ) ECC endogenous creatinine clear 
ance calculated by Cockcroft and Gault s formula14 NS not 
significant 
> < 0 01 
tp<0 05 
or heart rate when compared with its preceding 
placebo value Overall, blood pressure but not heart 
rate increased from the first to the second placebo 
infusion, but as shown in Table 2, this increase 
occurred during the equilibration period after ANF 
infusion rather than during the infusion experiments 
1 he changes in blood pressure throughout the exper 
iments were similar in both age groups 
Figure 1 shows the course of the mean FBF in 
relation to the time periods of ANF and SNP admin­
istration FBF gradually increased from 1 4±0 2 dur 
ing placebo to 6 0±1 0 ml/min/100 ml FAV during 
the highest ANF infusion rate in the young subjects 
with corresponding values of 1 4±0 2 and 3 9±0 6 
ml/min/100 ml FAV in the elderly subjects The 
administration of SNP induced comparable incre­
ments in FBF from I 7±0 3 during placebo to 
5 1 ±0 8 ml/min/100 ml FAV during the highest SNP 
infusion in the young subjects and from 1 5+0 1 
during placebo to 4 1 ±0 4 ml/min/100 ml FAV during 
the highest SNP infusion in the aged subjects 
Figure 2 presents dose-response curves of the 
percent decrease in the calculated FVR, as induced 
by ANF administration on the lett panel and by SNP 
administration on the right panel At the lowest 
infusion rale, ANF failed to lower the FVR in the 
aged subjects, whereas the young showed an obvious 
response to this dosage During the six ANF infusion 
rates the mean percent decrease in FVR measured 
- 5 6 ± 3 % in the young versus -31 ± 3 % in the elderly 
group (p=0 0002) In contrast, the mean fall in FVR 
after the three SNP infusion rates was not different 
between the young and elderly groups (young versus 
elderly, -45±2% versus -40±3<7r,/>>0 1) 
Humoral Effects 
The numbers for determination of ANF and 
cGMP levels were reduced, either because of insuf-
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V,dues .ire me<in + SL M ol sleady siale hemodynamic parameters calculated Irom measurements during the fourth 
to the fifth minute ol mira arterial administration of placebo I (Haemaccel) followed by atrial natriuretic factor and 
ol placebo 2 [Srr glucose solulion) followed bv sodium nitroprussidc in a group of young {n = 10) and elderly (*r = 10) 
volunteers Hlood pressure paramdc-rs were measured intra-artenallv 
SUP, systolic blood pressure. DBF diastolic blood pressure MAP mean arterial pressure, MR. heart rale I 131. 
forearm blood How I VR forearm vascular resistance AU jmitrarv units ANI atrial natriuretic factor SNP sodium 
nitroprussidc FAV fore.irm volume 
fìciency ol plasma quantities (x3) or because of 
hemolysis, of the plasma sample ( x2). Baseline ANI·" 
levels, measured during the first placebo infusion, 
were elevated in the elderly when compared with the 
young subjects: arterial plasma concentrations 
45H±2 7 versus 21 1 ±2.7 pmol/l (/7<0.001). and 
venous plasma concentrations 22 1 ± I 4 versus 
11.9±1 5 pmol/l (p=0.02) After the highest ANF 
infusion rate clear increments in the ANF levels were 
observed, both in elderly and young subjects, leading 
to arterial plasma levels of 763±110 pmol/l and 
644±260 pmol/l and to venous plasma levels at the 
side of intra-artenal infusion of 24,62()±2,570 pmol/l 
and 14,040±2,940 pmol/l. Forty-live minutes after 
interruption ol ΑΝΓ administration, during the sec­
ond placebo inluston, the ANF levels in the venous 
effluent were sharply decreased and no longer diHer-
FBF |ml/mm/100ml FAV I 
6 
F I G I RI 1 Graph show, time course oj forearm blood flow 
(FBn before, during, and after ¡he infusion of six dose steps of 
atrial natriuretic factor (ANF) and of three dose steps of 
sodium nitroprussidc (SNP) in soung (n = IO) and elderly 
<n = IO) subjects Mean-aSF.M P,. placebo I (Haemaicel), 
P.. placebo 2 (glucose 5c/r) hAV. forearm solume 
59 
Baseline 03 
ANF infusion rate 
l.ug/min/100ml FAV) 
30 100 SNP infusion rate |ng/mm/100ml FAV) 
F I G U R E 2 Line graphs show dose-response 
cunes of the percent changes (\) in forearm 
vascular resistance (FVR) induced by cumu­
lative intra-artenat infusion of atrial natri­
uretic factor (ANF) (Icfl panel) and of so­
dium nilroprusside (SNP) (righi panel) in 
young (n = 10) and elderly (n = 10) subjects 
Mean±SEM Probability value indicates the 
level of significance obtained by comparing 
the means of both curves NS, not significant, 
FA V, forearm volume 
ent from baseline: 46.7±3 4 versus 29.3±3.2 pmol/1 
in elderly and young subjects, respectively. 
During the first placebo infusion, the forearm ANF 
extraction was calculated from arterial and venous 
plasma ANF concentrations ANF extraction was 
43±5% in the young and 48±8% in the elderly. 
When corrected for forearm volume, ANF extraction 
was 4.2±0.6%/100 ml FAV and 5.4±0.8%/100 ml 
FAV, respectively. Between young and elderly no 
significant difference in forearm ANF extraction was 
observed. 
As was shown in Figure 2, the vasodilator response 
to ANF was reduced in the elderly When the 
individual vasodilator responses to ANF from both 
young and aged volunteers were plotted against the 
baseline plasma ANF concentrations, there appeared 
to be a significant correlation between these vari­
ables. As expected, this correlation was most pro­
nounced at the lowest ANF infusion rate (0 001 
μg/min/100 ml FAV) because the difference in the 
vasodilator effect of ANF between both age groups 
was largest at that particular ANF infusion rale 
(Figure 2) Figure 3 shows the scatter diagram on the 
individual baseline ANF levels and the correspond­
ing percent vasodilator response to the lowest ANF 
infusion rate in eight young and seven elderly sub­
jects in which a baseline arterial ANF level was 
available (n = 15, /-=0.79,p=0 0005; linear regression, 
y=*-49 7). When tne mean forearm vasodilator re­
sponse (calculated over all ANF dosages) was taken 
instead of the response to the lowest ANF infusion 
rate, there was still a significant correlation between 
the baseline ANF level and the response to ANF 
(n=\S, r = 0 72, p = 0 0025; linear regression, 
v=<).7*-67.4). 
Table 3 demonstrates arterial and venous cGMP 
values in the young and elderly group. Venous cGMP 
values increased in the young from 14 1±1.3 nmol/1 
during placebo infusion up to 25 5± 1 6 nmol/1 at the 
highest ANF infusion rate In the elderly, cGMP rose 
to significantly higher venous levels (from 15.0±0.9 
nmol/1 up to 31.8 ±1 7 nmol/1). Of course, to compare 
the local production of cGMP between both groups, 
the venous cGMP levels must be related to the local 
FBF, as has been done in the calculation of the 
cGMP spillover 
Δ Forearm vascular resistance (%) 
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TABLL 3. Arterial and Venous Cyclic (ìuanusine 
Monophosphate Concentrations 
0 20 40 60 80 
Baseline ANF concentration (pmol/l) 
FIGURE 3 Scatter diagram of individual baseline arterial 
plasma concentrations of atrial natriuretic factor (ANF) and 
the corresponding percent change (S) in forearm \ oscular 
resistance, induced by inlra-artenal infusion of the lowest dose 
of ANF (0 001 ßglminllOO ml forearm volume) m eight voung 
and seven elderly subjects 
Infused drugs 
Placebo 
Лгіегыі 
Venous 
A N F ((МП Mg/m 
Arterial 
Venous 
A N F (U 3 Mg/mi 
Arterial 
Venous 
Young ρ value 
(n=HI) (young vs elderly) 
12 6 * 0 8 
14 l ± l 1 
m/IUOml h A V ) 
I 3 8 ± ( ) 8 
1 7 S - 1 2' 
1/КЮ ml F A V ) 
21 3 ± 1 0 
2S S ± l f>' 
<(M>1 
(1(17 
<UU1 
Clderly 
(n = 9) 
14 S ± l 0 
1S()±()9 
I S K ± I ( I 
22 4 * 1 2' 
2S 1±1 2 
31 8 ± 1 7-
Values are mean±SEM of arterial and venous cyclic GMP 
concentrations (nmol/1) at ihe fifth minute of intrd-arlenal admin­
istration of placebo (HaemaLce!) and alna) natriuretic factor in a 
group of young and elderly volunteers 
ANF, atrial natriuretic factor, FAV, forearm volume Probabil 
ity values that were not significant arc not demonstrated 
'p<{){)\ venous vs arterial samples 
60 
cGMP Spillover (pmol/min/lOOml FAVI 
ЁЩ young (Ν 10 ) 
С П elderly (Ν 10 ) 
FlOLKL 4 liar цгаріі slum\ сиік Rúanosme monophos 
pliait IcGMP) \pillo\er m jonanns of \oung and ihkrh 
sttbjt!Lt\ dunng placebo (Huimautll injuuon and during 
infusion of amai nalnurem fai. ¡or (ANI) ut 0 01 ami al 0 ? 
pg/mm/ÌOO ml fonami \oluim (FAV) \han±Sl M \S nol 
significan! 
Figure 4 demónstrales ihis cGMP spillover in both 
groups studied In the young ANF induced d signif 
leant increase in the cGMP spillover from 1 2±1 1 at 
baseline to 2 1 2 ± 5 0 pmol/min/KX) ml FAV at the 
highest ANF infusion rate (/?<() 01 versus placebo) 
In the elderly, these values numbered 0 7±0 S and 
30 5±7 0 pmol/min/100 ml I AV (p<0 02 versus pia 
cebo) I hese ANF-induced increments in cGMP 
spillover were not significantly different between the 
young and the elderly subjects 
Side Effects 
During the local infusion ol ΑΝΓ into the brachial 
artery no hypotension hghi-headedness, or bradycar­
dia was observed With regard to the diuretic effects of 
ANF none of the subjects had any urge to micturate 
during or directly after the immobilization period 
Discussion 
In the present study, we observed elevated base­
line levels of ANF in our group of healthy elderly 
subjects, and when compared with the young, these 
aged subjects obviously showed an attenuated lore-
arm vasodilator response to AN Γ Although the 
forearm vascular bed is not very susceptible to age-
related atherosclerotic changes, we checked whether 
our selected elderly subjects showed any relevant 
structural vascular changes This is especially impor 
tant since, despite the well matched blood pressures 
at screening (Table 1), the intra-arierial blood pres 
sure level of the aged subjects appeared to be higher 
when compared with the young (Table 2) With 
respect to this item, it must be stressed that there 
were no differences in the vasodilator response lo 
intra-arterial infusion of the control vasodilator SNP 
Furthermore, it is important to realize that the 
highest dose of SNP induced trough values of FVR in 
the same range as alter ANF, and therefore we think 
that within the applied range of ANF dosages, the 
currently observed age-related reduction in sensitiv­
ity for ANF cannot be attributed to structural fore­
arm vascular changes in the elderly group Conse­
quently, aging seems lo be accompanied by a specific 
reduction in vasodilator potency of ANF in humans 
Until now, the human studies on ANF and aging 
were performed during systemic administration of 
ANF As a result of the lower total body clear­
ance ol ANF in ihe elderly, similar doses of this 
peptide resulted in higher plasma A N F levels in 
those studies complicating the interpretation of the 
results Although in the present study baseline levels 
of plasma ANF were higher in the elderly when 
compared wiih the young, there were no differences 
in the baseline forearm extraction of A N F between 
the young and elderly subjects, suggesting that the 
handling of ANF across the forearm was similar in 
both groups Consequently, the reduced vasodilator 
response to ANF in aged subjects seems to be of 
pharmacodynamic rather than of pharmacokinetic 
origin 
Despite relatively high systemic (arterial) plasma 
ANF levels we did not observe a significant fall in 
blood pressure during the intra-arterial ANF infu­
sion This was probably due to the short infusion 
periods never exceeding 5 minutes per dose The 
absence of any significant drug-related fall in blood 
pressure or rise in heart rate demonstrates that the 
local vasodilator effects of ANF and SNP were not 
associated with systemic hemodynamic effects Thus, 
the several procedures probably did not induce car­
diovascular reflex activation Therefore, it is unlikely 
that eventual differences in cardiovascular reflex 
activity between young and elderly subjects contrib­
uted to the observed differences in the vasodilator 
response to ANF However, we should note that no 
time control studies were performed, and therefore it 
is not possible to exclude a systemic hemodynamic 
effect of ANF during the infusions 
Our human in vivo data are in agreement with the 
shifted dose-response curve of ANF-induccd vasodi­
lation in aged rat thoracic aorta as demonstrated in 
vitro H Apart from the elderly, elevated endogenous 
ANF levels in humans have been found in several 
conditions, for instance in heart failure Recently 
Hirooka ct a l n showed that the forearm vasodilator 
response to intra-arterial A N F was attenuated in 
patients suffering from congestive heart failure 
Combined with our current results, this suggests that 
the elevated plasma ANF levels rather than aging 
itself are responsible tor the reduced vasodilator 
response to ANF Observations on a reduced re­
sponse of mesentery artery smooth muscle cells to 
ANF after exposure to elevated ANF concentrations 
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do also agree with this view l h AJlhough wc realize 
lhat our results do not prove that baseline ANb 
concentrations have a primary role in reducing the 
responsiveness of the vascular system to ANF in the 
elderly, the significant correlation between the base 
line plasma ANF concentrations and (he vasodilator 
response to A N F as observed in our study may 
further argue for this hypothesis (Figure 3) 
It has been demonstrated that even 24-hour expo 
sure to elevated A N F levels induces a reduced re 
sponse of mesentery artery smooth muscle cells to 
ANF lh If this relatively short period also holds for 
the human situation, this may be relevant with re 
spect to pharmacological agents that interfere with 
the endogenous A N F degradation such as the re 
cently developed neutral mctallocndopcptidase in 
hibitors 1 7 Furthermore, on account of the present 
results it may be clinically relevant that the vasoac 
tive effects of these neutral melalloendopeptidase 
inhibitors are expected to be less effective in aged 
subjects Whether the physiological role of endoge 
nous A N F becomes less important during aging 
remains to be established especially since the plasma 
ANF levels in the venous effluent reached in our 
study are in the pharmacological rather than in the 
physiological range However, the fact that the dif 
fcrcncc between young and aged subjects seems 
largest at the lowest infusion rate suggests that the 
reduced potency for ANF in the elderly mav also be 
ol relevance in the physiological range (Figure 2) 
From a theoretical point of view a reduced respon 
siveness of the vascular wall to ANI in lh(_ elderly 
may contribute lo the development of hvpcrtcnsion 
in these subjects However our data do not add much 
relevant information to this view because our clderlv 
subjects were normotcnsivc and it would onlv be 
speculative to extrapolate the current results to aged 
hypertensive patients Moreover as a result of our 
experimental design with regional infusions of low 
dosages of ANF into the forearm vascular bed the 
systemic blood pressure was not expected to show 
any change during the several infusion^ 1 heretore in 
our studv systemic blood pressure must be consid 
ered as an irrelevant parameter with respect to this 
problem Ал argument against an important role of 
the age related fall in vascular responsiveness to 
ANF in age related hypertension is the fact that the 
aged subjects have significant^ elevated baseline 
plasma ANF concentrations Together with a re 
duced vascular responsiveness to ANF these ele 
vated baseline plasma ANF concentrations may re 
suit in an ultimately unchanged ANF mediated 
vascular lone in the elderly 
Theoretically downregulalion of the ANF recep 
lor density is the most likely explanation for a 
reduced biologic response to ANF during states of 
elevated plasma ANF concentrations Indeed in 
vitro studies in rats have shown a reduced ANF 
stimulated response of its second messenger cGMP 
during exposure to elevated ΑΝΓ concentrat ions 4 l h 
and lhat may well reflect a lower ANF receptor 
densitv in those studies Howe\er we did not observe 
a reduced response ol cGMP to ΑΝΓ in the aged 
group (Figure 3) The ANF-induced increase in 
cGMP spillover was similar in the two groups during 
the two infusion rates Within this context, it is 
interesting that a similar discrepancy between a 
reduced vasodilator response and cGMP production 
was found in patients with heart failure ^ Appar 
ently the elevated plasma ANF levels of aged sub 
jeets induce a defect in intracellular mechanisms that 
is located beyond the level of cGMP production and 
that reduces the transduction of ihc ANF receptor 
mediated signal lo the cellular response Such an 
intracellular defect has also been hypothesized with 
respect to heart failure1" and may therefore be 
caused by the elevated plasma ANF levels rather 
than bv the underlying (patho)physiological state 
However it should be noted that we did not study the 
intracellular mechanisms of ANF nor its transduction 
io biologic responses, and therefore the aforemen 
tioned interpretations still remain hypothetical 
In conclusion short term intra-artcnal infusion 
of A N F induced acuK increments in FBF In aged 
subjects the dose response curve of the vasodilator 
effect of ANI clearly showed a significant shift to 
the right when compared with young volunteers 
whereas the response lo SNP was identical in both 
groups No arguments were found for an ANF 
receptor downregulalion with advancing age since 
ihc production of A N F s second messenger cGMP 
was not diminished in the clderlv when compared 
with the voung subjects Therefore we hypothesize 
that the age related reduction in the vasodilator 
response to ΑΝΓ is accompanied by alterations in 
posireccplor mechanisms 
Acknowledgments 
Wc thank bugenic Oldc Rickennk RN and 
Mane Cecile Jacobs MI) lor their helpful advice 
and technical assistance 
References 
1 Schw. in/ D Geller DM Manning PT Siegel NR Fok KF 
Smith С I Ncedlem in I1 Ser Leu Arg Arg Atriopeptin III 
The major circulating form of uri il peptide Siurut 148S 2">4 
197 4(10 
2 Ballerman BJ Brenner BM Role of alrial peptides in bodv 
fluid homeosiisis С in Ka 1486 S8 614-610 
1 Hurnclt J( Jr Atri il η ilriurelic ídclor Is it phvsiologicalK 
important ' (mululum 144082 |s21 1S2J 
4 Ballcrmann BJ Hooser RL Karnowskv MJ Brenni_r BM 
Physiologie regulation of atrial nairiurctic pepnde receptors in 
r il ren il glomeruli J С ¡m Imtsl I48S 76 2<>44-2(ls6 
5 ( achofuro V Schilfrin Fl FhlbiullG C.mlin M Ci ircij R 
Effect of a chronic infusion of atrial nairiurctic factor on 
glomerular ind sascular receptors in spontancousls hvperten 
sner t t s J Ihptmm 1484 7 11S-142 
6 Miller BCD 7uesi l l Sh i»S On idinger MP Uehlmger DE 
Weidmann Ρ Effects of posture ind igmg on circuì iling it π il 
natriuretic peptide levels in man 3 H\fttTTtn\ 1487 ч si l Ss6 
7 Ohashi M Fujio N Nasata H Kato К Ibavashi H Kangawa 
К Mustio 11 High pi isma toncentrations of human atrial 
natriuretic poKpcptide in iged men J С lm hndoinnal Milah 
1487 64 81 8s 
62 
8 Kawai Y Ohhashi Τ Age relatt_d changes m relaxant 
response of vascular smooth muscles to atrial natriuretic 
peptide J Pharmacol txp Iher 1990 252 1234-1239 
9 (jrimaldi R Zini I Agnati F Fuxe К Harfstrand A Intrave 
nous administration of ainopeptm III iffects arterial blood 
pressure diffcrentiallv in voung and old mak rats Ada Ph\siol 
Scand 1987 129 S 8 
HI I leim J M Guttmann К Weil J Strom TM Gerzer R Effects 
of ι bolus dose of atrial natriuretic laclor in voung and elderlv 
volunteers Fur J Clin fn\es¡ 1989 19 26S 271 
11 Jansen TLTA Tan ACITL Smits Ρ DeBooTh Bcnraad ThJ 
Thien Th Hemodynamic effects oí atrial natriuretic factor in 
voung and elderlv subjects Clin Pharmacol Iher 1990 48 
179 188 
12 Rosmalen FMA Tan ACITL Tan HS Benriad ThJ A 
sensitive radioimmunoassay of atrial natriuretic peptide in 
human pi isma using a tracer with in immobilized glvcounl 
agent Clin Cium Aita 19H7 1 (SS 33] 140 
13 Tan ΑΓΙΤΙ Ho._fnigcls WIIL Swinkels 1 MJW Kloppen 
borg PWC Bcnraad ThJ The effects of volume expansion on 
ι trial natriuretic peptide and evehc guanosine monophosph ile 
levels in voung and iged subjects J Лт Cieñan Soc 1990 18 
121S 1219 
14 Cockcroft DW Gault MH Prediction of creatinine clearance 
from serum creatinine Nephron 1976 16 Τ1-41 
\S Hirooka Y Takeshita A Imaizumi Τ Suzuki S Yobhida M 
Ando S Nakamura M Attenuated forearm vasodilative 
response to intra arterial atrial natriuretic peptide in patients 
with heart failure Circulation 1990 82 147-1S3 
In Hamet Ρ Tremblay J Pang SC, Skuherska R Schiffnn EL 
Garcia R Cantin M Genest J Palmour R, Ervin FR Martin 
S Goldwater R Cyclic GMP as mediator and biological 
marker of atrial natriuretic factor J Hypertens I986 4(suppl 
2) S49 S*ï6 
17 Syberi7 EJ Drugs inhibiting the metabolism and inactivation 
of atrial natriuretic factor Pharmacological actions and ther 
apeutic implications Cardioxasc Drug Rev 1990 8 71-82 
18 Riegger GAJ Eisner D Kromer EP Daffner С Forssmann 
WG Muders F Pascher EW Kothsiek К Atrial natriuretic 
peptide in congestive heart failure in the dog Plasma levels 
cvclic guanosine monophosphate ultrastructure of atrial myo 
endocrine cells and hemodynamic hormonal and renal 
effects Circulation 1988 77 398-406 
KLV WORDS · atrial natriuretic peptides · vascular reactivitv 
• cvclic GMP · aging 
63 

CHAPTER 7 
Impaired vasodilator response to atrial natriuretic factor 
in insulin-dependent diabetes mellitus 
(Submitted) 
IMPAIRED VASODILATOR RESPONSE TO 
ATRIAL NATRIURETIC FACTOR IN 
INSULIN-DEPENDENT DIABETES MELLITUS 
Paul Smits, Ferry M.R.J. Hersbach, Tim L.Th.A. Jansen, 
Theo Thien and Jos A. Lutterman 
Division of General Internal Medicine, Department of Medicine 
University Hospital Nijmegen, Nijmegen, The Netherlands 
Keywords: atrial natriuretic factor (ANF); vascular relaxation; forearm blood flow; 
hyperglycemia. 
66 
SUMMARY 
Diabetes mellitus has been associated both with elevated plasma concentrations of the 
natriuretic and vasorelaxant hormone atrial natriuretic factor, and with a reduced natriuretic 
response to this hormone. We now hypothesized that the vasodilator response to atrial 
natriuretic factor is attenuated in type 1 diabetes mellitus. Forearm vasodilator responses to 
the infusion of six increasing dosages of atrial natriuretic factor into the brachial artery were 
registered by venous occlusion strain gauge plethysmography in 10 patients with 
uncomplicated type 1 diabetes mellitus and in 10 age-, sex- and weight-matched controls. 
Baseline levels of blood pressure and forearm blood flow as well as of plasma concentrations 
of atrial natriuretic factor were not different between controls and diabetic patients. In 
controls, atrial natriuretic factor induced a percentage fall in the torearm vascular resistance 
of -29±5% at the lowest to -72±4% at the highest infusion rate. In the diabetic patients this 
fall was significantly attenuated, measuring respectively -2±7% and -45±4%(P<0.001 versus 
controls). During infusion of atrial natriuretic factor into the brachial artery, the calculated 
regional production of cyclic guanosine monophosphate (cGMP, second messenger of atrial 
natriuretic factor) increased from +1.2±1.1 to +228±48 pmol/min/100 ml in the controls, 
whereas hardly any change occurred in the patients with diabetes (from -2 1±12 to 
+ 2.9±4 7 pmol/min/100 ml). Both controls and diabetic subjects demonstrated an equal 
forearm vasodilator response to increasing infusion rates of the control vasodilator sodium 
nitroprusside. We conclude that uncomplicated insulin-dependent diabetes mellitus is 
associated with a specific reduction in the vascular responsiveness to atrial natriuretic factor. 
In association with the normal baseline plasma concentrations of this hormone in the present 
diabetic patients, these results suggest that the contribution of the atrial natriuretic 
factor-mediated vasodilation to the baseline vascular tone is reduced in diabetic patients 
when compared with healthy controls. This observation may be of relevance with respect to 
the regulation of blood pressure and vascular tone in patients with diabetes mellitus. 
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INTRODUCTION 
Atrial natriuretic factor (ANF) is an endogenous peptide with potent diuretic, natriuretic and 
vasorelaxant properties (1, 2) Several studies indicate that ANF may serve as an important 
volume-regulating hormone in (patho)physiological conditions (1, 3). Increased plasma 
concentrations of ANF are found in several states of extracellular volume expansion, for 
instance as a result of high sodium intake or in case of congestive heart failure (1,4). Apart 
from the initial phase which may be accompanied by dehydration, diabetes mellitus has also 
been associated with distinct volume expansion (5). An increase in the total exchangeable 
body sodium has been reported to exist in both type 1 and type 2 diabetes mellitus, and may 
be explained by the sodium retaining effect of insulin and by the sodium cotransport in the 
renal tubules during glucose reabsorption The increase in the extracellular volume in 
diabetes may be the base for elevated baseline levels of ANF in these patients as described 
by some (6-8), but not all investigators (9). 
Apart from the reports on increased baseline values of ANF, diabetes has been 
associated with a reduced biological response to ANF. Water immersion as well as an 
intravenous sodium load, both methods to induce increments in endogenous ANF plasma 
concentrations exerted an impaired diuretic and natriuretic response in diabetic patients 
when compared with controls (7, 8), and similar results were obtained after the 
administration of exogenous ANF (10,11). 
Up to now, however, it is not known whether this impaired renal responsiveness to 
ANF in diabetes also holds for the vasodilator effect of ANF. In the present study we used 
the perfused forearm technique to investigate whether the vasodilator response to ANF is 
impaired in insulin-dependent diabetes mellitus This technique enabled us to quantify the 
in vivo vasodilator effect of intra-arterially administered ANF in patients with diabetes 
mellitus and in matched controls without inducing systemic effects of ANF on blood 
pressure, autonomic nervous sytem or diuresis. 
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MATERIALS AND METHODS 
Subjects 
The study protocol was previously approved by the Ethics Committee of our Institute. Ten 
patients with insulin-dependent diabetes mellitus were selected from our outpatient clinic. 
The inclusion criteria for the diabetic patients were: a duration of diabetes oi more than four 
years, a normal blood pressure (< 160/90 mmHg), no evidence for microvascular 
complications like diabetic retinopathy, neuropathy or micro- or macroalbuminuria 
(nephropathy), and no clinical evidence for macrovascular disease. Furthermore, the patients 
were selected on signs of a chronic modest hyperglycemia with a glycosylated hemoglobin 
level (HbAl
c
) between 8.0 % and 11% (normal value <6.7%), because increased values of 
extracellular volume with raised baseline levels of ANF have been reported to occur in these 
patients (6). The control group consisted of ten non-smoking healthy volunteers who were 
matched for age, sex and body mass index. Before participation, informed written consent 
was obtained from each subject. All healthy subjects were submitted to clinical examination 
before admission in the study. Physical examination revealed no relevant abnormalities. None 
of the subjects smoked, took any drugs, oral contraceptives included, nor abused alcohol. 
Further, the subjects were instructed to eat their usual diet, not to drink any coffee or tea 
and to refrain from hard labour during 24 hours preceding the experiment. The diabetic 
patients were instructed to use their regular subcutaneous insulin dose and their regular 
breakfast at the morning of the experiment 
Design of the study 
The study was performed during a three hour immobilisation period in a climatized room 
о 
(temperature: 22.4±0.3 C, n=20). The tests were all performed in the morning after an 
equilibration period of at least 45 minutes with subjects in the supine position. The left 
brachial artery was cannulated with an Angiocath cannula (20 gauge) (Deseret Medical Ine, 
Becton Dickinson and Сотр., Sandy, Utah) for intra-arterial blood sampling and drug 
infusion (automatic syringe infusion pump, type STC-521, Terumo Corp., Tokyo, Japan) as 
well as for blood pressure monitoring (Hewlett Packard monitor, type 78353B, Hewlett 
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Packard GmbH, Böblingen, Germany). On the ipsilateral side an antecubital vein was 
cannulated for blood sampling. Since the dosages of all drugs were calculated per 100 ml of 
forearm volume (FAV), the FAV was measured in all participants by water displacement. 
The subjects remained supine throughout the study period of three hours. 
During the study, systolic and diastolic blood pressure, and mean arterial pressure 
(MAP) were recorded intra-artenally. Heart rate (HR) was monitored continuously by a 
precordial electrocardiographic lead. Forearm blood flow (FBF) was measured at the left 
experimental arm by venous occlusion plethysmography using mercury-in-silastic strain 
gauges. The circulation of the hand was completely occluded during all FBF measurements 
by inflating a wrist cuff up to 100 mmHg above the systolic blood pressure. All these 
parameters were measured during the several infusions of the study. The infusions started 
simultaneously with inflation of the wrist cuff, and FBF-recordings were started from one 
minute after starting the infusion until the end of the infusion, during which at least three 
FBF-recordings per minute were obtained. 
After the equilibration period, the experiment started with the infusion of placebo for 
five minutes (placebo 1). Subsequently, a 10-minute pause was introduced, during which the 
wrist cuff was deflated. Then, the ANF infusions were started with six increasing infusion 
rates from 0 001 to 0.3 μg/mln/100ml of FAV. Each dosage was administered for five 
minutes, and two consecutive infusion rates were applied within one 10-minute period of 
measurements. Afterwards, the wrist cuff was deflated again for a period of 10 minutes to 
allow recovery of the hand circulation. Thus, three 10-minute periods were needed to 
complete the full dose-response curve for ANF (1 s t period- 0.001-0.003, 2 n d period: 
0.01-0 03; 3 r d period: 0.1-0.3 Mg/min/100 ml FAV). 
Forty-five minutes after cessation of the highest ANF administration, a second period 
with infusion of placebo was performed for five minutes (placebo 2). Ten minutes 
afterwards, sodium nitroprusside (SNP) was infused in one session using three increasing 
infusion rates (10, 30 and 100 ng SNP/min/100 ml FAV, four min per dose). Sodium 
nitroprusside served as a control vasodilator, to find out whether possible defects in the 
response to ANF were specific tor the vasodilator effect of ANF, or were due to a more 
generalized process. The sequence of administration of the several drugs (placebo 1, ANF, 
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placebo 2, SNP) was blinded for the subjects. 
At baseline (last minute of the first placebo infusion), and at the end of the highest 
ANF infusion rate, blood was sampled in prechilled EDTA-tubes from the antecubital vein 
of the infused arm for determination of plasma ANF concentration. Also, at baseline, and 
at the end of the fourth and sixth ANF infusion rate, cyclic guanosine monophosphate 
(cGMP, the second messenger for the effects of ANF (12)), was determined in plasma from 
prechilled EDTA-tubes. These samples were taken from the antecubital vein as well as from 
the brachial artery to be able to calculate the regional production of the second messenger 
cGMP before and during the local ANF infusion, as described previously (4, 13). 
In the diabetic patients, plasma glucose concentration was measured at intervals of 
about 30 minutes throughout the experiments. When the plasma glucose level fell below 5 
mmol/1, glucose 20% was infused in the antecubital vein of the non-experimental right arm 
to prevent hypoglycemia during the experiments 
Laboratory determinations 
The method for ANF determination was described previously (14). A specific radioimmuno-
assay based on prior extraction of the plasma on Seppak C-18 columns was used. Sensitivity 
of the assay was 0.26 pg/tube (corresponding to 1.3 pg/ml). Recovery averaged 96 %, ìntra-
and mterassay coefficients of variation were 8.6 % and 11.6 % respectively. Normal values 
in 66 healthy volunteers ranged from 2.8 to28.9 pmol/1 (mean±SD: 11.8 ± 5.4 pmol/1). 
Plasma concentrations of cGMP were measured by radioimmunoassay as described 
previously (15). 
Drugs 
Alpha human atrial natriuretic factor was purchased from Bissendorf Peptide GmbH, 
Wedemark, Germany. Since we previously observed that adhesion of ANF to the silastic 
infusion system was greatly reduced when ANF was dissolved in Haemaccel in stead of 
saline (16), we now again diluted ANF in Haemaccel immediately before use. Consequently, 
pure Haemaccel was used during the placebo 1 period. Sodium nitroprusside (SNP) was 
purchased from Hoffmann-La Roche, Mijdrecht, The Netherlands, and dissolved in glucose 
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5% solution just prior to usage, and therefore placebo 2 consisted of a glucose 5 % solution. 
The nitroprusside solutions were continuously protected from light 
Data report 
All results are expressed as mean values ± standard error (SE), unless indicated otherwise. 
During the last two minutes of each dosage, when steady state effects were obtained, FBF's 
were averaged. These data were used to calculate absolute and percent changes from the 
preceding placebo values. The forearm vascular resistance (FVR) was calculated as the 
quotient of MAP and FBF, and expressed in arbitrary units (AU) 
The regional forearm production of cGMP was calculated as the product of the 
arteno-venous difference in plasma cGMP and the FBF, and is expressed in pmol/min/100 
ml FAV. 
Statistical analysis 
Differences in baseline values of the several parameters between the two study groups were 
evaluated by unpaired Student t-tests. To analyze the response to ANF infusion within each 
group of subjects, and to evaluate the difference in response between the diabetic patients 
and the control group, absolute and/or percent changes from placebo were analyzed by a 
two-factor analysis of variance (ANOVA) with repeated measures Significance was accepted 
at the 0 05 level of probability (two-sided) 
RESULTS 
Table 1 presents the characteristics of the two groups of participants. The blood pressure 
levels presented in table 1 concern the intra-artenal measurements at baseline conditions 
at the beginning of the experiments. Apart from the duration of diabetes and the 
HbAlc-level, both due to selection, there were no significant differences between the groups. 
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Table 1 Demographic data of the healthy volunteers and the diabetic patients Mean ± SD (and range) are 
given (blood pressure value was measured by the intra arterial line in the supine position ) 
Control Diabetes 
clinical parameters (N=10) (N=10) 
Sex rate 
Age 
Weight 
Height 
Body mass index 
Forearm volume 
Systolic blood pressure 
Diastolic blood pressure 
Heart rate 
Duration of diabetes 
Glycosylated hemoglobin 
(male/female) 
(year) 
(kg) 
(m) 
(kg/m2) 
(ml) 
(mmHg) 
(mmHg) 
(bpm) 
(year) 
(%) 
9/1 
20 5±0 9(19 22) 
74 7±10 4 (59 0-97 0) 
1 83±0 10 (1 55 1 92) 
22 5±3 0(18 4 28 3) 
1008+130(700 1125) 
134 0±5 5 (126 142) 
73 0±5 8 (62 80) 
710±9 0(60 84) 
--
--
7/3 
23 9±5 7 (18-33) 
76 9±9 1 (59 0-91 1) 
1 78+0 09 (1 62-190) 
24 3±1 8 (216-26 8) 
990+115 (700 1150) 
123 8+9 2 (110 136) 
66 9±4 8 (60-74) 
68 6±8 5 (55-86) 
12 1 ±6 2 (4-22) 
9 4±0 9 (8 0-106) 
Hemodynamic effects 
Table 2 presents steady-state hemodynamic parameters (last two minutes of infusion) during 
administration of the placebo's, and the several ANF and SNP dosages Neither intra-arterial 
administration of ANF, nor that of SNP induced a significant change in blood pressure or 
heart rate, when compared with its preceding placebo value However, from the beginning 
(placebo infusion) to the end of the experiment (highest SNP dose), mean arterial blood 
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Table 2 Mean values (±SE) from the mean arterial pressure (MAP), heart rate (HR), forearm blood flow 
(FBF) and forearm vascular resistance (FVR), calculated from measurements during the last two minutes of 
inlra-arterial administration (steady-state values) of placebo 1 (Haemacccl) followed by atrial natriuretic factor 
(ANF), and of placebo 2 (glucose 5% solution) followed by sodium nitroprusside (SNP) in a group of healthy 
volunteers (N=10, upper panel) and diabetic subjects (N=10, lower panel) MAP was measured intra-
artenally 
CONTROLS 
Placebo 1 
ANF dose ^g/min/100 
0 001 
0 003 
0 01 
0 03 
01 
0 3 
Placebo 2 
SNP dose (ng/min/100 
10 
30 
100 
MAP 
(mmHg) 
83±3 
ml FAV) 
83±3 
84+3 
87±3 
87±3 
87±4 
87±3 
93+3 
ml FAV) 
94+2 
95±2 
95±3 
HR 
(bpm) 
64±3 
62±2 
62+3 
64±3 
65±3 
63±3 
65±3 
63±3 
63+3 
65+3 
66±3 
FBF FVR 
(ml/min/lOOml) (AU) 
1.4+0 2 
2 1 ± 0 3 
2 7 ± 0 4 
3.1±04 
4 2+0 6 
5 0±0 8 
5 9 + 1 0 
1 8 ± 0 3 
2 4±0 4 
3 0+0 6 
4.9+08 
64+6 
47+6 
37±5 
32+3 
24±3 
21+3 
18+3 
62+8 
47±6 
38+4 
23±3 
DIABETICS 
Placebol 87±2 69±3 1 6 ± 0 2 61±6 
ANF dose ^g/min/100 ml FAV) 
0 001 87±2 
0003 88±2 
001 88±2 
003 89±3 
01 89±2 
0 3 89±2 
Placebo 2 90±2 
SNP dose (ng/min/100 ml FAV) 
10 91±2 
30 90±2 
100 91+3 
69±2 
69+2 
68+3 
69+3 
69+3 
70±3 
67±3 
69+4 
70±3 
71±3 
17±0 3 
19±0 3 
2 0 ± 0 4 
2 2 ± 0 4 
2 6±0 4 
3 2±0 6 
14±0 2 
17+0 3 
2 1 ± 0 4 
3 5±0 7 
62+8 
56±7 
55+7 
50+6 
41±5 
34±4 
82±12 
64+7 
56±8 
35+5 
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pressure, but not heart rate, increased significantly in the control group as well as in the 
diabetic patients (paired Student t-test: P<0.001 and P<0.05 respectively), but as shown in 
table 2 this increase occurred during the equilibration period after ANF infusion rather than 
during the infusions. In the control group, this increase in MAP was more pronounced than 
in the diabetic patients (11.8±2.4 versus 3 3±1.3 mmHg, unpaired Student t-test: P<0.01). 
Table 2 further shows the vasodilator effect of ANF in both groups, represented by 
a dose-dependent increase in FBF and fall in FVR. Figure 1 shows the course of the mean 
FBFfor each minute during the last two minutes of each infusion rate in relation to the time 
periods of ANF and SNP administration. Baseline FBF did not differ significantly between 
the two study groups. FBF gradually increased from 1.4±0.2 during placebo to 6 0±1.0 
ml/min/100 ml FAV at the last minute of the highest ANF infusion rate in the controls, with 
corresponding values of 1.6±0 2 and 3.1 ±0 5 ml/min/100 ml FAV in the diabetic patients. 
After ending the ANF infusion the FBF returned towards baseline levels at the second 
placebo infusion. The administration of SNP exerted comparable increments in FBF in both 
groups, from 1.8±0.3 during placebo to 5.1±0.8 ml/min/100 ml FAV during the last minute 
of the highest SNP infusion in the control group, and from 1.4±0.2 during placebo to 
3 6±0.8 ml/min/100 ml FAV during the highest SNP infusion in the diabetic patients Figure 
2 shows the course of the calculated FVR Since the mean FVR during infusion of placebo 
2 was higher (though not significantly) in the diabetic patients when compared with the 
controls (respectively 82±12 versus 62±8 AU, unpaired t-test: P=0.19), the statistical 
analysis of the ANF- and SNP-induced changes was performed on the percentage changes 
Figure 3 and 4 present dose-response curves of these percentage alterations of the 
FBF and the calculated FVR, as induced by ANF administration in the left panel, and by 
SNP administration in the right panel. At the lowest infusion rate, ANF failed to change 
FBF or FVR in the diabetic subjects, whereas an obvious vasodilator response to this dosage 
already occurred in the control group Repeated measures ANOVA on the percentage 
FBF-changes revealed a significant dose effect (P<0 001), and a significant difference 
between both groups (P<0.001), and similar results were obtained with respect to the 
changes in FVR (dose effect: P<0 001, between groups- P<0.001). In contrast, the mean 
changes in FBF and FVR following the three SNP infusion rates only showed a significant 
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dose effect (both P<0.001), but no significant difference between groups (FBF: P=0.36, 
FVR: P=0.27). Similar results were obtained when the absolute changes of FBF and FVR 
were analyzed instead of the percentage values. 
Figure 1 Line graph of the course of the mean (±SE) forearm blood flow (averaged for each minute for the 
last two minutes per infusion rate) during placebo and during the several infusion rates of atrial natriuretic 
factor (ANF) and sodium nitroprussidc (SNP) in diabetic patients and in matched controls 
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Figure 2. Line graph of the course of the mean (±SE) forearm vascular resistance (averaged for each minute 
for the last two minutes per infusion rate) during placebo and during the several infusion rates of atrial 
natriuretic factor (ANF) and sodium nitroprusside (SNP) in diabetic patients and in matched controls. 
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Figure 3: Bar diagram of Ihe mean (±SE) percentage changes from baseline of the forearm blood flow during 
the six dose steps of atrial natriuretic factor (ANF1 to ANF6) and during the three infusion rates of sodium 
nitroprussidc (SNP1 to SNP3) in diabetic patients and in matched controls. P-valuc refers to the two-factor 
analysis of variance with repeated measures (between groups); NS: not significant. 
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Figure 4: Bar diagram of the mean (±SE) percentage changes from baseline of the forearm vascular resistance 
during the six dose steps of atrial natriuretic factor (ANFl lo ANF6) and during the three infusion rales of 
sodium nitroprussidc (SNP1 to SNP3) in diabetic patients and in matched controls. P-value refers to the 
two-factor analysis of variance with repeated measures (between groups); NS: not significant. 
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Table 3: Mean (±SE) values of ihe plasma concentrations of atrial natriuretic factor (ANF in pmol/1) and of 
its second messenger cyclic 3',5'-guanosine monophosphate (cGMP in nmol/1) during placebo infusion 
(baseline) and during the administration of AN Γ in diabetic patients and in matched controls For cGMP, 
venous (ven) and arterial (art) levels as well as the calculated forearm production (pmol/min/100 ml) are given 
ANF y e n baseline 
ANF 6 t h dose step 
cGMP
a r t baseline 
cGMP
a r | 4
t h
 dose step 
cGMP
a r t 6
l h
 dose step 
cGMP
v 
cGMP„ 
baseline 
4 dose step 
cGMP 6 t h dose step 
cGMP-production baseline 
cGMP-production 4 dose step 
cGMP-production 6 dose step 
CONTROL 
1 1 9 ± 1 5 
14038±2977 
12 6 ± 0 8 
13 8+0 8 
2 1 3 ± 1 0 
14 1 ± 1 3 
1 7 5 ± 1 2 
25 5 ± 1 6 
12±1 1 
16 0±4 6 
22 8±4 8 
P-value 
NS 
NS 
NS 
NS 
• * * 
NS 
*** 
*** 
* 
«* 
*** 
DIABETES 
8 8±0 9 
11809±1895 
1 2 5 ± 0 4 
1 1 9 ± 0 5 
12 6 ± 0 4 
114±05 
9 8 ± 0 8 
14 3±2 1 
-2 1±10 
-3 6 ± 1 4 
2 9±4 7 
• P<0 05, *·Ρ<0 01, * " P<0 001 unpaired student t test 
Repeated measures ANOVA showed significant effects between dosages for the course of 
the venous cGMP levels and for the cGMP production, and between groups tor all cGMP 
data 
Humoral effects 
Table 3 demonstrates the humoral data for both study groups Because of insufficient plasma 
sample quantities or because of hemolysis of the plasma sample, the determination of ANF 
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concentrations could not be measured in two out of the ten subjects of each group. Baseline 
venous ANF levels, measured during the first placebo infusion, were similar in the diabetic 
subjects when compared with the controls, measuring respectively 8.8 ±0.9 (n=8) versus 
11.9±1.5 pmol/1 (n=8) (not significant). Following the highest ANF infusion rate, clear 
increments in the ANF levels were observed, both in diabetic and control subjects, 
respectively leading to venous plasma levels at the side of intra-arterial infusion of 
11,808+1,895 (n=8) versus 14,038±2,977 pmol/1 (n = 8), being not significantly different from 
each other. 
Table 3 further demonstrates arterial and venous cGMP values in the two groups of 
subjects. In the control group, venous cGMP values increased from 14.1 ±1.3 nmol/1 during 
placebo infusion up to 25.5±1.6 nmol/1 at the highest ANF infusion rate (n=10). However, 
in the diabetic subjects, venous cGMP concentrations hardly rose from 11.4±0.4 to 14.3±2.1 
nmol/1. Obviously, to compare the locoregional production of cGMP between both groups, 
the venous cGMP levels must be related to the local FBF, as has been done in the calcula-
tion of the cGMP production. In the healthy volunteers, ANF induced an increase in the 
cGMP spillover from +1.2±1.1 at baseline to +22.8±4.8 pmol/min/100 ml FAV at the 
highest ANF infusion rate. In the diabetic patients, these values respectively numbered 
-2.1±1.0 and +2.9±4.7 pmol/min/100 ml FAV. For the venous and arterial cGMP levels as 
well as for the cGMP production, repeated measures ANOVA showed significant P-values 
between the groups. 
At regular intervals, plasma glucose concentrations were sampled in the diabetic patients. 
Throughout the experiments, the mean plasma glucose concentration gradually declined from 
12.9±0.9 at the beginning to 10.5 +1.2 mmol/1 at the end of the experiment. In two subjects, 
short-lasting glucose infusion was necessary during the equilibration period between the ANF 
and SNP-infusions to prevent a fall of plasma glucose to levels lower than 5 mmol/1. 
Side effects: 
During the local infusion of ANF into the brachial artery no hypotension, light-headedness 
or bradycardia was observed. With regard to the diuretic effects of ANF no subject had any 
urge to micturate during or direct after the immobilisation period. 
80 
DISCUSSION 
A prominent finding of our study is the impaired forearm vasodilator response to a short-
lasting ANF infusion in patients with uncomplicated insulin-dependent diabetes mellitus. The 
vasorelaxing properties of ANF as demonstrated in our control subjects are in close agree­
ment with previous reports using the same technique (2, 4) In contrast, the diabetic subjects 
showed an attenuated response to ANF, with hardly any vasodilation during the lowest ANF 
infusion rate. At this lowest rate of 0.001 μg of ANF/min/100 ml of FAV, regional plasma 
ANF concentrations have been reported to be in the upper normal range (2). Therefore, the 
fact that the difference between diabetic patients and controls is most striking at the lowest 
ANF infusion rate (figure 3 and 4) at least suggests that our observations may be extra­
polated to endogenous ANF plasma concentrations in the (patho)physiological range 
In type 1 diabetes mellitus, Jungmann et al showed a reduction in the natriuretic response 
to ANF infusion without differences in the response of blood pressure, suggesting a normal 
vascular responsiveness to ANF (10) However, it must be stressed that the cardiovascular 
response to systemic administration of ANF is determined by the sum of several ANF-
mediated effects, including the relaxing effects on arterial and venous vascular beds, direct 
effects on the heart, the tall in intravascular volume by diuresis and by increased 
permeability, and the effects on several sites of the autonomic nervous system (1, 17, 18) 
Consequently, the blood pressure response to ANF infusion can not be considered to be a 
representative parameter for the direct vascular effects of ANF, and therefore the results 
of Jungmann et al.(10) may not be interpreted as arguing against our observations of an 
attenuated vasodilator response to ANF in uncomplicated type 1 diabetes. Furthermore, a 
recent elegant study of Fioretti et al. on the impaired natriuretic response to ANF in 
diabetes suggested a less pronounced blood pressure response to ANF infusion in the 
diabetic patients when compared with the controls (10). 
Although there was a slight difference in the forearm vasodilator response to SNP 
between the diabetic patients and controls, this was not statistically significant. Previous 
studies, including one of our department, neither observed a difference in the vasodilator 
response to nitroprusside between controls and a comparable population of diabetic subjects 
(19, 20). Even when the diabetic patients and the controls from the present study were 
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pooled with those of our previous study (20), no significant difference in the response to 
nitroprusside was found, making a statistical beta-error in our current study unlikely (pooled 
data of the percentage fall in FVR as a result of the highest SNP-infusion rate revealed 
values of respectively -71.3±4.1% in controls (n=21) versus -65.2±5.2% in diabetic subjects 
(n = 21), unpaired t-test: Ρ = 0.37). Consequently, the unaltered vasodilator response to nitro­
prusside in uncomplicated diabetes shows a striking contrast with the data on ANF and 
therefore emphasizes that the presently observed reduced response to ANF is a rather 
specific phenomenon. 
In our diabetic population, the impaired vasodilator response to ANF was associated with 
a blunted response of ANF's second messenger cGMP. This seems to be in contrast with the 
observations on ANF in the kidney, in which a reduced natriuretic response to ANF in 
diabetes was accompanied by a normal urinary excretion of cGMP (10). In general, the 
biological effects of ANF are mediated by ANF receptors coupled to the particulate guanylyl 
cyclase (GC) system (12, 18). Despite a very good correlation between the vasodilator effect 
of ANF and the production of cGMP (21), there is much doubt on the origin of the elevated 
plasma cGMP levels during infusion of ANF In fact, it is hard to believe that the elevated 
levels of cGMP are of vascular smooth muscle cell origin because nitrate-induced vaso­
dilation is not accompanied by increments in cGMP levels (4), whereas the second 
messenger of nitrates is also cGMP. Of course, in theory there may be a difference in the 
intracellular handling of cGMP between the particulate GC system (ANF) and the soluble 
GC system (nitrates), but we are not aware of any literature supporting this view. A second 
argument against the smooth muscle cell as origin of cGMP in our study is the fact that 
previous studies with a very similar design have shown an impaired vasodilator response to 
ANF in the elderly (13) and in patients with heart failure (4) without any sign of a reduced 
production of cGMP 
Besides the smooth muscle cells of the forearm vascular bed, the vascular endothelium 
also contains ANF receptors coupled to the GC system (12). Therefore, it is tempting to 
speculate that the reduced production of cGMP represents an early endothelial dysfunction 
in uncomplicated diabetes mellitus, as is suggested in animal experiments (22). In that case, 
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measurement of the cGMP production during ANF administration would be a sensitive way 
to evaluate early endothelial dysfunction. This would even be more sensitive than 
measurement of endothelium-dependent relaxation because we and others could not find 
any evidence for endothelial dysfunction in a comparable group of diabetic patients by 
measuring the endothelium-dependent vasodilation during infusion of acetylcholine analogues 
in the forearm vascular bed (19, 20). 
When we, despite the aforementioned arguments, assume that the very low increase in 
cGMP production in the diabetic patients represents a low increase in intracellular levels of 
cGMP in the forearm vascular smooth muscle cells, the observed reduced vasodilator 
response to ANF suggests that patients with uncomplicated diabetes show defects either at 
the level of the ANF receptor or at the coupled GC system. From our data, it is not possible 
to differentiate between a down-regulation of ANF receptors, a desensitization of these 
receptors or a post-receptor defect located at the level of the particulate GC system. 
In contrast to several animal studies (23, 24) and human investigations on diabetes (6-8), we 
did not find any difference in the baseline plasma ANF concentrations between controls and 
diabetic patients. This may be due to the small sample or to the selection of our diabetic 
patients, since some investigators have shown that increased levels of ANF in diabetes only 
occur in patients with signs of microvascular disease (9). Moreover, it must be emphasized 
that our study participants were not controlled with respect to their sodium intake, and that 
may well explain the different observations on baseline levels. This absence of any difference 
in baseline plasma ANF concentrations between our two study groups strongly argues against 
the explanation that the reduced vasodilator response to ANF is caused by a down-
regulation of ANF receptors based on chronically increased baseline levels of ANF in the 
diabetic subjects, as may be the case in heart failure or in the elderly (4, 13). Nonetheless, 
the combination of an impaired vasodilator response to ANF and the absence of any 
increase in baseline ANF concentration implicates a reduced baseline ANF-mediated 
vasodilation contributing to the overall vascular tone in diabetes. Consequently, our 
observations may be relevant with respect to the regulation of vascular tone and or blood 
pressure in diabetes. Although our diabetic patients did not seem to have a higher blood 
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pressure when compared with the controls, Wiegmann et al. have shown that distinct 
differences may occur in the blood pressure between controls and patients with 
uncomplicated type 1 diabetes, when 24 hour ambulatory blood pressure recordings are 
taken into account (25). 
Apart from a vasodilator effect in the skeletal muscle vascular bed, ANF has also been 
reported to induce afferent (but not efferent) vasodilation in the kidney, resulting in an 
elevated glomerular capillary hydraulic pressure and an augmented glomerular filtration rate 
(18) Since the early stages of diabetes are characterized by the aforementioned intrarenal 
changes, one might hypothesize that elevated plasma ANF levels in diabetes may contribute 
to the state of glomerular hyperfiltration Elegant animal studies from Ortola et al. seem to 
confirm this hypothesis (24). However, if the blunted vasodilator response to ANF also holds 
for the renal vasculature, this would implicate a less important role for ANF in eventual 
intrarenal changes This is especially true in our particular group of diabetic patients because 
they even did not show elevated plasma ANF levels when compared with matched controls. 
In conclusion, in the human skeletal muscle vascular bed of patients with uncomplicated type 
1 diabetes, the in vivo vasodilator response to ANF is specifically attenuated. This reduced 
vasodilator response to ANF is associated with a reduced regional production of ANF's 
second messenger, cGMP. The normal plasma ANF concentrations in association with the 
reduced vasodilator response to ANF, suggest that the contribution of ANF-mediated 
vasodilation to the baseline vascular tone is less in diabetic patients when compared with 
healthy controls. Our observations may be of relevance in the understanding of the 
regulation of vascular tone and/or blood pressure in insulin-dependent (type 1) diabetes 
mellitus. 
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CHAPTER 8 
Atrial natriuretic Tactor potentiates the human forearm 
vasoconstrictor response to sympathetic stimulation 
(Submitted) 
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ABSTRACT 
1. Atrial natriuretic factor (ANF) affects the human sympathetic nervous system 
activity. The interaction between atrial natriuretic factor and the sympathetic 
nervous system has not been fully elucidated yet, but may occur at different sites. 
We studied this modulator effect at the adrenergic nerve terminal: the forearm 
vasoconstrictor response was examined following α-adrenergic sympathetic 
stimulation in healthy volunteers during the simultaneous and locoregional 
administration of atrial natriuretic factor, sodium nitroprusside and placebo. As 
sympathetic stimulation test the technique of the lower body negative pressure 
(-2()mmHg) was used. 
2. Lower body negative pressure increased the forearm vascular resistance by 
+ 37±8% during concomitant intra-arterial infusion of placebo (N=10). During a 
predilator state achieved by infusion of a low dose of atrial natriuretic factor 
(10ng/min/l(X)ml forearm volume) into the brachial artery, lower body negative 
pressure subsequently induced a forearm vasoconstrictor response of +153±22% 
(P<0.05 versus placebo), whereas this was +64±14% when the predilator state 
was achieved by infusion of an equipotent vasodilator dose of sodium 
nitroprusside (P>0.1 versus placebo; Ρ < 0.05 versus ANF). 
3. Calculations from arterial and venous plasma norepinephrine and epinephrine 
concentrations combined with forearm blood flow values revealed a significant 
increase of forearm norepinephrine spillover to LBNP during the placebo and 
SNP test, but not during the ANF test, which might indicate ANF's inhibition of 
catecholamines' synthetizing enzyme system. The response of the calculated 
forearm clearance of norepinephrine to LBNP seemed to be significantly lowered 
in the presence of atrial natriuretic factor, whereas this clearance remained 
unchanged during the placebo and SNP test, which might indicate that 
catecholamine clearance modulation plays a role in the LBNP-induced 
sympathopotentiator effects in forearm vasoconstriction. 
4. In a second experiment (N=10), we demonstrated that atrial natriuretic factor 
did not alter the forearm vasoconstrictor response to the intra-arterial 
administration of norepinephrine, thereby excluding a postsynaptic modulation by 
the atrial natriuretic factor. In the presence of atrial natriuretic factor, the 
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subsequent infusion of two dosages of norepinephrine (0.1 and 1.0 ng/min/100ml 
forearm volume) increased the forearm vascular resistance by +118±29% and 
+ 387±79% respectively, whereas these numbered +129±18% and +316±41% 
when atrial natriuretic factor was replaced by sodium nitroprusside. 
5. In a third additional series of experiments (N = 5) the possibility of a central 
pathway of baroreceptor reflex modulation by atrial natriuretic factor was 
investigated: the forearm vasoconstrictor response to LBNP was +145±16% in 
the experimental arm with regional predilation by atrial natriuretic factor, 
whereas this was only +52±14% in the contralateral arm (P<0.05 experimental 
vs contralateral arm) during the same procedure. The respective values with 
placebo infusion were +42±7% and +49±15% (NS). The potentiation of the 
forearm vasoconstrictor response to lower body negative pressure by atrial 
natriuretic factor occurring in the experimental arm only, and not in the 
contralateral arm, excludes the possibility that ANF modulates the baroreceptor 
reflex via a central pathway in the presented protocols. 
6. We conclude, that atrial natriuretic factor potentiates the forearm 
vasoconstrictor response to α-adrenergic sympathetic stimulation in man, and 
that this effect may be located at the level of the adrenergic nerve terminal. This 
potentiation cannot be explained by an increased vascular α-adrenergic 
sensitivity, nor by an augmented release of norepinephrine. Calculations with 
(nor)epinephrine plasma levels suggest that this forearm vasoconstrictor 
potentiation is accompanied with an atrial natriuretic factor-induced decrease in 
the local clearance of norepinephrine during endogenous sympathetic activation. 
More detailed studies with tritiated norepinephrine, are needed to analyze the 
precise effects of atrial natriuretic factor at the level of the adrenergic nerve 
terminal. 
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INTRODUCTION 
It is now evident that the atrial natriuretic factor (ANF) exerts important effects 
on the renin angiotensin system and the autonomic nervous system, in addition to 
direct vasodilator and renal effects In fact, many of its hemodynamic actions may 
well be influenced by interference with autonomic nervous system reflexes [1-4]. 
Experiments in rats suggested that the inhibitory effect of ANF on sympathetic 
outflow was mediated by sensitization of cardiac receptors with inhibitory vagal 
afférents [5,6]. In man, the reports on the interaction between ANF and the 
sympathetic nervous system activity were contradictory, and different investiga-
tors have shown different results, ranging from an attenuated to an unchanged 
and even to a potentiated forearm vascoconstrictor response following sympathe-
tic stimulation (7-9]. Up to now, the mechanism of interaction between atrial 
natriuretic factor and the sympathetic nervous system has not been fully 
elucidated, but theoretically, may occur at different sites: the cardiopulmonary 
baroreceptors, the carotid baroreceptors, the central nervous system, the sympa-
thetic ganglia or the adrenergic nerve terminal. A recent study on this item of 
Floras et al. described an ANF-mediated attenuation of the sympathoneuronal 
response to cardiopulmonary receptor unloading, via a central or ganglionic 
pathway, as measured by the direct microneurographic technique [8]. However, 
the simultaneously recorded forearm vasoconstrictor response was not changed 
by ANF. The unaltered vasoconstrictor response coupled with the reduction in 
sympathetic nerve firing suggested a local ANF effect at the adrenergic nerve 
terminal. Apart from its effects on other sites of the sympathetic nervous system, 
we now investigated whether ANF alters the response to sympathetic stimulation 
at the level of the adrenergic nerve terminal. Furthermore, we searched for 
interrelationships between altered forearm vascular responses and ANF's 
influences on the local spillover or clearance of norepinephrine, or ANF's 
influences on the postsynaptic sensitivity to norepinephrine. 
Therefore, the main objective of our study was: does atrial natriuretic 
factor when regionally administered into the brachial artery, alter the forearm 
vasoconstrictor response on a regional level to selective cardiopulmonary 
baroreceptor unloading; and if so, is this altered forearm vasoconstrictor 
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response associated either with changes in the regional norepinephrine handling 
in the forearm vascular bed, or with an ANF-mediated effect on the postsynaptic 
α-adrenoceptor. 
MATERIALS AND METHODS 
Subjects 
The study protocol was previously approved by the Ethics Committee of our 
Institute. Two groups of 10 and one additional group of 5 healthy young 
volunteers, recruited from the general population, gave their written informed 
consent Each subject participated in only one test All subjects were submitted 
to clinical examination before admission into the study. Physical examination 
revealed no relevant abnormalities Plasma creatinine levels and the endogenous 
creatinine clearances as calculated by the Cockcroft & Gault's formula were all 
within the normal range [10]. None of the subjects took any drugs, oral contra­
ceptives included, nor abused alcohol The subjects were instructed to edt their 
usual diet, not to smoke, not to drink any coflee or tea and to refrain from hard 
labour during 24 hours preceding the experiment 
Procedures 
The study was performed during a four hour immobilisation period in a 
climatized room (temperature: 22 6±0 2 C; n=25). At least two hours before 
the test the subjects were allowed to use a light meal. The tests were performed 
alter an equilibration period of at least 45 minutes with subjects in the supine 
position. The left brachial artery was cannulated with an Angiocath cannula (20 
gauge) (Deseret Medical Ine, Becton Dickinson and Сотр., Sandy, Utah) for 
intra-arterial blood sampling and drug infusion (automatic syringe infusion pump, 
type STC-521, Terumo Corp., Tokyo, Japan) as well as for blood pressure moni­
toring (Hewlett Packard monitor, type 78353B, Hewlett Packard GmbH, 
Böblingen, West-Germany). On the ipsilateral side an antecubital vein was 
cannulated for blood sampling The forearm blood flow (FBF) was measured by 
ipsilateral (in first and second protocols) / bilateral (in third protocol) venous 
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occlusion mercury-in-silastic strain gauge plethysmography. During all recordings 
of FBF, and during the arterial and venous blood sampling, the hand circulation 
was completely occluded by a wrist cuff inflated 100 mmHg above the systolic 
blood pressure The subjects remained supine throughout the study period. 
Study protocols 
Figure 1 presents the schedule of measurements of both protocols. The first 
protocol was performed to investigate whether regional atrial natriuretic factor 
infusion alters the forearm vasoconstrictor response to an endogenous stimulus of 
the sympathetic nervous system. In this first protocol, the healthy subjects 
(N = 10) were positioned in a plexiglass box with an airtight apron seal above the 
iliac crest. This device enabled us to apply a lower body negative pressure 
(LBNP) of -20 mmHg by using an adjustable source of vacuum. After the 
equilibration period, the protocol started with an intra-arterial infusion of 
placebo (NaCI 0 9%) during 13 minutes (baseline). Three minutes after the start 
of placebo infusion the wrist cuff was inflated al a pressure of 100 mmHg above 
systolic blood pressure in order to obtain the FBF-recordings (three per minute), 
and at the end of the infusion period arterial and venous blood samples were 
drawn for the determination of plasma (nor)epinephnne levels, and for the 
subsequent calculation of locoregional norepinephrine kinetics. After cessation of 
the placebo infusion a 10 minute-recovery period for the hand circulation was 
allowed. Then, a similar second placebo infusion was performed, again with FBF-
recordings and blood samplings, but now LBNP was applied for the last 10 
minutes. Afterwards, an equilibration period of 30 minutes was taken. 
The aforementioned schedule of FBF-recordings and blood samplings 
during intra-arterial placebo infusion (baseline), followed by a similar session 
with the application of LBNP was repeated twice· once with the intra-arterial 
administration of atrial natriuretic factor instead of placebo, and once with 
sodium nitroprusside (SNP) instead of placebo (Figure 1) In a pilot study we 
had already observed that the repeated application of non-hypotensive LBNP 
(3x) within the same group of volunteers induced a similar forearm vaso-
constrictor response (FBF-change. -1.3±0.2, -1.1±0.2 and -1.1±0.3 ml/min/100ml 
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FAV, FVR-change· +24±8.1, +18.7±4.2 and +20±4.6 AU, N=15, unpublished 
data) The dose of the intra-artenally administered atrial natriuretic factor was 
chosen to induce a slight local vasodilator response without inducing systemic 
effects [11], and was adjusted to the forearm volume: 10 ngANF/min/lOOml 
forearm volume (FAV). As a control vasodilator, an equipotent dose of SNP was 
chosen to induce vasodilation in the forearm comparable with ANF, numbering 
40 ngSNP/min/lOOml FAV. The sequence of the ANF- and ANF+LBNP-tests 
versus the SNP- and SNP+LBNP-tests was randomized. Between the ANF- and 
SNP-sessions, an equilibration period of 45 minutes was taken. Within the 
placebo-, ANF- and SNP-sessions, a 10 minute pause was taken for the recovery 
of the hand circulation between the baseline infusion and the subsequent infusion 
together with LBNP. 
The second protocol was performed to investigate whether the local 
infusion of ANF does alter the postsynaptic response to α-adrenergic stimulation. 
In this protocol, either ANF (lOng/min/lOOml FAV) or the equipotent control 
vasodilator SNP (40ng/min/100ml FAV) was infused into the left brachial artery 
during 15 minutes in healthy volunteers (N=10). Seven minutes after the start of 
this infusion, two increasing dosages of norepinephrine were given (0.1 - 1.0 
ng/min/100ml FAV, four minutes per dose). Before and during the 
norepinephrine infusions, FBF-recordings were obtained three times per minute. 
During this protocol no blood samples were drawn. The sequence of the ANF-
and SNP-administration was randomized, and an equilibration period of 45 
minutes was taken between these infusions. To exclude possible ß-adrenoceptor 
mediated effects, all norepinephrine infusions were accompanied by the regional 
infusion of propanolol (6 μg/mln/100ml FAV). 
Forty-five minutes after the cessation of the norepinephrine experiments, 
the ANF- and SNP-administration was repeated, again for 15 minutes, but now 
without norepinephrine infusion. These observations were performed to ascertain 
that single ongoing vasodilator infusion of currently used dosages of ANF or SNP 
exerted a steady state forearm vasodilator response without systemic effects. 
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Figure 1. The two basic protocols are drawn schematically. In protocol 1 the endogenous· 
sympaticostimulation test with the application of lower body negative pressure (-20 mmHg; 
LBNP) is used during the locoregional administration of placebo, the atrial natriuretic factor 
(ANF) or sodium nitroprusside (SNP). In protocol 2 exogenous norepinephrine (NOR) is 
infused locoregionally during a ß-blocking infúsate of propranolol (Propr.) and the simultaneous 
infúsate of the vasodilating ANF or SNP. 
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After the evaluation of the study results we decided to perform a third, 
additional series of experiments by investigating the forearm vasoconstrictor 
response following LBNP in a group of healthy volunteers (N=5). In this group 
we registered the forearm vasoconstrictor response to LBNP during the regional 
infusion of placebo or ANF in a similar way as described in protocol 1. In this 
series of experiments we were capable to measure the forearm blood flow 
simultaneously in both arms. This gave us the opportunity to differentiate 
between centrally mediated effects of LBNP influencing the blood flow in the 
control arm, and locoregionally modulated effects evoked by LBNP influencing 
only the forearm blood flow in the experimental arm. Thus, the locoregional and 
the systemic effects of the intra-arterial infusion of ANF could be differentiated. 
In this group no plasma samples were taken. 
Laboratory determinations 
Five ml of the blood samples were collected in a prechilled tube on melting ice 
and immediately centrifuged at +4 С for the determination of norepinephrine 
and epinephrine. The plasma was stored at -20 С and all samples were analyzed 
within 4 weeks from collection by a catechol-O-methyltransferase-based 
radioenzymatic assay with thin layer chromatography [12]. The interassay 
coefficient of variation for plasma epinephrine is 9% and for norepinephrine 
7.5%. The lower limit of detection was 0.05 nmol/1 for both catecholamines. 
Drugs 
Sodium nitroprusside (SNP) was purchased from Hoffmann-La Roche, Mij­
drecht, The Netherlands, and dissolved in a glucose 5% solution just before use. 
Alpha-human (99-126)ANF was purchased from Bissendorf Peptide GmbH, 
Wedemark, FRG. Immediately before use, ANF was diluted in a Haemaccel 
(Hoechst) solution to prevent adhesion to the silastic infusion system as 
described previously [13]. All drugs, including the placebo infusions were 
administered at a rate of 50 μΙ/min/lOOml FAV. 
96 
Data report and statistics 
All results are expressed as mean values ± standard error of the mean (SE), 
unless indicated otherwise. For the first protocol, the FBF-readings during the 
last four minutes of each infusion were averaged to one mean value Afterwards, 
LBNP-induced percentage changes were calculated from these means, using the 
differences between the baseline recordings with placebo, ANF or SNP on the 
one hand, and the recordings during the subsequent corresponding session with 
LBNP on the other hand. The forearm vascular resistance (FVR) was calculated 
by the quotient of the mean arterial pressure (MAP) and the simultaneously 
registered FBF, and the FVR is expressed in arbitrary units (AU). 
The fractional extraction (FE) of epinephrine (Epi) in the forearm was 
calculated as ([Epi]art - [Epi]ven )/ [Epi]art. The extraction (E) of norepinephrine 
(NOR) was estimated by the product of the fractional extraction of Epi and the 
arterial NOR concentration: E N O R = FEE * [NOR]art, assuming that the FE's 
of NOR and Epi are similar in the forearm [14] The spillover of NOR in the 
forearm was calculated as the product of the FBF and the sum of the 
arteriovenous NOR-difterence plus the NOR-extraction: SpilloverNOR = FBF * 
([NOR]ven - [NOR]art + E N O R ) . The forearm NOR-clearance was calculated as 
the product of the FBF and E N O R : ClearanceNOR = FBF * E^QR-
The differences in responses between placebo, ANF and SNP were 
analyzed by analysis of variance. For the hemodynamic data, we used a one 
factor ANOVA for repeated measures, and Scheffe F-tests for contrasting 
between the two groups. Since the humoral data on norepinephrine 
concentrations did not show a Gaussian distribution, these parameters were 
evaluated by a non-parametric ANOVA (Friedman procedure) with subsequent 
contrasting by paired Wilcoxon's tests. 
Comparisons of parameters from before versus after an intervention were 
evaluated by paired Student t-test for hemodynamic data, and by paired 
Wilxocon's test for humoral data. 
Significance was accepted at the 0.05 level of probability (two-sided). NS 
means not significant. 
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RESULTS 
Table 1 presents the characteristics of the healthy volunteers of all groups. None 
of the parameters showed differences between the groups. 
Table 1 Group characteristics Quetelet index= weight/height (kg/m ) E C C = endogenous 
creatinine clearance, calculated by Cockcrofl & Gault's formula [10] Means ± SD are given 
Protocol 1 Protocol 2 Protocol 3 
clinical parameters (N=10) (N=10) (N=5) 
10/0 5/0 
27±6 23+2 
22 7 ± 1 8 23 5 ± 1 4 
1140±200 1010±65 
73 ±6 
61-83 
123±16 
Lower body negative pressure (LBNP) experiments 
Table 2 summarizes the absolute mean values on blood pressure, heart rate, FBF 
and FVR both before and during non-hypotensive LBNP during placebo, ANF 
and SNP. Following the LBNP-procedure blood pressure and heart rate 
remained unchanged. The FBF was significantly decreased by LBNP from 
1.8±0.2 to 1.4±0.1 ml/min/lOOml FAV during regional placebo infusion. During 
the ANF and SNP experiments, the baseline FBF-values rose to 3.5+0.4 and 
2.9±0.3 ml/min/100ml FAV, respectively The subsequent application of LBNP 
also exerted a significant fall in FBF in the ANF and SNP experiments, but the 
percentage LBNP-induced fall in FBF is significantly greater during ANF (-
57±4%) when compared with placebo (-24±4%) or SNP (-35+5%) (ANOVA: 
P=0.0001). This also accounted for the calculated changes in FVR Figure 2 and 
3 show the changes in FVR as induced by LBNP during the three experiments 
with placebo, ANF and SNP infusion. The mean percentage LBNP-induced 
increase in FVR is significantly greater during ANF infusion (+153±22%) when 
compared with placebo ( + 37±8%) or SNP (+64±14%) (ANOVA· P=0 0001) 
Sex rale (M/F) 10/0 
Age (yr) 27+8 
Quetclet index (kg/m2) 22 5±2 0 
Arm volume (ml) 1090±80 
c r e a t i n i n e
s e r u m
 (μπιοΐ/l) 80±7 
creatinine
r a
 (μιτιοΙ/1) 69-94 
ECC (ml/тіпД 73 m 2 ) 121±14 
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Table 2 Mean (±SE) values of systolic blood pressure (SBP), diastolic blood pressure (DBP), 
mean arterial pressure (MAP), heart rate (HR), forearm blood flow (FBF) and forearm vascular 
resistance (FVR) at steady state during the locoregional infusion of placebo, atrial natriuretic 
factor (ANF) or sodium mtroprusside (SNP) alone and with concomitant lower body negative 
pressure (LBNP) as described in protocol 1 
SBP DBP MAP HR FBF FVR 
mmHg mmHg mmHg bpm ml/min/lOOmlFAV AU 
Plac 110+2 71±1 88±2 66±2 1 8 ± 0 2 51±4 
* + 
Plac+LBNP 111±2 73±1 89±1 67±3 1 4 ± 0 1 70±7 
ANF 122±2 80±2 100±2 67+4 3 5±0 4 33±5 
ANF+LBNP 123±3 82±2 101+2 66±3 1 4 ± 0 1 76±6 
SNP U 9 ± 2 77±1 % ± 2 65+2 2 9 ± 0 3 38±5 
SNP+LBNP 118+3 78±2 96±2 68+3 1 8 ± 0 2 59±6 
* P<0 05, ** P<0 005 and ·** P<0 0005 when compared without vs with LBNP, 
insignificant Ρ values are not demonstrated 
Table 3 Mean (±SEM) values of plasma concentrations of norepinephrine (NOR) and epinc 
phrine (Epi) from arterial (art) and venous (ven) samples, and the calculated regional forearm 
spillover (pmol/min/100 mlFAV) and clearance of norepinephrine (pmol/min/lOOmlFAV) during 
infusion with placebo, atrial natriuretic factor (ANF) or sodium mtroprusside (SNP) alone ( ) 
and with ( + ) concomitant lower body negative pressure (LBNP) 
LBNP 
EP'art 
EP lven 
N O R
a r t 
N O R
v e n 
SpilloverN O R 
ClearanceNQR 
Placebo 
+ 
0 24 ** 
(0 05) 
0 07 # 
(0 02) 
0 87 · 
(0 10) 
104 ** 
(0 11) 
091 ** 
(027) 
107 
(011) 
0 47 
(015) 
010 
(0 04) 
1 17 
(009) 
178 
(0 23) 
197 
(0 48) 
131 
(016) 
ANF 
044 ** 
(0 08) 
0 17 
(0 03) 
1 15 " 
(010) 
1 34 ** 
(0 13) 
2 27 
(054) 
2 20 ·* 
(019) 
+ 
0 72 
(0 14) 
0 20 
(0 03) 
158 
(0 16) 
2 17 
(0 23) 
2 24 
(0 47) 
141 
(013) 
SNP 
041 · · 
(0 10) 
0 16 
(0 04) 
095 ** 
(0 11) 
122 ** 
(0 15) 
160 # 
(0 29) 
161 
(0 23) 
+ 
0 67 
(0 22) 
021 
(0 04) 
131 
(012) 
192 
(021) 
2 34 
(046) 
146 
(019) 
* P<0 05, ** P<0 01 when compared without vs with LBNP, 
insignificant Ρ values are not demonstrated 
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Figure 2. Absolute values of forearm vascular resistance during the regional infusion of placebo 
(circles), atrial natriuretic factor (ANF; triangles) and sodium nitroprusside (SNP; triangles) 
according to protocol 1 without (-) and with (+) the simultaneous application of lower body 
negative pressure (LBNP) of -20 mmHg in 10 healthy subjects. 
porearm vascular 
resistance (AU ) 
150 
IBNP 
Figure 3. Percentage changes in forearm vascular resistance induced by lower body negative 
pressure (-20 mmHg) during the regional infusion of placebo (circles), atrial natriuretic factor 
(ANF; closed triangles) and sodium nitroprusside (SNP; open triangles) according to protocol 1. 
Indvidual changes are demonstrated from the 10 healthy subjects. 
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Table 3 presents the arterial and venous plasma concentrations of the catechol-
amines epinephrine (Epi) and norepinephrine (NOR), and the calculated loco-
regional spillover and clearance of NOR during these experiments. The venous 
and arterial plasma concentrations of (nor)epinephnne were slightly but signifi-
cantly increased by the regional infusion of ANF or SNP. The application of 
LBNP raised arterial plasma (nor)epinephrine level significantly during the 
placebo as well as the ANF and SNP experiments; which does not account for 
the venous epinephrine concentration during either ANF or SNP vasodilatation 
When compared with placebo, the regional infusion ot ANF and SNP, both signi-
ficantly increased the baseline norepinephrine (NOR) spillover and clearance 
(for both parameters· ANOVA: P<0.01) During the placebo experiment, LBNP 
alone induced an increase in NOR spillover without a significant effect on the 
clearance of NOR In fact, the LBNP-induced alterations in regional nor-
epinephrine kinetics showed the same pattern during SNP infusion when 
compared with the placebo experiments During the regional ANF infusion 
LBNP failed to induce a significant increase in norepinephrine spillover, which is 
an interesting finding, especially since NOR spillover significantly increased 
following LBNP during both regional placebo and SNP administration During 
the regional ANF infusion however, LBNP further induced a fall in the clearance 
of NOR of -0 79±0 16 pmol/min/lOOml FAV, being significantly different from 
the corresponding changes during placebo and SNP of +0 23±0.13 and -0.15± 
0 19 pmol/min/lOOml FAV respectively (ANOVA P<0 005) 
After the evaluation of the study results of the first protocol, an additional group 
of five healthy subjects were investigated to find out whether the effects of ANF 
occurred only at the infusion arm (left arm). In this subgroup, the locoregional 
infusion of ANF into the left brachial artery lowered the FVR from 48±17 to 
29±10 AU at the ipsilateral side, whereas the FVR at the right, contralateral 
arm remained unchanged (36±10 before, versus 38±11 AU during leftsided 
ANF infusion) Again, during ANF infusion LBNP evoked a significantly increa-
sed forearm vasoconstrictor response at the experimental, left arm when com-
pared with placebo (FVR change: +42±7% during placebo versus +145±16% 
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during ANF, N = 5, P<0.05). Infusion of ANF into the left arm did not potentiate 
the forearm vasoconstrictor response to LBNP at the contralateral, right arm; 
forearm vascular resistance increased by: +49±15% during placebo versus 
+ 52±14% during ANF (N=5, placebo vs ANF: NS). 
Norepinephrine infusion 
In the second protocol the forearm vasoconstrictor response to the locoregional 
norepinephrine administration was registered, both during the simultaneous intra-
arterial administration of ANF and during the administration of the control 
vasodilator SNP. Figure 4 illustrates the individual increments in forearm 
vascular resistance induced by the norepinephrine infusion superimposed on the 
predilated state induced by ANF or SNP. The mean percentage increments in 
FVR as a result of the two increasing norepinephrine dosages were similar in the 
ANF- and SNP-experiments, with respective values of +118±29 and +387±79% 
during the ANF, and of +129±18 and +316±41% during the regional SNP 
administration. As demonstrated in figure 5, an infusion of ANF and SNP alone 
without the concomitant norepinephrine infusion, induced a stable vasodilator 
response throughout the whole 15-minute period in these healthy subjects. 
Moreover, no changes in the systemic blood pressure or heart rate occurred 
during this procedure. 
Side effects 
During ANF infusion no severe hypotension, light-headedness or bradycardia was 
observed. With regard to the diuretic effects of ANF one subject had an urge to 
urinate within 30 minutes after the first ANF infusion. 
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Figure 4 The individual and absolute values of the forearm vascular resistance (FVR) are 
demonstrated during the locoregional infusion of placebo and 2 doses of norepinephrine in a 
predilated state with the atrial natriuretic factor (ANF) on the left and sodium nitroprusside 
(SNP) on the right panel, according to protocol 2 
FVR(AU 
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ANF-vasodilated SNP-vasod 
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-Γ 
Figure 5 The 15 minute course of the absolute values of the forearm vascular resistance (FVR) 
is shown during the regional administration of the atrial natriuretic factor (ANF) and cquipotent 
vasodilating dose of sodium nitroprusside (SNP), according to protocol 2 
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DISCUSSION 
The current study has clearly shown a potentiating effect of ANF on the forearm 
vasoconstrictor response to sympathetic stimulation in humans The most pro-
minent result, however, was the evidence of a local effect of ANF at the level of 
the adrenergic nerve terminal. Up to now, all studies on the interaction between 
ANF and the autonomic nervous system concerned measurements during syste-
mic infusion of ANF in dosages of 50 to 100 ng/kg of body weight/min for about 
30 minutes or more after a loading dose of 500 ng/kg [8,9,14] The systemic 
administration of ANF was necessary to evaluate ANF's effects at the afferent, 
central or ganglionic sites of the sympathetic nervous system, and indeed for all 
these sites a modulating effect of ANF has already been claimed [5,8,9] An 
effect of ANF at the level of the adrenergic nerve terminal might well have 
occurred in these latter experiments without having been detected, at least in 
part because of shortcomings in the experimental design. 
In the present study, we have chosen for a locoregional intra-arterial 
infusion of ANF in a low dose of 10 ng/min/100ml FAV, without a loading dose, 
and with a rather short infusion duration It can be calculated that the total dose 
of ANF used in our protocol is more than a 100-times lower than in the 
previously reported studies on ANF and the sympathetic nervous system [8,9,15]. 
This approach was chosen to avoid the induction of systemic effects by ANF 
both on the circulation and on the sympathetic nervous system And indeed, even 
the 15-minute period of ANF infusion in the second protocol did not exert 
changes in blood pressure or heart rate, arguing against any systemic hemo-
dynamic effect Moreover in an extra group of five subjects, the regional infusion 
of ANF into the brachial artery induced a regional forearm vasodilation, without 
affecting the forearm vascular resistance at the contralateral side. 
During the regional administration of ANF, an augmented forearm 
vasoconstrictor response to sympathetic stimulation was observed This seemed 
not to be explained by a nonspecific effect of a decreased baseline vascular 
resistance since equipotent dosages of sodium nitroprusside induced a 
comparable vasodilator response in the forearm vascular bed without altering the 
LBNP-induced forearm vasoconstrictor response when compared with placebo. 
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Because ANF did not alter blood pressure or heart rate in the currently used 
protocols, we further demonstrated that the ANF mediated potentiation ot the 
forearm vasoconstrictor response to LBNP is not evoked by systemic triggering ot 
cardiovascular reflex mechanisms. The present findings suggested a local 
interaction between ANF and the sympathetic nervous system at the level of the 
adrenergic nerve terminal. 
Of course, theoretically the augmented vasoconstrictor response to 
sympathetic stimulation during the regional ANF administration might reflect a 
systemic effect of ANF, for example at the level of the vagal afférents of the 
cardiopulmonary receptors. Volpe et al. observed that pharmacological, systemic 
dosages of ANF potentiated the forearm reflex vasoconstriction induced by 
cardiopulmonary receptor deactivation in man, and their observations suggested 
that this effect was localized at the level of the vagal afférents [9]. As pointed out 
before, the systemic plasma concentrations of ANF reached at the level of the 
cardiopulmonary receptors in the present study were calculated to be more than 
a 100-times lower than in the study ot Volpe et al. [9], making a similar 
mechanism of interaction between ANF and the sympathetic nervous system 
unlikely. Moreover, in an extra group of hve subjects, we were able to register 
the forearm blood flow response at the contralateral, non-infused arm during the 
regional ANF infusion and a simultaneous endogenous sympathostimulation test. 
Our experiments have convincingly shown that the forearm vasoconstrictor 
response to LBNP at the right arm is not augmented when ANF is infused into 
the left brachial artery. 
Apart from the local vasoconstrictor response to LBNP, we have also 
analyzed the response of plasma norepinephrine and epinephrine levels during 
the different procedures LBNP at -20 mmHg is known to decrease central 
venous pressure without inducing a significant effect on arterial blood pressure 
[16,17]. Indeed, our data do not reveal a tall in blood pressure, nor an increase 
in heart rate during LBNP. The LBNP-activated sympathetic nervous system, as 
documented by the forearm vasoconstrictor response to LBNP, therefore 
probably reflected the selective unloading of the cardiopulmonary baroreceptors 
without evoking an effect on the arterial baroreflex simultaneously. LBNP was 
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known to induce an increase in the sympathetic nerve firing to the forearm 
vascular bed, as assessed by microneurographic recordings [7] The calculated 
parameters of regional norepinephrine kinetics in our study, indeed show an 
increase in the norepinephrine spillover across the forearm during LBNP, 
reflecting the increased regional sympathetic activity. In fact, our data suggest 
that the LBNP-mduced increase in norepinephrine spillover was not augmented 
by the concomitant infusion of ANF. Therefore, we have no arguments for an 
ANF-mediated potentiation of the LBNP-induced release of norepinephrine as 
an explanation for the observed augmented forearm vasoconstrictor response to 
LBNP during the administration of ANF Others even have described an in vitro 
decrease of catecholamine synthesis by ANF's potency of inhibiting tyrosine 
hydroxylase in neural tissue [18] Interestingly, in the present study LBNP was 
associated with a fall in the forearm clearance of norepinephrine during ANF 
infusion, whereas this was not found during the application of LBNP in the 
presence of either placebo or of sodium nitroprusside. It is not clear whether 
these differences in clearance have contributed to the observed differences in the 
forearm vasoconstrictor response to LBNP between the three tests We realize 
that more reliable conclusions would have been possible when a tracer dose of 
tntiated norepinephrine had been used to calculate the regional norepinephrine 
kinetics as reported by Esler et al. [19]. However, the assumption that the 
forearm extraction of norepinephrine equals that of epinephrine has been 
confirmed in a human study [14], and as such our conclusions, based on the 
estimates of the spillover and clearance of norepinephrine, are the best 
approximation in our laboratory at present 
Although ANF seemed able to reduce the forearm clearance of 
norepinephrine during LBNP, ANF infusion alone did not show such an effect 
when compared with the infusion of placebo alone It must be emphasized 
however, that the clearance from the forearm vascular bed of norepinephrine is 
dependent on the forearm blood flow [20] Using tntiated norepinephrine, Chang 
et al have convincingly shown that an elevation in forearm blood flow increased 
the regional clearance of norepinephrine [20] Consequently, the raised clearance 
of norepinephrine during infusion of ANF alone, and to a lesser extent during 
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the infusion of sodium nitroprusside alone, may at least partly be explained by 
the vasodilator effect of these agents 
Apart from an effect on the kinetics of norepinephrine in the forearm, an 
augmented response to LBNP in the presence of ANF, may theoretically be 
based on a postsynaptic sensitization of α-adrenergic receptors by ANF The 
results as presented in figure 3 show that the postsynaptic vasoconstrictor 
response is not altered by the concomitant ANF infusion as compared with the 
concomitant administration of an equipotent vasodilator dose of SNP. Since 
these experiments were performed in the presence of the ß-adrenergic blocking 
drug propranolol, these observations have shown that ANF has not altered the 
vascular α-adrenergic sensitivity 
In conclusion, ANF potentiated the forearm vasoconstrictor response to 
selective cardiopulmonary baroreceptor unloading in man This effect may at 
least partly be located at the adrenergic nerve terminal This potentiation seems 
not to be based on an augmented release of norepinephrine, nor by an increased 
vascular a-adrenergic sensitivity, but may be based on an ANF-induced decrease 
in the locoregional clearance of norepinephrine during sympathetic activation 
Further studies are needed to confirm and further define the mechansisms by 
which ANF decreases norepinephrine clearance during sympathetic activation in 
man 
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CHAPTER 9 
General discussion and summary 
In the following chapter we aim to formulate summarized answers on the 
questions of this thesis. 
In literature several indications can be found that ANF may play an important 
role in the regulation of the lung circulation. The major quantity of ANF is 
secreted from the right atrium and thus is primarily delivered to the lungs, as 
they are the first organs through which right atrial blood passes. Indeed, in man 
high circulating concentrations of ANF are found in pulmonary arteries. Pulmo-
nary clearance of ANF is reported to be very high, and the pulmonary vascula-
ture contains specific receptors for ANF. In chapter 2 the vasodilator potency of 
rat atrial natriuretic factor (ANF) and two closely related peptides were 
compared in main, hilar and segmental pulmonary arteries of the pig in vitro. 
We wondered whether atrial peptides had vasodilator effects in the pulmo-
nary vasculature, in vitro ? The presented results demonstrate that functionally, 
isolated vascular lung preparations could be dilated dose-dependently following 
the administration of ANF. In the pulmonary arteries this vasodilator effect was 
independent of a removal of the vascular endothelium. By comparing ANF's 
vasodilator potency in the pulmonary with the renal arteries, we demonstrated 
that the pulmonary vessels were more sensitive to ANF than the renal vessels 
were. These data suggest that indeed, ANF may play a role in the regulation of 
pulmonary vascular tone, which may be of (patho)physiological importance. 
In chapter 3 - 6 several biological responses to ANF are described with a 
comparison between a group of healthy elderly and a group of healthy young 
volunteers. The results from chapter 3 - 5 all originate from the same 
experimental setting. 
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In chapter 3 the pharmacokinetics of ANF were compared between healthy 
young and elderly volunteers using equal amounts of ANF (2.0 μ^πιιη) for 
infusion 
Baseline plasma levels of circulating ANF were known to be higher in 
elderly as compared with young subjects. We determined the kinetic parameters 
of ANF to retrieve which pharmacokinetic determinant alters with advancing age, 
and might explain the higher baseline ANF levels in the elderly: plasma half life, 
metabolic clearance and/or distribution volume ? To answer this question a 
model independent analysis was used. 
The elimination half life of ANF was age-independent. The apparent 
distribution volume of ANF at steady state was not significantly reduced in the 
elderly when compared with the young. In the elderly however, the total body 
clearance of ANF was lower than in the young, a phenomenon which might, at 
least partly, explain the higher baseline ANF levels m the elderly when compared 
with the young Furthermore, in the elderly the total body clearance of ANF 
correlated significantly with the estimated creatinine clearance. In the young 
group this was not the case. This correlation in the elderly group suggested that 
in this group the number of functional glomeruli were an important determinant 
for ANF clearance. As the diminished endogenous creatinine clearance, a 
measure for the glomerular filtration rate, was associated with the number of 
functional glomeruli. 
In chapter 4 the skin microcirculatory effects of ANF are described as was 
obtained in young and elderly healthy volunteers using two different infusion 
rates of ANF (0.25 and 2.0 /ig/min) From pharmacological studies in which ANF 
was administed intra-arterially, ANF was suggested to be a potent vasodilator of 
the skin microcirculation. We questioned whether in a more physiological range 
this was still the case, as this may be relevant to pathological low skin flux states. 
Therefore we quantified microcirculatory effects by measuring 1) the nutritional 
skin circulation with a transcutaneous oxygen probe adjusted to the 4 l h finger, 2) 
the total skin flux with a laser Doppler probe on the 3 finger, and 3) the skin 
temperature with a thermometer located on the cheeks and on the 2 n d finger. 
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The skin microcirculation did respond, and even in an age-dependent 
manner. When ANF plasma concentrations were within the high physiological 
range, the shunting microcirculation in the skin of the healthy elderly subjects 
was slightly increased by ANF. At supraphysiological plasma levels, ANF only 
tended to induce a slight vasodilator response in the shunting microcirculation, 
which was more pronounced in the elderly than in the young. These data 
however, are not consistent with ANF being a potent dilator of healthy skin 
microvasculature. Thus, ANF's therapeutic value in low-flux states of the skin is 
probably nihil. 
In chapter 5 the hemodynamic effects of ANF are reported which were evoked 
in young and elderly healthy volunteers using two different infusion rates of ANF 
(0.25 and 2.0 μ^ιτπη). So far, most hemodynamic studies had been performed at 
supra-physiological ANF plasma levels, or following the intra-arterial 
administration. Therefore we questioned, whether ANF did induce any 
hemodynamic effect within one hour after reaching the high physiological range 
of ANF plasma levels. 
However, within one hour following the elevation of ANF plasma 
concentration to high physiological levels, obtained by the intravenous infusion of 
exogenous ANF, no major cardiovascular effects could be detected. The absence 
of a peripheral hemodynamic response might be due to either cardiovascular 
reflex mechanisms competing for direct ANF-induced effects, or shortage of the 
observation period. Another possible explanation was an inadequacy of the 
achieved ANF plasma level. 
Realizing that ANF plasma levels rose with advancing age, we further 
questioned whether the hemodynamic effects following the elevation of the ANF 
plasma concentration was diminished with ageing. After comparison of the 
hemodynamic effects in the group of elderly and young volunteers, we concluded 
that within one hour following the elevation of ANF's plasma concentration to 
pharmacological levels, indeed significant cardiovascular effects could be 
detected. These effects however, were more pronounced in the elderly than in 
the young. This might be due to lower ANF plasma clearance in the elderly than 
i n 
in ihe young, explaining the higher ANF plasma levels achieved in the elderly 
group when compared with the young group After correction of the hemo­
dynamic responses for this greater increase in ANF plasma levels, the hemo­
dynamic responses in both age groups were essentially identical. So far, our data 
did not provide any arguments for the hypothesis that cardiovascular responsive­
ness to ANF is decreased with advancing age. Whether any limitations on these 
conclusions are imposed by simultaneously induced compensating biological 
effects, remains speculative. 
Chapter 6 deals with the forearm vasodilator potency of ANF which was studied 
in young and elderly healthy volunteers using six increasing dose steps of ANF 
(0.001 - 0.3 д^тіп/100 ml forearm volume). Contradictory reports have been 
published on the density of vascular binding sites after exposure to elevated ANF 
concentrations. The interpretation of these studies was complex, because of 
unequal ANF plasma concentrations which were achieved, or because of the 
induction of a mixture of direct cardiovascular ANF effects and of indirect 
compensating reflexes (see previous chapter). These difficulties in the inter­
pretation may be avoided by low dose ANF administration, especially the direct 
intra-arterial infusion. We wondered whether the high baseline plasma ANF 
levels in the elderly were accompanied by a reduced forearm vascular sensitivity 
to ANF, and if so, we wished to retrieve arguments for the phenomenon of 
receptor down-regulation. 
In the elderly when compared with the young, the dose-reponse curve of 
ANF-induced vasodilation was shifted to the right, whereas the regional 
production of ANF's second messenger (cGMP) was not. Sodium nitroprusside 
(SNP), used as a control vasodilator, induced a similar degree of forearm 
vasodilation in both young and elderly Therefore, we concluded that 1) 
structural vascular changes in the human forearm of the elderly group when 
compared with the young as a possible explanation for the reduced vasodilator 
response was excluded, and furthermore that 2) human ageing was accompanied 
by a specific reduction in forearm vasodilator potency of ANF. 
To explain the discrepancy between the impaired vasodilator potency of 
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ANF with advancing age and the unimpaired i.e. age-independent regional 
production of cGMP the origin of the cGMP must be known. In the explanation 
that we described in chapter 6, we assumed, in accordance with data from the 
literature, that the cGMP in the forearm was produced by the vascular smooth 
muscle cell which also was primarily responsible for the forearm vasodilation. 
Within this concept, an explanation for the discrepancy between the impaired 
vasodilator potency and the unimpaired regional cGMP production in the elderly, 
could not be found in the phenomenon of down-regulation of ANF receptors. 
This discrepancy then, might be explained by changes in postreceptor processes, 
as described in chapter 6. 
However, most of the literature suggests that the ANF receptor is down-
regulated in situations of chronic exposure to elevated concentrations of ANF In 
our study the origin of the in vivo cGMP generation in the forearm was 
undetermined. As the cGMP generation did not necessarily come from the 
vascular smooth muscle cell being primarily responsible for the vasodilation, one 
might speculate about its origin from the vascular endothelium. Therefore, we 
now formulate a second concept, based on the endothelial origin ot cGMP. 
Then, the explanation for the afore-mentioned discrepancy may be found in a 
phenomenon of down-regulation of ANF receptors on vascular smooth muscle 
cells. The unimpaired regional cGMP production may be interpreted as a sign ot 
unimpaired endothelial function in the elderly when compared with the young. 
Which concept is the right one ? This cannot be deduced from our study, 
nor from literature. However, it is hard to believe that the cGMP is generated 
from vascular smooth muscle cells, as previous studies have shown that SNP-
induced forearm vasodilation is not accompanied by an increase in cGMP level. 
A difference in cGMP generation following ANF or SNP stimulation might be 
based on differences in intracellular cGMP handling, which cannot be excluded 
completely. Indeed, ANF and SNP use different forms of GC with different 
intracellular localizations. Overall, we have arguments for the second concept in 
which cGMP is supposed to originate from the endothelium Herein the ageing-
associated reduction of ANF-dependent vasodilation may be accompanied with 
ANF receptor down-regulation in the forearm vascular smooth muscle cell. 
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In chapter 7 the forearm vasodilator potency of ANF is described in patients 
with insulin-dependent diabetes mellitus (IDDM). The forearm vasodilation was 
compared between IDDM patients and healthy young volunteers using six 
increasing dose steps of ANF (0.001 - 0.3 μg/min/100 ml forearm volume). 
Diabetes mellitus has been associated with elevated ANF plasma concentrations 
and a reduced natriuretic response to ANF infusion. We wondered whether the 
elevated plasma ANF concentrations in IDDM were accompanied by a reduced 
forearm vascular sensitivity to ANF, and if so, whether there were arguments for 
down-regulation of ANF receptors ? 
In this small group of IDDM patients ANF plasma concentrations were 
similar to those in the control group. The forearm vasodilator response to ANF 
infusion was impaired in the IDDM patients when compared with the controls. 
Interestingly, the reduction in vasodilator effect was already most prominent at 
the lowest ANF infusion rate suggesting a (patho)physiological relevance. The 
vasodilator response to SNP, the control vasodilator, was similar in both groups, 
underscoring that the reduced vasodilator response to ANF was a rather specific 
phenomenon in IDDM. The administration of ANF did hardly evoke any 
regional cGMP production in the forearms of the IDDM patients. According to 
the second concept in which cGMP was generated primarily from the vascular 
endothelium, the blunted regional cGMP production might suggest a functional 
defect of the forearm vascular endothelium. Possibly, this is based on down-
regulation or desensitization of ANF receptors in the forearm vascular smooth 
muscle cell of uncomplicated IDDM. In association with the normal baseline 
ANF plasma concentrations, the contribution of the ANF-mediated vasodilation 
to the baseline vascular tone is reduced in uncomplicated IDDM when compared 
with healthy controls. 
In a distinct human in vivo study we investigated the effects elicited by ANF on 
the forearm vascular adrenergic nerve terminal. Chapter 8 deals with the 
locoregional effect of ANF on the forearm vasoconstrictor response to a 
sympathetic stimulation test. A plexiglass box with an airtight apron seal just 
above the iliac crest was used to induce a lower body negative pressure (LBNP) 
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at -20 mmHg, evoking an acute decrease in central venous pressure without 
altering the arterial blood pressure. In physiological terms this means a selective 
cardiopulmonary baroreceptor unloading. We questioned whether ANF modula­
ted the baroreceptor-induced reflex at the level of the vascular adrenergic nerve 
terminal ? Via a central, possibly even ganglionic pathway, ANF was supposed to 
evoke sympathoinhibitory effects. We hypothesized, that the vascular tree must 
have an ANF-dependent pathway to prevent inappropriate vasodilation when the 
peripheral vessels are incapacitated to constrict properly, such as in the case of 
ANF-induced sympathoinhibition. 
Indeed, the locoregional administration of ANF into the brachial artery 
potentiated the forearm vasoconstrictor response to sympathetic stimulation in 
man. Calculation of the catecholamine kinetics suggested that this increased 
forearm vasoconstrictor response was accompanied with a decrease in local 
norepinephrine clearance, and not in an increase of norepinephrine production, 
as might have been expected. The administration of exogenous norepinephrine in 
predilated forearm vasculature, did not reveal any change in vasoconstrictor 
response when the ANF- and SNP-predilated states were compared. The latter 
finding excluded postreceptor modulation of the vascular α-adrenoceptor by 
ANF. 
We concluded that indeed, the vascular tree was not fully incapacitated by 
inducing a central or ganglionic sympathoinhibition in cases in which ANF 
plasma levels are chronically elevated. Our data show that forearm 
vasoconstrictor potentiation by ANF is not based on an augmented local release 
of norepinephrine, nor on an increased vascular α-adrenergic sensitivity, but our 
data suggest an ANF-induced decrease of forearm vascular norepinephrine 
clearance. Yet, these data need to be confirmed by more sensitive studies of 
catecholamine kinetics using tritiated ( H)-norepinephrine. 
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General conclusions: 
1) Isolateci vascular lung preparations can be dilated dose-dependently 
following the administration of ANF. Removal of the vascular endothelium 
made no difference to the pulmonary arterial relaxation. The in vitro 
vasodilator potency of ANF is greater in the pulmonary than in the renal 
arteries. 
2) In the elderly group the total body clearance of ANF is lower than in the 
young, which may at least partially explain the increased baseline ANF 
plasma concentrations in the elderly group. 
3) The elevation of ANF's plasma concentration by the intravenous infusion of 
exogenous ANF evokes a minor vasodilation in the human skin micro-
circulation, but evokes a more pronounced vasodilation in the 
macrocirculation. 
4) The forearm vasodilator potency of ANF is reduced with advancing age. 
This may be due to a postreceptor defect of the ANF receptors, although 
down-regulation of these receptors could not be excluded completely. 
5) The forearm vasodilator response to ANF in uncomplicated insulin-
dependent diabetes mellitus is reduced when compared with young healthy 
controls. This may be due to down-regulation or desensitization of ANF 
receptors. 
6) The forearm vasoconstrictor response to sympathetic stimulation is 
potentiated by ANF. This effect may be located at the level of the 
adrenergic nerve terminal. The potentiation of the forearm vasoconstrictor 
response is not due to an increased vascular sensitivity for norepinephrine, 
but may be due to alteration of the locoregional norepinephrine kinetics. 
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CHAPTER 10 
(HOOFDSTUK 10) 
Algemene discussie en samenvatting 
In dit hoofdstuk staan de belangrijkste bevindingen uit het proefschrift samengevat. 
Hierbij zal per hoofdstuk nog in het kort worden ingegaan op de vraagstellingen en op 
de interpretatie van de resultaten. 
Uit de literatuur blijkt dat de atnumnatnuretische factor (ANF) een belangrijke rol 
speelt in de regulatie van de longdoorbloeding. ANF wordt afgegeven door de rechter-
boezem, en passeert dus als eerste het longvaatbed. In de longslagader wordt bij de 
mens dan ook een hoge ANF-plasmaconcentratie gevonden. Hoofdstuk 2 handelt over 
de vaatverwijdende effecten van ANF in het longvaatbed Daartoe werd het verwijdend 
effect van ANF en van twee verwante eiwithormonen (beide van de rat) in-vitro 
bestudeerd in hoofd-, hilus- en segmentale takken van de longslagdder bij het varken 
In een opstelling met geïsoleerde longvaatpreparaten bleek ANF op een dosis-
afhankehjke manier tot vaatverwijding te leiden, overigens los van de eventuele 
aanwezigheid van vaatendotheel In een vergelijkend experiment met niervaten bleken 
de longvaten gevoeliger te zijn voor de vaatverwijdende effecten van ANF. Deze waar-
nemingen wijzen op een mogelijk belangrijke rol van ANF in de regulatie van de long-
vaattonus, hetgeen van (patho)fysiologisch belang kan zijn 
De hoofdstukken 3-6 beschrijven in hoeverre veroudering de respons op toediening van 
ANF beïnvloedt De gegevens van hoofdstuk 3-5 zijn alle afkomstig uit hetzelfde onder-
zoek en zijn bij vrijwilligers uitgevoerd. 
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Hoofdstuk 3 gaat in op de verschillen in farmacokinetiek van ANF tussen gezonde 
jongeren en ouderen Tijdens en na infusie van gelijke hoeveelheden ANF (2.0 /ig/min) 
werden verscheidene farmacokinetische parameters van ANF bepaald, en vervolgens 
met een model-onafhankelijke methode geanalyseerd. 
Zoals ook reeds uit de literatuur bekend was, bleek de basale ANF-plasma-
concentratie bij ouderen hoger te zijn dan bij jongeren. Nadere analyse leerde dat dit 
ten minste voor een deel verklaard kon worden door een lagere totale lichaamsklanng 
(total body clearance) bij ouderen. De gemiddelde verblijftijd (mean residence time) 
evenals de halfwaardetijd (t1 / 2) van ANF was daarentegen onafhankelijk van de leeftijd. 
Binnen de groep ouderen bleek de totale lichaamsklanng van ANF significant te 
correleren met de geschatte endogene creatinmeklanng. Binnen de groep jongeren was 
dit echter niet het geval. Aangezien de endogene creatinmeklanng een maat is voor het 
aantal functionerende glomeruli, suggereert deze correlatie dat bij de ouderen het 
aantal nog functionerende glomeruli een belangrijke rol speelt bij de klaring van ANF 
uit het plasma 
Hoofdstuk 4 beschrijft de effecten van ANF in de microcirculatie van de huid bij 
bovengenoemde groep jongere en oudere gezonde vrijwilligers. Door anderen werd op 
grond van farmacologische studies met relatief hoge doseringen van ANF gesuggereerd 
dat ANF een krachtige vaatverwijder van de microcirculatie in de huid was. Hierbij was 
het echter onopgehelderd of deze microcirculatoire effecten van ANF ook bij fysio­
logische ANF-plasmaconcentraties op zouden treden. Ten einde zowel fysiologische als 
farmacologische concentraties te bereiken werd ANF in twee doseringen toegediend: 
0.25 and 2.0 μg/mln. 
Tijdens toediening van de hoge dosering ANF trad er een vaatverwijdend effect 
op in de microcirculatie van de huid. Dit laatste effect was meer uitgesproken bij de 
ouderen dan bij de jongeren. Toediening van de lage dosis ANF gaf een significante 
toename in de huiddoorbloeding bij de ouderen maar met bij de jongeren. Toediening 
van de lage dosis ANF bleek hierbij overigens tot ANF-plasmaconcentraties in het 
hoog-fysiologische bereik aanleiding te geven. Bij gezonde proefpersonen lijkt ANF dus 
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géén sterke vaatverwijder in het microcirculatoire vaatbed van de huid te zijn. Als 
zodanig lijkt ANF dan ook geen therapeutische waarde te hebben bij doorbloedings-
stoornissen van de huid. 
In hoofdstuk 5 worden de hemodynamische effecten van ANF beschreven tijdens de 
twee ANF-dosenngen (0.25 and 2.0 μg/mln) bestudeerd bij bovengenoemde groep 
jongeren en ouderen. In de literatuur ging men tot dusverre slechts in op de effecten 
van relatief hoge doseringen van ANF. Een van de belangrijkste vraagstellingen van dit 
onderzoek was dan ook of toediening van een lage dosis ANF tot systemische vaat-
verwijding zou leiden. Een tweede vraagstelling was of veroudering, bijvoorbeeld door 
langdurige blootstelling aan verhoogde basale ANF-plasmaconcentraties, gepaard ging 
met een verminderde respons op de toediening van exogeen ANF. 
De toediening van de hoge dosis ANF leidde inderdaad tot significante 
cardiovasculaire effecten, te weten een daling van de bloeddruk, een stijging van de 
hartfrequentie, en een toename van de doorbloeding in de onderarm. De hemo­
dynamische respons op ANF was meer uitgesproken bij de groep ouderen dan bij de 
jongeren. Echter, ook de bereikte ANF-plasmaconcentratie tijdens ANF-infusie was bij 
de ouderen hoger dan bij de jongeren. Na correctie hiervoor bleek de hemodynamische 
respons m beide leeftijdsgroepen in essentie gelijk. Deze gegevens leverden geen 
argumenten op vóór vermindering van cardiovasculaire gevoeligheid voor ANF bij 
veroudering 
De toediening van de lage dosis ANF bleek géén effect te hebben op bloed-
druk, hartfrequentie of doorbloeding in de onderarm. Dit suggereert dat op de korte 
termijn ANF binnen fysiologische concentraties geen sterke vaatverwijder is. Deze 
conclusie moet echter gerelativeerd worden omdat niet kan worden uitgesloten dat 
eventuele vaatverwijdende effecten van ANF gecompenseerd werden, eventueel door 
effecten van tegenregulatie. 
Hoofdstuk 6 handelt evenals hoofdstuk 5 over de vaatverwijdende effecten van ANF. 
Vanwege de bemoeilijkte interpretatie van de gegevens uit hoofdstuk 5 werd in dit 
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hoofdstuk een andere methodiek gebruikt Hierbij werd ANF in zeer lage doseringen 
toegediend via de armslagader (ter hoogte van de elleboogsplooi arteria brachial«), 
en distaal daarvan werd de doorbloeding in de onderarm gemeten. De doseringen 
werden zo laag gekozen dat wèl regionale, maar géén systemische effecten optraden. 
Op deze wijze konden de gegevens niet of nauwelijks vertroebeld worden door 
eventuele tegenregulatie. In totaal werden zes oplopende ANF-dosenngen bestudeerd. 
Binnen dit model bleek ANF een krachtige vaatverwijder te zijn, zelfs bij de 
relatief lage intra-arteriele doseringen. Vergelijkende experimenten tussen jongeren en 
ouderen toonden nu wèl dat het vaatbed in de onderarm van de ouderen in vergelijking 
tot dat van de jongeren minder gevoelig was voor het verwijdend effect van ANF. Dit 
verschil tussen jong en oud bleek geen aspecifieke bevinding te zijn, aangezien beide 
groepen identiek reageerden op de intra-arteriele toediening van een controle-
vaatverwijder (natrium nitroprusside) In deze groep ouderen was wederom de basale 
ANF-plasmaconcentratie hoger dan die van de jongeren. Gevoegd bij de gegevens uit 
de literatuur, ligt het voor de hand om de vermindering in de vaatverwijding door ANF 
bij ouderen te verklaren met behulp van een "down"-regulatie van de ANF-receptoren 
op de gladde spiercel in de vaatwand, mogelijk als gevolg van de langdurige bloot-
stelling aan verhoogde basale ANF-plasmaconcentraties 
Ondanks het overtuigend jong/oud-verschil in de vaatverwijdende effecten van 
ANF in het vaatbed van de onderarm, werd géén verschil gevonden tussen de jongeren 
en ouderen ten aanzien van de regionale produktie van cGMP, de second messenger 
van ANF. In feite pleit dit gegeven tegen de eerder veronderstelde "down"-regulatie van 
ANF-receptoren Het is opmerkelijk dat de gemeten produktie van cGMP geen direkte 
afspiegeling is van het vaatverwijdend effect van ANF. Als zodanig kan men betwijfelen 
of het gemeten cGMP wel afkomstig is uit de gladde spiercel Bij deze veronderstelling 
dat het cGMP niet uit de gladde spiercel maar bijvoorbeeld uit het vaatendotheel 
afkomstig is, kan de hypothese standhouden dat de gemeten vermindering van de 
vaatwandgevoehgheid voor ANF bij ouderen inderdaad berust op "down"-regulatie van 
ANF-receptoren. Anderzijds, de verminderde vaatverwijding van de onderarm bij de 
ouderen met de ongestoorde regionale produktie van het cGMP, lijkt verklaard te 
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moeten worden door een bij ouderen optredend post-receptor defect van het ANF-
receptorsysteem wanneer het gemeten cGMP inderdaad uit de gladde spiercel 
afkomstig is. 
Voor hoofdstuk 7 werden dezelfde parameters bestudeerd als voor hoofdstuk 6 maar 
nu bij een groep patiënten met insuline-afhankelijke diabetes mellitus. De achter-
liggende gedachte was dat in de literatuur diabetes mellitus, evenals veroudering, 
geassocieerd is met verhoging van basale ANF-plasmaconcentraties Op grond hiervan 
kan wederom verondersteld worden dat de vaatwandgevoehgheid voor ANF ook bij 
patiënten met diabetes mellitus verminderd is als gevolg van "down"-regulatie van ANF-
receptoren. Met behulp van hetzelfde onderarmsmodel als beschreven in hoofdstuk 6 
werd deze veronderstelling getoetst. Het vaatverwijdend effect van zes opklimmende 
doseringen ANF bij patiënten met ongecompliceerde insuline-afhankelijke diabetes 
mellitus werd vergeleken met het effect bij gezonde jonge vrijwilligers. 
Ondanks tegengestelde bevindingen in de literatuur, bleek dat de basale ANF-
plasmaconcentratie bij de groep diabetespatiënten niet verhoogd was Het vaat-
verwijdend effect van ANF was echter bij de diabetespatiënten duidelijk zwakker dan 
bij de gezonde controlepersonen. Ook hier bleek het verschil tussen de diabetes-
patiënten en controleper.sonen specifiek betrekking te hebben op ANF aangezien de 
controlevaatverwijder (natrium nitroprusside) vergelijkbare effecten liet zien in beide 
groepen. Verder bleek in dit onderzoek de produktie van het cGMP in het vaatbed van 
de onderarm wèl een goede weerspiegeling te zijn van het vaatverwijdend effect van 
ANF. Als pathofysiologisch substraat voor de verminderde vaatwandgevoehgheid voor 
ANF bij ongecompliceerde insuline-afhankelijke diabetes mellitus komt dan in 
aanmerking óf "down"-regulatie еп/òf desensitizatie van de cGMP-afhankelijke ANF-
receptoren op de gladde spiercel in de vaatwand. 
Hoofdstuk 8 behandelt de vaatverwijdende effecten van ANF binnen het 
bovengenoemde onderarmsmodel, en in het bijzonder het effect van ANF op het 
sympatisch zenuwstelsel. Andere onderzoekers hadden reeds aangetoond dat ANF het 
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sympatisch zenuwstelsel op verschillende niveaus beïnvloedt, bijvoorbeeld ter hoogte 
van de drukreceptoren, en ter hoogte van het centraal zenuwstelsel. Tot op heden werd 
echter niet onderzocht of ANF het sympatisch zenuwstelsel beïnvloedt ter plaatse van 
de zogenaamde postganglionäre synaps, daar waar de uiteindelijke prikkeloverdracht 
op de vaarwand plaatsvindt. Er waren echter in de literatuur wel indirekte aanwijzingen 
dat ANF deze prikkeloverdracht bij de mens zou versterken. Stimulatie van het 
sympatisch zenuwstelsel leidt onder meer tot vaatvernauwing. Voor dit hoofdstuk werd 
nagegaan of ANF deze vaatvernauwing bij sympaticusstimulatie ter hoogte van de post-
ganglionäre synaps versterkte. Als sympaticusprikkel werd gebruik gemaakt van de 
zogenaamde "lower body negative pressure"-techniek. De proefpersoon ligt dan op een 
onderzoekbank; vanaf het middel in een af te sluiten bekisting, waarin middels een 
stofzuiger onderdruk kan worden aangebracht. Door middel van het aanbrengen van -
20 mmHg onderdruk ter plaatse van het onderlichaam, worden de cardiopulmonale 
drukreceptoren geprikkeld hetgeen reflexmatig tot sympaticusstimulatie leidt. 
Locoregionale toediening van ANF in de armslagader (ter plaatse van de elle-
boogsplooi: arteria brachialis) versterkte inderdaad het vaatvernauwend effect van de 
sympaticusprikkeling. Dit versterkend effect werd alléén in die arm (ipsilateraal) gezien 
waar ANF intra-arterieel werd toegediend en niet in de andere arm (contralateraal). 
Dit laatste gegeven onderstreept dat de interactie tussen ANF en de sympaticus zich 
in deze studie alleen op het niveau van de postganglionaire synaps afspeelde. Aan-
vullende experimenten leerden dat de resultaten niet konden worden verklaard door 
het vaatverwijdend effect van ANF, en evenmin door een hogere vaatwandgevoeligheid 
voor noradrenaline tijdens ANF-toediening. Dit impliceert dat de toegenomen vaat-
vernauwende respons op sympaticusstimulatie tijdens ANF moet berusten op een 
veranderde kinetiek van noradrenaline ter plaatse van de postganglionaire synaps, 
bijvoorbeeld een toegenomen afgifte óf een verminderde afbraak van noradrenaline. 
Blijkens berekeningen van de kinetische parameters met behulp van arteriële en 
veneuze concentraties van (nor)adrenaline leek er eerder sprake te zijn van een 
verminderde afbraak dan van een toegenomen afgifte van noradrenaline. Benadrukt 
moet worden dat er een aantal methodologische bezwaren kleeft aan de gebruikte 
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berekeningen. In feite kan de regionale kinetiek van noradrenaline slechts betrouwbaar 
worden gemeten na toediening van een speurdosis van getntieerd ( H)-noradrenahne 
Voor een definitieve conclusie zouden aanvullende experimenten met toediening van 
een dergelijke speurdosis getntieerd noradrenaline nodig zijn. 
Algemene conclusies: 
1) ANF leidt tot een dosis-afhankelijke verwijding van geïsoleerde 
longvaatpreparaten; verwijdering van het vaatendotheel had hierop geen invloed. 
Bij een vergelijkend onderzoek in-vitro blijken de longvaten gevoeliger te zijn 
voor dit verwijdende effect van ANF dan de niervaten. 
2) Bij ouderen is de totale lichaamsklanng van ANF verminderd, hetgeen op zijn 
minst gedeeltelijk de verhoogde basale ANF-plasmaconcentraties bij ouderen 
verklaart. 
3) Verhoging van de ANF-plasmaconcentratie leidt tot vaatverwijding, in de micro-
circulatie van de huid maar vooral in de vaten van de macrocirculatie. 
4) Bij kwantificering van het direct vaatverwijdende effect van ANF in het vaatbed 
van de onderarm blijkt veroudering gepaard te gaan met een verminderde 
vaatwandgevoehgheid voor ANF. Dit berust waarschijnlijk op een post-receptor 
defect, alhoewel "down"-regulatie van ANF-receptoren in de vaatwand niet werd 
uitgesloten. 
5) Ongecompliceerde insuline-afhankelijke diabetes mellitus gaat gepaard met een 
verminderde vaatwandgevoehgheid voor ANF Dit lijkt te berusten op "down"-
regulatie of desensitizatie van ANF-receptoren in de vaatwand. 
6) ANF versterkt de vaatvernauwende response op sympaticusstimulatie ter hoogte 
van de postganglionäre synaps Dit effekt berust niet op een hogere vaatwand-
gevoehgheid voor noradrenaline tijdens ANF-toediening, maar lijkt samen te 
hangen met een verandering in de locoregionale kinetiek van de 
neurotransmitter noradrenaline 
123 
Acknowledgements 
I wish to express my gratitude to everyone who contributed to the realisation of the 
present thesis, and the Faculty's research funds for creating the financial 
opportunities. 
My thanks go to all volunteers who participated in the experiments. 
My thanks further go to all members of the circulation research group, and 
especially Marie-Cecile Jacobs, Eugenie Olde Riekerink and Joeke Reijenga, who 
helped whenever extra hands were needed. 
Also to the members of the laboratory of Chemical and Experimental 
Endocrinology (Prof.Dr. Benraad), Brigiet Pichel-Theelen and Dr. J. van Laarhoven. 
Their flexibility enabled a rapid progress in the experiments. Special thanks to dr. 
Adriaan Tan for the enjoyable discussions with a positive impact on this thesis. 
Next I thank, Dr. Alyn Morice and Prof.Dr. Morris Brown from Clinical 
Pharmacology Unit of Addenbrooke's Hospital, Cambridge, United Kingdom, who 
aroused my interest in atrial peptides, and Dr. R.G. Hill, who enabled the in-vitro 
studies at Parke Davis Research Unit in Cambridge. 
I thank all members of the Department of Internal Medicine from Rijnstate 
Hospital Arnhem, and in particular Dr. Jan Werre, Dr. Louis Verschoor and Dr. 
Chris Mulder who have stimulated my scientific activities and enabled the combination 
of science and clinical practice during the first year. 
Thanks to Cees Nicolasen for the medical illustrations, and to the members 
from the Medical Library who assisted in the search for articles. I wish to thank Leon 
van Raaij for the cover illustration of this thesis. 
Last but bot least, special thanks for my parents and Mariken, who supported me 
whenever needed. 
124 
Dankwoord 
Op deze plaats wil ik iedereen bedanken die heeft bijgedragen aan de totstandkoming 
van dit proefschrift. Allereerst gaat mijn dank gaat uit naar de Medische Faculteit die 
mij in de gelegenheid stelde dit onderzoek uit te voeren in het kader van de arts-
assistentenpool. 
Alle vrijwilligers die deelnamen als proefpersoon in de verschillende onderzoekingen 
wil ik bedanken. 
Ook alle leden van de Circulatiegroep wil ik dankzeggen, in het bijzonder 
Marie-Cecile Jacobs, Eugenie Olde-Riekennk en Joeke Reijenga, die mij met raad en 
daad bijstonden wanneer extra hulp nodig was. 
De medewerkers van het Endocrinologisch Laboratorium (prof.dr. Th. 
Benraad) wil ik danken, met name Brigiet Pichel-Theelen en dr. J. van Laarhoven; 
hun flexibiliteit maakte een snelle voortgang van de experimenten mogelijk. Verder 
wil ik dr. Adriaan Tan danken voor de plezierige discussies over de atrium-
natriuretische factor. 
Ik wil dr. Alyn Morice en prof.dr. Morris Brown bedanken, destijds beiden 
werkzaam aan de "Clinical Pharmacological Unit, New Addenbrooke's Hospital, 
Cambridge, United Kingdom". Zij hebben mijn belangstelling voor de 
atriumnatriuretische factor gewekt. Dr. R.G. Hill van "Parke Davis Research Unit, 
Cambridge, United Kingdom", wil ik bedanken voor het creëren van een in-vitro-
onderzoeksplaats op zijn laboratorium. 
Alle medewerkers van de Afdeling Inwendige Ziekten van het Ziekenhuis 
Rijnstate te Arnhem wil ik bedanken, in het bijzonder dr. Jan Werre, dr. Louis 
Verschoor en dr. Chris Mulder die mijn wetenschappelijke activiteiten stimuleerden; 
zij maakten het bovendien mogelijk deze aktiviteiten te combineren met het 
eerstejaars-artsassistentschap. 
Dank aan Cees Nicolasen voor de medische illustraties, en de leden van de 
Medische Bibliotheek voor hun hulp bij mijn zoektocht naar artikelen. Speciale dank 
aan Leon van Raaij voor het ontwerpen van de omslag. 
"Last but not least", gaat mijn speciale dank gaat uit naar mijn ouders en Manken, die 
mij steun gaven wanneer dat nodig was. 
125 
Curriculum vitae 
The author of this thesis was born April 19th 1963 in Arnhem, The Netherlands. In 
1981 he graduated at the Thomas à Kempis College in Arnhem. He then started to 
study Medicine on the Catholic University of Nijmegen, The Netherlands. 
During the Medicine study as assisting-student, he gave lessons in First Aid on 
the Subfaculty of Dental Medicine. After his doctorate examination he worked as 
microscopist on the Institute of Pathologic Anatomy (prof.dr. G.P. Vooijs). As a board 
member he participated in the Coassistant Association. 
In February 1986 he passed the doctorate examinations. Being elective 
student, he performed under the supervision of dr. A.H. Мопсе, several pharmaco­
logic investigations on the in vitro vasodilator properties of the atrial natriuretic factor 
(ANF) at the Clinical Pharmacology Unit of New Addenbrooke's Hospital, 
Cambridge, United Kingdom (prof dr. M J Brown). He continued ANF research at 
the Department of Medicine, Division of General Internal Medicine (prof.dr. A. van't 
Laar), Clinical Physiology Unit (prof dr. Th. Thien), University Hospital Nijmegen, St 
Radboud, Nijmegen, The Netherlands. 
In November 1988 he passed the final examination for Physicians. From 
January 1989 he worked on the Department of Internal Medicine at the Rijnstate 
Hospital in Arnhem. With the financial support from the Radboud Research Funds 
and with the co-supervision of dr. P. Smits, he finished his in vivo ANF research from 
July 1990 to January 1991 leading to this thesis. 
Since then he is in training for internal medicine on the Department of 
Internal Medicine at Rijnstate Hospital in Arnhem (dr. J.M. Werre, dr. С van 
Gastel) 
126 


STELLINGEN 
behorend bij het proefschrift 
'Pharmacological and vascular studies 
on the short-term effects of the 
atrial natriuretic factor' 
1) De gevoeligheid voor het vaatverwijdend effect van ANF in vitro, is in de long 
hoger dan in de nier. 
(dit proefschrift) 
2) De hogere ANF-plasmaconcentraties bij ouderen kunnen worden verklaard 
doordat de plasmaklaring van ANF bij ouderen is verminderd. 
(dit proefschrift) 
3) Het vaatverwijdend effect van ANF in de normale microcirculatie van de 
humane huid is slechts gering 
(dit proefschrift) 
4) Veroudering gaat bij de mens gepaard met een verminderde gevoeligheid 
voor het vaatverwijdend effect van ANF in het skeletspiervaatbed van de 
onderarm. De ongestoorde produktie van cGMP ("second messenger" van 
ANF) bij ouderen tijdens ANF-toediening suggereert een defect voorbij het 
niveau van de ANF-receptor 
(dit proefschrift) 
5) Ongecompliceerde insulme-afhankelijke diabetes mellitus (IDDM) gaat 
gepaard met een verminderde gevoeligheid voor het vaatverwijdend effect van 
ANF in het skeletspiervaatbed van de onderarm. De eveneens verminderde 
produktie van cGMP ("second messenger" van ANF) bij de IDDM-patienten 
tijdens ANF-toediening suggereert desensitizatie of "down"-regulatie van 
ANF-receptoren bij ongecompliceerde IDDM. 
(dit proefschrift) 
6) ANF versterkt de baroreceptorreflex zonder dat het de vaatwandgevoehgheid 
voor exogeen noradrenaline beïnvloedt 
(dit proefschrift) 
7) ANF speelt een rol bij de hyponatriemie van het kleincellig longcarcinoom, 
een argument temeer te spreken van SIAD in plaats van SIADH in navolging 
van Verbalis. 
(D Ρ Bliss et al. in J Nati Cancer Inst 1990; 
82- 305-10.) 
8) De eerste jaren na de ontdekking van ANF worden gekenmerkt door 
ongelukkige naamgeving waardoor veel klinici onterecht denken dat ANF 
geassocieerd is met auto-immuunziekten. 
(eigen waarneming.) 
9) Coeliakie wordt in Nederland ondergediagnostiseerd. De laatste jaren is men 
echter bezig met een inhaalmanoeuvre. 
(T.L.Th.A. Jansen et al. in Eur J 
Gastroenterol & Hepatol 1993; 5: 73-8.) 
10) Met behulp van eetbare gluten-coatings, bijvoorbeeld op groeten en fruit, 
zouden plastic-coatings deels kunnen worden teruggedrongen. Gluten is echter 
geenszins inert. Door een goede regelgeving waarbij een officiële verplichting 
om gluten als additief op de verpakking te vermelden, kunnen ook 
coeliakiepatienten onbezorgd een appeltje blijven eten. 
(T.L.Th.A. Jansen et al. in The Lancet 1992; 
339: 1062.) 
11) Toediening van een radio-aktief farmacon kan soms nog tot 60 jaar na dato 
katastrofale gevolgen hebben. 
(T.L.Th.A. Jansen et al. in Ned Tijdschr 
Geneeskd 1992; 136: 1413-7.) 
12) Als gevolg van de technologische vooruitgang moet differentiaal diagnostisch 
bij de anunsche patiënt ook de mogelijkheid van pseudoanurie ten gevolge 
van superabsorberende luiers worden overwogen. 
(J.H. Barada. in N Engl J Med 1991; 325: 
892-3.) 
13) Lezen is een veel minder boomonvriendelijke daad dan het eten met saté-
stokjes in een Chinees restaurant. 
(S. Rozendaal. Natuur & Techniek 1990; 58 
(nr 11): 811-5.) 
14) Door verzending van informatietijdschriften in plastic verpakking, zoals dat 
onder meer gebeurt bij het Medisch Contact en The Netherlands Journal of 
Medicine, getuigt men van weinig betrokkenheid met het milieu. 
Tim L.Th.A. Jansen Nijmegen, 20 april 1993 
"This is not the end; 
il is not even ihc beginning of ihe end; 
but perhaps il is the end of the beginning." 
Winston Churchill 


